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Summary 
The aim of this thesis was to assess the relationships between glycaemic exposure 
and β-cell function with prevalence, incidence and progression of diabetic 
retinopathy (DR) over 5 years in newly-diagnosed treatment-naïve subjects with 
type2 diabetes mellitus (T2DM). 
 
At diagnosis, we studied 544 subjects and demonstrated DR was independently 
associated with fasting and postprandial hyperglycaemia and reduced fasting β-cell 
function during standardized meal and intravenous glucose challenge. The insulin-
independent component of glucose tolerance (SG) was also impaired and 
independently associated with presence of DR at diagnosis.  
 
We followed up 233 subjects over 5 years and established independent association 
between chronic glycaemic exposure (HbA1c,/fasting/ postprandial hyperglycaemia) 
at diagnosis and incident DR during this period. We also demonstrated that fasting 
and postprandial β-cell responsiveness to nutrient challenge along with SG at baseline 
was independently associated with development of DR over 5 years. There was no 
difference in glycaemic status between those with or without DR at 5 years 
highlighting the relevance of early history of glycaemic exposure in our subjects to 
future incidence of DR.  
 
Finally, in 45 T2DM subjects with DR at diagnosis, fasting, postprandial glucose and 
HbA1c along with fasting, postprandial β-cell
 
responsiveness at diagnosis were all
 
independently associated with DR progression.  
vii 
 
Thus, this study has indicated that hyperglycaemia resulting from pancreatic β-cell 
deficiency contributes to the risk of development and progression of DR. The data 
emphasises the need for earlier diagnosis of T2DM and cautious normalization of 
glycaemia to eliminate glucotoxicity on the already impaired β-cell function. The 
evidence indicates the potential value of supporting β-cell function aiming to achieve 
near-normal glycaemia and thus preventing the onset and progression of DR in 
subjects with T2DM. 
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1.1 General Introduction 
There is a worldwide epidemic of Diabetes Mellitus (DM) (IDF Diabetes Atlas (7
th
 
edition) (IDF 2015), with  an estimated prevalence worldwide in the adult population 
of around 415 million in 2015 and this is predicted to increase to 642 million by 
2040. In high-income countries approximately 90% of the adult population have 
Type 2 DM (T2DM). Worldwide healthcare costs are rising with 12% of the global 
health expenditure related to DM and its complications, which accounts for most 
(approximately 80%) of the total expenditure. Future increases in global health 
expenditure will be driven by population growth expected in low and middle income 
countries, where 75% of diabetic subjects live, accentuated by increasing 
urbanisation and adverse lifestyle changes. DM is currently the fifth most common 
reason for death in the world - around 1 in 8 people between 20 and 79 years old 
have their death attributed to DM and this figure is expected to rise. The life 
expectancy on average is reduced by (Prince CB 2002) more than 20 years for 
people with Type 1 DM (T1DM) and up to 10 years for people with T2DM. Further 
the Framingham Heart Study also reports that men and women with DM ≥ 50 years 
lived on average 7.5 and 8.2 years less than their non diabetic equivalents (Franco et 
al. 2007). 
 
Since 1996, the number of people with DM in the UK has risen from 1.4 million to 
3.5 million , with DM prevalence in the UK estimated to rise to 5 million by 2025 
(https://www.diabetes.org.uk/Documents/Position%20statements/DiabetesUK_Facts
_Stats_Oct16.pdf). That means 1 in every 17 people having diabetes (includes 
diagnosed and undiagnosed). It is also predicted that up to 630,000 people in the UK 
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have DM but not diagnosed. In 2015, the number of people diagnosed with diabetes 
in the adult population across the UK was: England: 2,913,538, Northern Ireland: 
84,836, Scotland: 271,312 and Wales: 183,348. (England-
http://www.hscic.gov.uk/catalogue/PUB18887 et al.) The majority of these cases are 
of T2DM, which has been linked to increasing cases of obesity. 90% of adults with 
DM have T2DM and 2 % of children with 85% of all subjects with DM having 
T2DM. The prevalence of T2DM especially has been increasing at a high rate and 
this is now one of the world’s most common long-term health conditions. 
 
Diabetes is currently classified into: Type 1 DM (secondary to β-cell destruction, 
usually resulting in absolute insulin deficiency), T2DM (secondary to a progressive 
insulin secretory defect on the backdrop of insulin resistance (IR). Other types 
include Gestational diabetes mellitus (GDM), which is diagnosed in the 2
nd
  or 3
rd
 
trimester of pregnancy and specific types of DM due to other causes, e.g., 
monogenic diabetes syndromes (such as neonatal DM and maturity-onset DM of the 
young [MODY]) and diseases of the exocrine pancreas (such as cystic fibrosis). 
Other agents which can cause or precipitate diabetes include drugs such as 
glucocorticoids, those used in the treatment of HIV/AIDS or after organ 
transplantation, or chemical pollutants such as food toxins/preservatives (American 
Diabetes Association 2015). However in 2015, Leslie et al. have noted that the 
current classification does not completely capture the different disease forms. (Leslie 
et al. 2016). They note that both T1DM and T2DM have common features 
encapsulated by adult-onset autoimmune diabetes and MODY. Thus they have 
outlined evidence that the use of laboratory testing could improve disease 
5 
 
classification and the efficacy of treatment for major types of DM (Leslie et al. 
2016). 
 
The pathogenesis of T2DM is multifactorial (Stumvoll M et al. 2005) and presents at 
different stages of dysglycaemia reflecting varying degrees of insulin deficiency and 
insulin resistance. There are different phenotypes of T2DM. These include 
individuals who have lost weight due to a relative or absolute lack of insulin 
secretory capacity (insulinopaenia); however, the majority are overweight or obese 
and they are predominantly insulin resistant (Beck-Nielsen H and Groop LC 1994; 
Kahn CR 1994; Robertson RP 1995). It is difficult to determine the exact cause in an 
individual subject without detailed evaluation. Furthermore, the clinical expression 
of the disease may arise through genetic and/or environmental influences. 
Hyperglycaemia itself impairs pancreatic β cell function and exacerbates IR, leading 
to a vicious cycle (Li Y et al. 2004). This is summarised in Figure 1.1 
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Figure 1.1: Proposed sequence of the key pathological features of T2DM [Adapted 
from (Leahy JL 2005)]. 
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Maintenance of normal glucose homeostasis is precise. In the fasting/basal state 50% 
of glucose uptake occurs in brain, 25% in splanchnic tissues (liver and 
gastrointestinal tissues) both of which are insulin-independent mechanism (De 
Fronzo RA 2004). The final 25% occurs in insulin dependent tissues i.e. muscle and 
adipose tissue. Post glucose intake, resulting in an increase in plasma glucose 
concentration, there is stimulation of both insulin release and glucose uptake by 
splanchnic (liver and gastrointestinal tissues) and peripheral tissues (muscle) whilst 
suppressing predominantly endogenous hepatic glucose production. The liver has an 
important role in maintaining euglycaemia via glycogenolysis when plasma glucose 
is low, supported by the generation of glucose from non-carbohydrate carbon 
substrates such as pyruvate, lactate, glycerol, glucogenic amino acids, and fatty acids 
(both even-chain and odd-chain). Plasma glucose levels are controlled by hepatic and 
renal glucose production with the liver contributing approximately 80% and the 
kidneys 20% (Stumvoll M et al. 1997; Ekberg K et al. 1999). Insulin inhibits hepatic 
glucose production by inhibiting glucagon secretion, reducing plasma non-esterified 
fatty acid levels, reducing the amount of gluconeogenic precursors supplied to the 
liver, and changing the neural input to the liver (Girard J 2006). Insulin also 
increases glucose uptake for storage and thereby reduces plasma glucose (Figure 
1.2). 
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Figure 1.2: Schematic representation of normal effects of insulin. Insulin secretion 
from the pancreas normally reduces glucose output by the liver, enhances glucose 
uptake by skeletal muscle, and suppresses fatty acid release from fat tissue [Adapted 
from (Stumvoll M et al. 2008)]. 
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Association of T2DM with central abdominal obesity is well recognised. Obesity 
leads to IR with increased levels of non-esterified fatty acids (NEFA) which are 
transported to the liver, where they reduce glucose utilisation, and stimulate hepatic 
gluconeogenesis resulting in increased glucose production (Pickup J and Wiliiams G 
1997). Fat cells also play an important role in the pathophysiology of glucose 
intolerance through multiple pathways. NEFAs are stored as triglycerides in 
adipocytes and serve as an energy store during fasting and when they become 
resistant to the anti-lipolytic effects of insulin (Groop LC et al. 1989), this leads to 
elevation of fasting plasma NEFA (Fraze E et al. 1985), in parallel with increasing 
hyperglycaemia. Chronic elevation of NEFA, in addition to stimulating hepatic 
gluconeogenesis (Ferrannini E et al. 1983), induces liver and muscle IR (Roden et al. 
1996) and also causes impairment of insulin secretion (Carpentier et al. 2000) 
referred to as lipotoxicity. Dysfunctional fat cells also secrete inflammatory, 
atherosclerotic adipocytokines which lead to IR (Bays et al. 2004), instead of 
secreting insulin-sensitising adipokines (e.g. adiponectin). Furthermore enlarged 
adipocytes become insulin resistant which decreases their ability to store fat, and this 
excess lipid finally leads to muscle and liver IR (Bays et al. 2004). Roy Taylor’s 
group stated the twin cycle hypothesis which postulated that a chronic positive 
caloric balance in the background of existing peripheral IR lead to hyperinsulinaemia 
and increase accumulation of intrahepatic triglyceride and start a vicious cycle of 
lipo and glucotoxicity (Taylor 2008) (Figure 1.3). They further state that, T2DM is a 
potentially reversible condition where sustained weight loss achieved by the 40% 
who responded to a very low calorie diet by achieving fasting plasma glucose of <7 
mmol/L led to  remission of DM for at least 6 months in (Steven et al. 2016). 
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Figure 1.3: Vicious cycle of lipo and glucotoxicity: During long-term excess calorie 
intake, especially in the presence of muscle insulin resistance, the raised plasma 
insulin levels will expedite chronic excess calorie storage from carbohydrate via de 
novo lipogenesis [Adapted from (White et al. 2016)]. 
.
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Increased glucose production by the liver contributes to fasting and postprandial 
hyperglycaemia, which are hallmarks of T2DM. An important feature of this 
pathologic response is impaired insulin action in the liver a result of impaired β-cell 
function and hepatic IR. Hyperglucagonaemia also plays an important role in 
dysregulated hepatic glucose production and consequent abnormal glucose 
homeostasis (Mitrakou A et al. 1992). Plasma glucagon concentrations are 
inappropriately elevated in diabetic subjects, and suppression of the pancreatic α-
cells by hyperglycaemia is blunted (D'Alessio D 2011). This leads to greater hepatic 
glucose production in the fasting state and attenuated reduction after meals. Studies 
in animal models show that reduction of glucagon action can mitigate effects of 
hyperglycaemia, even in the face of severe hypoinsulinaemia. Currently there are no 
definitive treatments for diabetic subjects yet available that act specifically on the 
glucagon signalling pathway but relatively newer agents including glucagon-like 
peptide-1 (GLP-1) receptor agonists inhibit plasma glucagon secretion and this 
possibly contributes to their action to lower blood glucose. 
  
Of note, insulin has anti-inflammatory and anti-oxidant properties which are intrinsic 
to the pathophysiology of DM. This has been well demonstrated by (Figure 1.4) 
Dandona et al.  (Dandona P et al. 2007). 
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Figure 1.4 Current view of the action of insulin. The anti-inflammatory, anti-
apoptotic, cardio-protective, and neuroprotective effects of insulin have been 
demonstrated in humans and in animal models. The vasodilatory, reactive oxygen 
species (ROS)–suppressive, antiplatelet, antithrombotic, and profibrinolytic effects 
have been demonstrated in humans. cAMP - cyclic adenosine monophosphate; CRP 
- C-reactive protein; eNOS - endothelial nitric oxide synthase; ICAM -  intracellular 
cell adhesion molecule; I_B _ inhibitor _B; MCP - monocyte chemo-attractant 
protein; NF-B - nuclear factor–B; NO - nitric oxide; PAI - plasminogen activator 
inhibitor; TF - tissue factor[Adapted from (Dandona P et al. 2007)]. 
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During normal glucose homeostasis, the pancreatic β-cell adapts to insulin resistance 
(IR) by enhancing insulin secretion. A curvilinear relationship exists between normal 
β-cell function and Insulin Sensitivity (IS) (Bergman RN 1989). When the β-cell is 
unable to adapt sufficiently, Impaired Glucose Tolerance (IGT) or T2DM develops 
(Figure 1.5). Studies on Pima Indians have reported that β-cell dysfunction is critical 
in the pathogenesis of T2DM (Weyer C et al. 1999 ) and β-cell dysfunction leading 
to abnormality in insulin secretion occurs early in the pathophysiology of DM and 
can often be demonstrated in 1
st
 degree relatives of subjects with T2DM, who have 
Normal Glucose Tolerance (NGT).  
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Figure 1.5: Hyperbolic relationship between β cell function and insulin sensitivity. 
In subjects with normal glucose tolerance a quasi-hyperbolic relationship exists 
between β-cell function and insulin sensitivity. With deviation from this hyperbola, 
deterioration of glucose tolerance occurs. Abbreviations: IGT, impaired glucose 
tolerance; NGT, normal glucose tolerance; T2DM, type 2 diabetes mellitus 
(Stumvoll M et al. 2008).  
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Reduced β-cell mass either through genetic and/or β-cell cytotoxic factors predispose 
to glucose intolerance. As the blood glucose level rises above normal, acquired 
defects in the glucose homeostasis system occur to further impair the β cell’s glucose 
responsiveness to meals. In response to an intravenous bolus of glucose, an 
impairment of the first phase insulin response is clearly evident in the pre-diabetic 
state of impaired glucose tolerance. The elevated blood glucose, in conjunction with 
the excess fatty acids, a typical feature of obesity and IR, causes additional 
deterioration in β-cell function progressing over time to overt DM (Leahy JL 2005). 
In the early setting of T2DM, there is an initial enhancement of β-cell 
function/secretion in response to the increased fasting and postprandial 
hyperglycaemia (Stumvoll M et al. 2003 Apr).  
 
Hovorka and colleagues examined newly presenting subjects with T2DM and found 
a close inverse relationship between β-cell responsiveness and FPG (Hovorka R et 
al. 2001) and showed that pancreatic responsiveness was reduced in the fasting state 
by approximately 50% and during meal simulation by approximately 80% (Hovorka 
R et al. 1998). The estimated β-cell function was impaired in subjects with normal 
body weight and a higher FPG (UK Prospective diabetes study group V 1988). 
Previously the UKPDS in addition reported a lower Insulin Sensitivity (measured by 
HOMA methodology) in obese, male, sedentary Caucasian subjects with newly 
diagnosed T2DM. On a similar note, Owens et al suggested a concentration-
dependent inhibitory effect of chronic fasting hyperglycaemia on the ability of the β-
cell to further respond to an acute increase in plasma glucose, following an 
intravenous glucose challenge. Thus these newly diagnosed Caucasian subjects with  
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T2DM were characterised by dysfunctional β-cell function, resulting in a 
quantitative and qualitative deficit in insulin secretion, accompanied by a relative 
hyper-proinsulinaemia (Owens DR et al. 1996) Proinsulin is increased in the fasting 
and postprandial state in the earlier stages of diagnosis but at the later stages of 
T2DM this falls. 
 
DeFronzo et al. reported that the upper tertile of individuals with NGT have a 50% 
decline in β-cell function.  However, subjects in the upper tertile of IGT are 
maximally/near-maximally insulin resistant, have lost 70–80% of their β-cell 
function (Ferrannini E et al. 2005; Abdul-Ghani MA et al. 2006a; Abdul-Ghani MA 
et al. 2006b) and have approximately a 10% incidence of DR. Therefore, 
preservation of the remaining 20–30% of  β-cell function is critical to prevent future 
development of T2DM (DeFronzo RA and Abdul-Ghani MA 2011). Maneschi et al 
has also shown that in subjects with T2DM, the residual β-cell function is important 
for the degree of diabetic control but failed to establish a direct relationship between 
the degree of insulin deficiency and presence of diabetic microangiopathy (Maneschi 
F et al. 1982). 
 
The current epidemic of obesity leads to a state of IR and causes stress on the β cells 
to enhance insulin secretion to overcome the state of IR with normal glucose 
tolerance, maintained as long as β-cell compensation is viable. However, with 
progression of time, β cells are unable to offset the effects of IR with further 
enhancement of insulin secretion, and initially postprandial plasma glucose and then 
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fasting plasma glucose levels increase leading to a diagnosis of T2DM. Therefore, it 
is progressive β-cell failure that predicts the rate of progression of T2DM. This has 
been illustrated by the Starling’s Curve of the Pancreas (DeFronzo et al. 2013) by 
DeFronzo et al. The plasma insulin response depicts the classic ‘Starling’s Curve of 
the Pancreas’ and is illustrative of the natural history of T2DM (Figure 1.6). In 
summary, increased insulin resistance is important in the early stages of T2DM; 
however there is relentless decrease in β-cell function across the whole spectrum of 
T2DM. 
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Figure 1.6  Starling’s Curve of the Pancreas (DeFronzo et al. 2013) shows the 
progressive increase of mean plasma glucose during the OGTT from lean NGT to 
obese diabetic subjects. The rise and fall in the mean plasma insulin reflects the 
early β-cell compensation followed by β-cell exhaustion. The insulin-mediated 
glucose uptake in these subjects shows a steady initial decline and then a 
significantly reduced basal steady state which is illustrative of the natural history of 
T2DM. The two white arrows are indicative of the transition point from IGT to 
T2DM in these parameters. (NGT: Normal Glucose Tolerance, IGT: Impaired 
Glucose Tolerance, OB:  Obese, Diab: Diabetes Ins: Insulin) 
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The defects in glucose homeostasis that occur as the diabetes metabolic environment 
evolves were first identified by studies showing that in intensively-treated subjects 
with T2DM, when blood glucose values were brought as close to normal as possible, 
improved β-cell function was noted (Turner RC et al. 1976), with later studies also 
showing some reversal of IR. This reversal effect is unrelated to the type of 
treatment—it does not matter how the glucose level is lowered (Kosaka K et al. 
1980), and is most effective early in the course of the disease. Several studies have 
shown substantial recovery of glucose tolerance after short-term insulin infusions or 
high dose sulfonylurea therapy in newly diagnosed subjects with T2DM (Peters AL 
and MB. 1996; Li Y et al. 2004). However Weng et al. showed that early intensive 
insulin therapy in subjects with newly-diagnosed T2DM has better outcomes on the 
recovery and maintenance of β cell function and sustained glycaemic remission 
compared with subjects who were treated with Oral Hypoglycaemic Agents (OHA) 
(Weng J et al. 2008). 
 
Monnier et al. demonstrated that the deterioration of glucose homeostasis in subjects 
with T2DM progressed from postprandial to fasting hyperglycaemia following a 3 
step process. The 1
st
 step related to the three diurnal post-meal periods considered as 
a whole the 2
nd
 step occurred during the morning period, and the 3
rd
 and final step 
corresponded to sustained hyperglycaemia over the nocturnal fasting periods. This 
describes the key stages in the evolution of T2DM (Monnier L et al. 2007). 
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In T2DM, hyperglycaemia results in enhanced oxidative stress due to the formation 
of excess reactive oxygen species (ROS) formation leading to β-cell damage i.e. 
glucose toxicity (Owens DR et al. 1996). Normally β cells have only low amounts of 
catalase and superoxide dismutase, proteins which metabolize ROS (Robertson RP et 
al. 2003). ROS activate NF-kB, which is pro-apoptotic. It has also been observed in 
an animal model of diabetes that pancreas duodenum homeobox-1 (PDX-1), a 
regulator of insulin gene transcription, is diminished by hyperglycaemia, another 
possible mechanism of “glucose toxicity.” In addition, altering uncoupling protein-2 
(UCP-2) by high glucose leads to uncoupling of oxidative glucose metabolism from 
ATP formation in the mitochondrion resulting in lower ATP (Patane G et al. 2002) 
and consequently reduced insulin secretion. 
 
Although free fatty acids (FFA), also termed NEFA, can acutely increase insulin 
secretion, chronic FFA overload diminishes β-cell function. T2DM subjects often 
have increased FFA due to IR to (adipocyte) lipolysis. This FFA increases linearly 
with Fasting Plasma Glucose (FPG). It is now clear that high glucose inhibits β-cell 
fatty acid oxidation, which may lead to accumulation of long-chain coenzyme A 
(LC-CoA) (Robertson RP et al. 2004). This has been suggested to interfere with 
normal potassium channel activity, or to lead to activation of UCP-2, which would 
lead to uncoupling of oxidative glucose metabolism from ATP formation in the 
mitochondrion leading to lower ATP. 
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To reiterate one of the most controversial topics within the field of T2DM over many 
years - is this disease of IR or β cell dysfunction? The confusion for many years was 
that once T2DM and even IGT had been diagnosed, both defects were invariably 
present. Attempts to investigate earlier in the course of the disease by studying 
individuals at high-risk who were still normoglycaemic, high-risk ethnic groups such 
as Pima Indians, those whose parents both had T2DM, and women who previously 
had had gestational DM - often reported that IR was present, but not β-cell 
dysfunction (Martin BC et al. 1992), concluding that IR was the initial (and thus 
dominant) defect in this disease in these population groups. 
 
However, these early studies based their conclusions regarding unimpaired β-cell 
function on experimental techniques that were generally misinterpreted. IR was 
relatively easily measured by several methods - glucose clamping that is labour 
intensive and usually only done with a limited number of subjects, or several 
computer models that could be done with large groups. In contrast, the assessment of 
β-cell function is much more complex. The insulin response to intravenous glucose 
normally occurs in a biphasic pattern and the amount of insulin released is highly 
responsive to the prevailing glucose value. As glucose tolerance moves from normal 
to minimally impaired, the insulin secretion that occurs within the first 30 minute of 
eating (first phase) becomes markedly attenuated, resulting in an elevated prandial 
rise in glycaemia, i.e., this is the physiologic definition of impaired glucose 
tolerance. It is this postprandial hyperglycaemia that causes the insulin secretion 
after the first 30 minute (second phase) to be higher as a compensatory response 
during the relatively early stages of T2DM. The early studies typically assessed β-
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cell function by measuring the insulin value pre and 2 hours after a meal. 
Consequently, it was concluded, based on the 2-hour insulin value being higher than 
normal, that there was no β-cell dysfunction in the early stages of T2DM; thus IR 
only was assumed to be responsible for the supernormal 2 hour insulin value. This 
misinterpretation was eventually corrected by studies that also measured 30-minute 
post-meal insulin values, or acute insulin responses to intravenous glucose, and 
showed that defective early phase insulin secretion occurred before the onset of 
T2DM (Perley MJ and DM. 1967; Gerich JE 1998).  
 
More informative were large cross-sectional and natural history studies in terms of 
the relative importance of β-cell dysfunction versus IR in this disease. They 
confirmed the findings of the earlier studies that IR occurs early in the disease, 
typically when glucose values are still within the normal glucose tolerance range. 
The reason is multifactorial - in some related to a genetic abnormality that affects 
insulin sensitivity, and others from lifestyle factors such as obesity, lack of exercise, 
high-fat diets, aging, etc. Thereafter, however, IR does not change much - once 
present, it remains present. Thus, it is not worsening of IR that causes blood glucose 
values to go from normal to IGT to T2DM, but worsening of β-cell function. The 
natural history studies of T2DM invariably reported a biphasic pattern of β-cell 
function, hyperinsulinaemia early on maintaining blood glucose values normal to 
mildly impaired, and then a falling insulin level (so-called β-cell failure) resulting in 
rising glycaemia (Lillioja S et al. 1988; Lillioja S et al. 1993), (Starling Curve of the 
Pancreas). As glycaemia starts to rise, the acquired β-cell dysfunction occurs 
(defective first phase insulin secretion), and glycaemia worsens even more, often to 
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overt T2DM. Thus, whereas IR is an important contributory pathogenic element in 
T2DM, current dogma is that the β-cell determines the level of glycaemia in 
individuals who are genetically at risk for T2DM.    
 
It was argued some years ago that IR caused the β-cell failure through exhaustion, 
i.e., continued stimulation of an otherwise normal β-cell eventually causes it to 
become permanently dysfunctional. However, that concept does not fit the facts. 
Many highly insulin-resistant subjects never get T2DM; only about a third of 
morbidly obese subjects and a third of those with Cushing’s disease or acromegaly 
develop T2DM. Also, puberty, pregnancy, and aging are periods of profound IR — 
most of us do not get T2DM because our β cells are able to continuously 
compensate. Thus, it seems that a necessary part of T2DM is a compromised β-cell 
compensatory ability and many consider the disease to be a failure of β-cell 
compensation (Cavaghan MK et al. 2000; Ehrmann DA et al. 2004) or an inability to 
sustain an adequate  β-cell response in the face of increasing insulin resistance. 
 
The most recent studies have returned to the question of which comes first, IR or β 
cell dysfunction, because of development of more precise experimental techniques to 
assess β-cell function. One of the most utilized is the disposition index, which is 
based on the principle that β-cell function normally varies dependent on the degree 
of insulin sensitivity, i.e. the insulin response to a meal or other stimulus in an 
insulin-sensitive person such as a marathon runner is normally considerably less than 
for normoglycaemic IR subjects. The curve of this relationship is hyperbolic 
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(Bergman RN et al. 1981; Kahn SE et al. 1993) and is called the disposition index. It 
is important to realize everyone goes through times of IR (puberty, pregnancy, 
aging), but most do not get T2DM because of β-cell compensation.  
 
IR is an early and characteristic feature of the natural history of T2DM in high-risk 
populations but overt T2DM develops only when the β cells are unable to 
appropriately augment their insulin secretion to compensate for the defect in insulin 
action. Furthermore there is an insulinopaenic group of subjects with T2DM (more 
common in south African populations (Joffe BI et al. 1992) and Swedish middle 
aged men (Grill V et al. 1999) whose insulin sensitivity is normal at the onset of 
T2DM, whereas insulin secretion is severely impaired (De Fronzo RA 2004). 
 
Thus in summary, even when blood glucose levels are minimally above normal in 
the pre-diabetes stage then the glucose responsiveness of the β-cell to a carbohydrate 
challenge is impaired. As glucose intolerance progresses in the presence of excess 
fatty acids, a typical feature of obesity and insulin resistance, then β-cell function 
deteriorates even further to overt DM (Leahy JL 2005). 
 
The chronic state of hyperglycaemia caused by both IR, and relative impairment in 
insulin secretion leads to long-term complications affecting various organ systems in 
the body. They can be divided into those affecting larger blood vessels 
(macrovascular) and smaller blood vessels (microvascular). The former include 
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Coronary Artery Disease, Cerebrovascular and Peripheral Vascular Disease while 
the latter involves Retinopathy, Nephropathy and Neuropathy.  
 
Most of the mortality and morbidity of DM arise from these complications and lead 
to the financial burden on the National Health Service (NHS). 10% of the NHS 
budget for England and Wales is spent on DM, which is an estimated 14 billion 
pounds of which 11.7 billion pounds relates to T2DM (Kanavos P et al. 2012). The 
St. Vincent declaration published in 1989 (Diabetes Care and Research in Europe 
1989), by the World Health Organisation (WHO) in collaboration with the European 
Association for the Study of Diabetes (EASD), set down targets for improvements in 
diabetes care including reductions in the incidence of complications. The aims of the 
St. Vincent declaration included a 30% reduction in the incidence of new-onset 
blindness, a 30% reduction in the incidence of renal failure and a 50% reduction in 
the number of major amputation (Diabetes Care and Research in Europe 1989).  
 
1.2 Diabetic Retinopathy 
Recent analysis suggests that there are approximately 93 million people with 
Diabetic Retinopathy (DR), 17 million with proliferative DR, 21 million with 
diabetic macular oedema, and 28 million with vision-threatening DR worldwide 
(Yau et al. 2012). DR is the most common and feared microvascular complication of 
DM and was until recently regarded as the most prevalent cause of visual 
impairment in the working-age (16-64 years) population in developed countries 
(Heng LZ et al. 2013) (Bunce C and Wormald R 2008). However, a recent report has  
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indicated that in the United Kingdom (UK), DR has been overtaken by inherited 
retinal conditions as the leading cause of blindness in the working age group which 
the authors suggested was possibly a result of DR screening programmes and 
improved diabetes care (Liew G et al. 2014). Liew et al. further report that there has 
been a reduction in certified blindness from retinopathy/maculopathy from 17.7 % in 
1999-2000 to14.4 % in 2009-2010. Thus the setting up of the screening services has 
led to a positive outcome though the St. Vincent declaration had not been met. 
 
The early detection and treatment of modifiable risk factors known to influence its 
onset and progression is imperative. Approximately 17-18% of subjects with T2DM 
have DR at presentation, 40-60% have some DR after 20 years of known DM 
duration, with 10% developing sight threatening lesions e.g. proliferative DR and/or 
exudative maculopathy (Stefansson E et al. 2000). Diabetic maculopathy is the 
commonest cause of visual loss in individuals with DM due to the much higher 
proportion of individuals with T2DM.  
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Figure 1.7: Cross sectional diagram representing the internal structure of the eye 
(Gupta D) showing the structures in the anterior and posterior chamber of the eye 
with the fovea and macula located at the posterior pole. 
 
28 
 
A cross sectional diagram representing the internal structure of the eye is shown in 
Figure 1.7. In it we see the retina, which is the inner-most, light sensitive layer of the 
eyeball at the back of the eye. It gathers light, codes the information as an electrical 
signal and transmits it via the optic nerve to the processing area of the brain 
(Denniston AKO and Murray PI 2014). It is supplied by numerous small blood 
vessels and contains photoreceptors which are light-sensitive cells. The retina 
consists of 95% of neural tissue and 5% vascular tissue (Figure 1.8) It is essentially a 
neurovascular unit comprising the layers depicted (Figure 1.8) (Antonetti DA et al. 
2012a). This neural retina is a thin (150-400 microns) layer of transparent neural 
tissue continuous with the non-pigmented layer of the ciliary body anteriorly. The 
retina comprises photoreceptors (rods, cones), integrators (bipolar, horizontal, 
amacrine, ganglion cells), an output pathway (nerve fibre layer) and support cells 
(Muller cells). On histological examination, the retina is typically divided into 
multiple layers: three layers mainly contain nuclei (outer/inner nuclear layers and 
ganglion cell layer) and two layers mainly contain synaptic connections (outer and 
inner plexiform layers) (Denniston AKO and Murray PI 2014). 
 
The macula is an oval-shaped pigmented yellow spot near the center of the retina of 
the eye. It has a diameter of around 6 mm and near its center is the fovea, which is a 
small pit that contains the largest concentration of cone cells/photoreceptors in the 
eye and is responsible for central and high resolution vision (Kanski JJ and Bowling 
B 2011). A transparent, jelly-like substance that forms the main bulk of the eyeball is 
the vitreous humour. It maintains the shape of the eye and also refracts light onto the 
retina. 
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Figure 1.8 The neurovascular unit of the retina (Antonetti DA et al. 2012a) 
showing the various nerve fibre, vascular and cellular layers. 
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Diabetic macular changes in the form of yellowish spots and full or partial thickness 
extravasations through the retina were observed for the first time by Eduard Jäger 
(Wolfensberger TJ and Hamilton PA 2001 ) and published in 1855. Jaeger’s findings 
were not accepted until 1872, when Edward Nettleship published his paper “Oedema 
or cystic disease of the retina,” providing the first histopathological proof of “cystoid 
degeneration of the macula” in subjects with DM (Nettleship E 1872 ). Soon 
afterwards in 1876, Wilhelm Manz described proliferative vascular changes and the 
importance of tractional retinal detachments and vitreous haemorrhages in 
individuals with diabetes (Manz W 1876 ). Arthur James Ballantyne in 1943 
demonstrated that DR represents an unique form of vascular disease (Ballantyne AJ 
and Loewenstein A 1943 ). In T1DM early changes appear by five years post 
diagnosis; however, in T2DM, DR was diagnosed in about 19% during the 1
st
 year 
after DM diagnosis in UK general practices (Kostev K and Rathmann W 2013). 
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DR is mainly a lesion of the retinal capillaries. Prior to the development of any 
clinically visible lesions, histological changes appear i.e. basement membrane 
thickening, death of pericytes which leads to the formation of microaneurysms 
(Figure 1.9), loss of vascular smooth muscle cells and endothelial cell proliferation.  
Microaneurysms are the earliest ophthalmoscopically visible lesion in persons with 
diabetes regarded as pathognomonic of diabetes (Figure 1.9). These earliest lesions 
are seen only on fluorescein angiograms, which show up as small areas of non-
perfusion. Fluorescein angiography demonstrates areas of non-perfusion and the 
presence of microaneurysms (Figure 1.11). The response to non-perfusion of some 
capillaries (Figure 1.10) is dilatation of others (Kohner EM 1993). When dilatation is 
localised, as more commonly seen, a microaneurysm forms, but dilatation can be 
generalised, and this is more commonly seen at the posterior pole in the macular 
region.  
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Figure 1.9: Retinal vasculature changes depicting early DR i.e. pericyte loss and 
microaneurysms. Black arrows: microaneurysms. 
 
Figure 1.10: Retinal vasculature changes depicting early DR i.e. retinal capillary 
closure leading to non-perfusion and thus to ischaemia. Black arrows: Upper right 
panel: microaneurysms, Lower right panel: pericyte loss. 
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Figure 1.11: Fluorescein angiogram with microaneurysms fluorescing (Goatman K 1997) 
 
 
 
Figure 1.12: Retinal vasculature changes depicting DR i.e. excessive capillary permeability leading 
to retinal oedema and hard exudate formation. Black arrows left panel: leakage. Black arrows 
right panel: retinal oedema. Lower right panel: High resolution image of intraretinal cyst 
formation leading to retinal oedema. 
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Dilated capillaries are usually incompetent and leaky. This leakage from a reduced 
number of dilated capillaries leads to exudative and oedematous forms of the sight-
threatening diabetic macular oedema (Figure 1.12). With increasing number of 
capillaries becoming occluded the larger vessels become affected. As arteries are 
involved, there is always a large area of capillary non-perfusion. When this occurs 
suddenly, cotton wool spots are formed; when it occurs gradually, only a featureless 
atrophic retina is visible (Kohner EM 1993). Large blot haemorrhages usually form 
at the interface of the perfused and ischaemic areas of the retina. Dilated capillaries 
are seen in this largely avascular area and are known as intra-retinal microvascular 
abnormalities (IRMAs).  These are commonly found near ischaemic cotton wool 
spots, which remain as dilated capillaries or progress to form new vessels 
(neovascularisation), especially when present together with other lesions, that 
include abnormal dilatation and beading of the veins. Whereas venous dilatation 
occurs relatively early in DR and is non-specific, the formation of venous tortuosity 
in the form of loop formation, beading, and reduplication indicates severe retinal 
ischaemia in the surrounding retina which causes dilatation (Kohner EM 1993). This 
constellation of lesions suggest imminent new vessel formation, which represents the 
stage of Pre-proliferative Diabetic Retinopathy (PPDR)  
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The next stage of development is the appearance of new vessels (Proliferative DR) is 
usually formed from veins initially in the more ischemic retinal periphery or on the 
optic disc. The new vessels themselves do not cause visual symptoms; it is bleeding 
from the new vessel that is responsible for visual impairment in most subjects with 
T1DM. They arise secondary to large areas of ischaemia under the influence of 
VEGFs. When the new vessels break through the internal limiting membrane they 
become attached to the posterior surface of the vitreous, which they utilise as a 
scaffold upon which to further proliferate (Kohner EM 1993). The retracting vitreous 
then pulls on these newly-formed friable blood vessels causing pre-retinal 
haemorrhage. In response to the bleeding and the formation of fibrous tissue, retinal 
traction and detachment may occur. The visual loss related to these is sudden and 
unexpected. This sudden visual loss is in contrast to the visual loss seen in diabetic 
macular oedema, where vision fails gradually with fluid accumulating at the fovea. 
Patients with T1DM may lose vision from macular oedema, but this is occasionally 
profound or (especially when associated with renal failure) causes blindness (Kohner 
EM 1993). In older T2DM subjects, macular oedema is associated with ischaemia or 
extensive formation of hard exudates and is the main cause of visual loss due to DR. 
Individuals with mild-to-moderate Non-proliferative DR (NPDR) have impaired 
contrast sensitivity and visual field defects that cause difficulty with driving, reading, 
and managing diabetes and other activities of daily living. Visual acuity, as 
determined with the use of Snellen/Log MAR charts, declines when the central 
macula is affected by oedema, ischemia, epiretinal membranes, or retinal detachment 
(Antonetti DA et al. 2012a). The various stages of DR are summarised in Fig 1.13 
and evolution of Diabetic Retinopathy in Fig 1.14. 
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Stages of Diabetic Retinopathy
Stage Pathogenesis Cause of Blindness
Ischaemic
Proliferative
Fibrotic
Capillary leakage, macular 
oedema and  haemorrhages
Vitreous hemorrhage
Traction included 
retinal detachment
Small vessel occlusion
Ischaemia, pericyte 
degeneration (micro aneurysms 
and arteriovenous shunts)
Angiogenesis factor occlusion 
Neovascular proliferation
Protein leakage
Vitreous fibrosis, attachment 
to retina, and contraction
 
 
Figure 1.13: Represents the stages associated with Diabetic Retinopathy in relation 
to the underlying pathogenesis and the associated possible causes of blindness. 
[Adapted from (https://diabetesalert.wordpress.com/2014/05/25/stages-of-diabetic-
retinopathy/)].
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Hyperfusion
Vasoactive factors
Retinal ischaemia
Capillary              
non-perfusion
Endothelial damage
Capillary damage
Pericyte loss
(capillaries and veins) 
Growth
factors
New
vessels
Abnormal
autoregulation
 
 
Figure 1.14: Evolution of Diabetic Retinopathy: Adapted from (Kohner EM 1993). 
The highlighted boxes represent the key stages in the pathogenesis of DR (A detailed 
schematic representation is shown in Figure 1.25) 
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Classification of DR used in this thesis was based on the Diabetic Retinopathy 
Screening Service for Wales (DRSSW) grading protocol (Table1.1), which is an 
enriched version of the UK National DR grading protocol (Harding S et al. 2003).  
Classification was as follows:  
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8181Table 1.1: Grading Protocol for the Diabetic Retinopathy Screening Service for 
Wales  
R0 No Diabetic Retinopathy 
R1 Background Diabetic Retinopathy (BDR) 
R1.1 Mild BDR 
 < 5 Mas > 1 DD from fovea  
 < 4 Hms > 1 DD from fovea 
 3 Mas < 1 DD from fovea 
 ≤ 3 MA < 1 DD from fovea with VA better than 6/12 
 exudates > 2 DD from fovea with or without CWS (< 5) 
R1.2 Moderate BDR 
 ≥ 5 MAs > 1 DD from fovea  
 ≥ 4 < 8 HMs > 1DD from fovea  
 > 3 MAs < 1 DD from fovea with VA > 6/12 
 Circinate or grouped exudates > 2 DD from fovea but within arcades 
 Questionable IRMA only in the presence of MA/HM  
R2 Severe BDR (Pre-Proliferative DR, PPDR) 
 ≥ 8 blot haemorrhages per eye (superior and inferior hemi-fields) 
 Venous irregularities, beading, reduplication, venous loops (but not on their own) 
 Definite IRMA 
 With or without CWS (but not CWS on their own) 
R3 Proliferative DR (PDR)/Advance Diabetic Eye Disease (ADED) 
 New vessels on disc (NVD) 
 New vessels elsewhere (NVE) 
 Pre-retinal haemorrhage 
 Vitreous haemorrhage 
 Pre-retinal fibrosis 
 Traction retinal detachment 
M0 No Maculopathy 
M1 
 
 
Possible Maculopathy 
 Exudates < 2 DD >1DD from fovea 
 > 3 Mas <1 DD from fovea with VA < 6/12 
 Hm < 2DD from fovea 
M2 Definite Maculopathy 
 Exudates < 1 DD from fovea 
 Retinal thickness changes < 1 DD from  
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Normal retina
1 Disc 
Diameter
2 Disc 
Diameter
1 Disc 
DiameterFovea
Macula
 
 
Figure 1.15: Normal Retina (Right Eye) 45 degree field with the fovea as a 
depression in the retinal surface at the centre of the macula. 
Figures 1.15 to 1.19 illustrate the normal retina and the different grades of severity of 
DR.
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Left Eye
Microaneurysms –
Pathognomonic of DR
microaneurysms
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Figure 1.16: Background DR Pathologic processes: multiple microaneurysms, 
early exudates and blot haemorrhage 
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Figure 1.17: Pre-proliferative DR Pathologic processes: multiple blot and flame 
haemorrhages, cotton wool spots and hard exudates.  
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Proliferative Diabetic Retinopathy (PDR)
(Severe active– Sight threatening)
New vessels on the disc
Fluorescein angiogram 
Intra-retinal blot 
haemorrhages
 
 
Figure 1.18: Proliferative DR Pathologic processes: Proliferation of new blood vessels 
and  intra-retinal blot hemorrhages 
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Figure 1.19: Extensive Maculopathy including exudative changes Pathologic 
processes: Excessive vascular permeability 
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The WHO’s first Global Report on diabetic retinopathy has reported that about 8.5% 
of adults globally have DM (World Health Organization 2016). Thus, diabetic 
macular ooedema (DME) and PDR have increased and cause Visual Acuity (VA) 
loss, leading to approximately 2.6% of cases of global blindness in 2010 (Bourne RR 
et al. 2013; World Health Organization 2016).  However the leading cause 
worldwide in 2010 for blindness remained cataract (33%) with uncorrected refractive 
error (21%), and macular degeneration (7%) following suit and for moderate and 
severe vision impairment were uncorrected refractive error (53%), cataract (18%), 
and macular degeneration (3%) (Bourne RR et al. 2013). 
 
Over the last few decades, development of clinically significant DME or PDR 
represented a threshold for administering ocular-specific treatment, with laser 
therapy being the main treatment for both. Laser treatment for DME minimises the 
risk for progressive visual loss by about 50% (Early Treatment Diabetic Retinopathy 
Study Research Group 1991a), and application of appropriate Pan Retinal 
Photocoagulation (PRP) for PDR (Figure 1.19 b) minimises the risk for severe vision 
loss (The Diabetic Retinopathy Study Research Group 1981). Diabetic Retinopathy 
Study (DRS)  (Diabetic Retinopathy Study Group 1978) and the Early Treatment 
Diabetic Retinopathy Study (ETDRS) (Early Treatment Diabetic Retinopathy Study 
Research Group 1985) showed the beneficial effects of retinal photocoagulation, 
which significantly reduced the severe visual loss due to PDR and DME (Figure 1.20 
a, b) and these studies led to guidelines (The Royal College of Ophthalmologists 
2012) and screening programs for the timely detection and treatment of DR. 
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Since the initial studies it has been shown that when DR approaches PDR, PRP 
should proactively be considered to prevent progression to high risk PDR. In ETDRS 
very severe NPDR (ETDRS 53E) had a 48.5% risk of progressing to high risk PDR 
within 1 year and recommendations stated that even where follow-up was possible 
PRP treatment should be considered in these eyes because they showed increased 
risk of severe visual loss and need for vitrectomy (Davis MD et al. 1998b). Earlier 
laser has been recognised to prevent progression to high risk DR, and that PDR has 
higher risk of blindness was reported in both DRS and ETDRS. However the balance 
of risks with laser modalities available at that time meant that laser intervention was 
recommended only when DR approached high risk PDR. With modern laser 
techniques, PRP is often done before the development of PDR (Lövestam-Adrian M 
et al. 2003). 
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Figure 1.20: Appearance of retina after photocoagulation treatment a) Scatter 
Photocoagulation b) Pan-retinal Photocoagulation with new vessel formation (white 
arrows) on the disc (NVD) and elsewhere (NVE) 
(https://upload.wikimedia.org/wikipedia/commons/3/3f/Fundus_photo_showing_scat
ter_laser_surgery_for_diabetic_retinopathy_EDA09.JPG) 
 
a)                                               b)                                         c) 
 
Fig 1.21: Types of Retinal Photocoagulation (a) Focal treatment is used to treat 
macular oedema due to focal leakage b) Grid treatment is used to treat macular 
oedema due to diffuse leakage c) Pan-retinal treatment may be used to treat PPDR 
and PDR (http://www.theeyepractice.com.au/optometrist-
sydney/eyes_diabetes_diabetic_retinopathy_and_possible_treatments) 
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Although laser treatment is a recognised therapy for DME, its efficacy may be 
limited and it may have untoward effects. Macular laser treatment for DME may not 
improve VA (Elman MJ et al. 2010; Nguyen QD et al. 2012; Korobelnik J.F et al. 
2014) and Pan Retinal Photocoagulation can also lead to peripheral visual field 
defects, night-visual impairment, and reduction of contrast sensitivity. Often 
additional PRP is needed in 45% of patients with DME and vitrectomy in about 5% 
of cases (Ferris F 1996; Gross JG et al. 2015).   
 
Inhibitors of vascular endothelial growth factors (VEGF) (Ranibizumab, 
Bevacizumag, Aflibercept) administered directly into the eye via intravitreal 
injection block the activity of vascular endothelial growth factors. These agents have 
revolutionized the treatment of DME and PDR over the past 10 years and in many 
subjects treatment has changed dramatically from laser to medical options. 
Randomized controlled trials have reported that anti-VEGF agents are effective for 
treating both centre-involved DME leading to VA loss (Nguyen QD et al. 2012) 
(Korobelnik J.F et al. 2014; Wells JA et al. 2015) and less severe stages of PDR 
(Gross JG et al. 2015) used in combination with laser treatment. 
 
Starting ocular-specific treatments at earlier stages of DR is now advocated as it is 
clinically relevant to treat in earlier stages of DR from patients' perspective. DR 
severity graded by the Diabetic Retinopathy Severity Scale (DRSS) (Early Treatment 
Diabetic Retinopathy Study Research Group 1991b) indicate that worsening of two 
or more steps on the DRSS leads to an increased risk for subsequent vision loss 
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(Klein R et al. 2001). Thus for diabetic subjects when an eye has developed DME or 
PDR, the patient has possibly already had a significant decrease in his/her visual 
function. 
 
Anti-VEGF pharmacologic agents currently used to treat DME (Diabetic 
Retinopathy Clinical Research Network et al. 2015) and milder forms of PDR 
(Writing Committee for the Diabetic Retinopathy Clinical Research Network et al. 
2015) show additional benefits in substantially altering the natural history of 
progressive DR which worsening over time.  The treatment slows progression to 
more advanced DR stages, improving DR status in many eyes and slowing the 
underlying disease process central to DR itself, which is progressive retinal non-
perfusion. Population-based analyses and clinical trial data show that the threshold to 
initiate ocular-specific anti-VEGF treatments for DR is being lowered to earlier 
stages of DR such as severe BDR/ PPDR . 
 
Subjects with recently diagnosed T2DM have a much lower life time risk of PDR, 
macular oedema, and visual impairment as compared with patients from earlier 
periods (Kempen JH et al. 2004 Apr; Sloan FA et al. 2008 Nov; Klein R and BE. 
2010). This reduction may reflect improved management of glycaemia, blood 
pressure, and lipid levels (Klein R and BE. 2010). These improvements have resulted 
from the introduction of new devices for self-monitoring of blood-glucose levels and 
the administration of insulin, new medications (e.g., statins and hypoglycaemic 
agents), surgical interventions (including vitrectomy), an increased awareness of the 
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need for intensive control of glycaemia and blood pressure, and the implementation 
of educational and screening programs.  
 
1.3 Risk factors affecting diabetic retinopathy     
Various risk factors associated with the development and progression of DR include 
non-modifiable factors like duration of DM (Klein R et al. 1984; Zhang X et al. 
2010),  and modifiable risks like hyperglycaemia (Klein R et al. 1984; Kohner EM et 
al. 1998; UK Prospective diabetes study group (UKPDS) 1998; Zhang X et al. 
2010), hypertension (Klein R et al. 1984; Klein R et al. 1989b; Kohner EM et al. 
1998; UK Prospective Diabetes Study Group 2004), dyslipidaemia (Chew EY et al. 
1996; Cusick M et al. 2003) and BMI (Klein R et al. 1984)  
 
1.3.1 Hyperglycaemia 
Pirart conducted a large prospective survey on 4440 patients between 1947 and 
1973, including 2795 patients from diagnosis of DM with metabolic control being 
monitored by a urine glucose score. It provided strong early evidence that poor 
glycaemic control was associated with an increased risk of DR (Pirart J 1977 Dec,). 
The association between chronic hyperglycaemia and retinopathy has been studied in 
detail with a review by Colwell in the 1960’s commenting on the association 
between poor glycaemic control and retinopathy (Colwell JA 1966 Jul). Similarly, 
another review by Knowles (Knowles HCJr 1964) also commented on the 
relationship between dysglycaemia and  microvascular disease.  
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Introduction of home blood glucose monitoring and assessment of glycaemic 
control, led to keynote prospective studies to explore the relationship between 
glucose control and diabetes complications. The Diabetes Control and Complications 
Trial (DCCT) in Type 1 DM (The Diabetes Control and Complications Trial 
Research Group 1993 Sept 30) and the UK Prospective Diabetes (UKPDS) in T2DM 
(UK Prospective diabetes study group (UKPDS) 1998) have both provided definitive 
evidence that microvascular complications of DM are reduced by improved 
glycaemic control. The UKPDS and DCCT, along with their 10-year follow-up, have 
further demonstrated the benefits of early and sustained improvement in glycaemic 
control with respect to DR (The Diabetes Control and Complications 
Trial/Epidemiology of Diabetes Interventions and Complications Research Group 
2000 Feb; Holman RR et al. 2008) i.e. the legacy effect/metabolic memory. 
 
One of the major effects of chronic hyperglycaemia of DM is enhanced 
glycosylation of proteins. Glucose binds (irreversibly) to tissue proteins leading to 
structural and chemical changes in their properties leading to the formation of 
advanced glycosylation end products (AGE) (Brownlee M et al. 1988 May 19 ). 
HbA1c (Haemoglobin A1c) being one such glycosylated protein is used to monitor 
chronic blood glucose control in DM. Red blood cells (RBC) contain haemoglobin 
which, in the presence of glucose in the plasma, is constantly glycosylated to HbA1c. 
The lifespan of RBC is approximately 120 days, and the rate of glycosylation 
depends on the blood glucose concentration over this time period. Thus the level of 
HbA1c indicates the average glycaemia over the previous 3 months (average age of 
RBC) (Krall LP and RS. 1989). However, to be more specific, about 50% of the 
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HbA1c represents  the glycaemic exposure over the preceding month with 25%  in 
the 2
nd
 month prior to the HbA1c  measurement and the final 25% over the 3
rd
 month 
prior to the HbA1c monitoring (Tahara Y and Shima K 1993). Other conditions 
related to haemoglobinopathy and haemolysis is also known to affect the integrity of 
the HbA1c measurement, as the red cell turnover increases and thus the amount of 
glycosylated haemoglobin is decreased.  
 
It is believed that tissue damage from glycosylation leads to both microvascular and 
macrovascular complications of DM (Andreani D et al. 1991; Brownlee M 1992 
Dec,). AGE accumulation in proteins renders significant structural and functional 
changes to the vascular system. Collagen also manifests these morphological 
changes as glycosylated collagen. The accumulation of AGE leads to generation of 
reactive oxygen species, which trap soluble proteins such as albumin and 
immunoglobulin G (Figure 1.22). When these proteins are trapped by glycated 
collagen, they retain their ability to form immune complexes in situ which may 
explain the characteristic diabetic tissue changes i.e. thickening of the capillary 
basement membrane in the retina and kidney (Creutzfeldt W and Lefebvre P 1988). 
Capillary basement membrane thickening, endothelial cell proliferation and capillary 
closure are some initial changes of DR (Ashton N 1974; Kohner EM 1993). The 
binding of AGE to endothelial cells increases permeability (Esposito C et al. 1989) 
and leads to capillary leakage in the retina (Antonetti DA et al. 2012b). Fluorescein 
angiography was the first technique to document the abnormal leakage of fluorescein 
through the retinal vessels (Cunha-Vaz JG and Maurice DM 1967). The technique is 
still used in the diagnosis and aids in the management of DR. 
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Figure 1.22: Formation of advanced glycation end products (AGEs) [Adapted from 
(Tarr JM et al. 2013)] Glucose irreversibly binds to tissue proteins leading to 
structural and chemical changes in their properties. This leads to the characteristic 
diabetic tissue changes i.e. thickening of the capillary basement membrane in the 
retina. 
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Hyperglycaemia also leads to the activation of the polyol pathway of glucose 
metabolism (Andreani D et al. 1991). Glucose is enzymatically reduced to sorbitol 
by aldose reductase intracellularly. Sorbitol is then oxidised to fructose (Figure 
1.23). Sorbitol penetrates cell membranes slowly and the increased flux of glucose 
via the polyol pathway results in abnormally raised sorbitol concentrations. This 
increases the osmotic potential of cells and induces oedema or swelling. The early 
stages of DR show damage and degeneration of the pericyte cells, which support the 
walls of the retinal capillaries. Hyperglycaemia activates the polyol pathway in the 
mural pericyte cells, which contain the enzyme aldose reductase, leading to 
accumulation of sorbitol to damaging concentrations and pericyte death (Kador PF et 
al. 1990). Unfortunately, agents which inhibit aldose reductase (e.g. Alrestatin, 
Epalrestat) have not altered the development of retinopathy. Epalrestat is the only 
commercially available inhibitor till date. In addition, some other ARIs such as 
Sorbinil and Ranirestat had been advanced into late stage of clinical trials and found 
to be safe for human use. However clinical trials of ARIs had little therapeutic 
success in DR (Grewal et al. 2016). 
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Figure 1.23: Polyol pathway[Adapted from (Tarr JM et al. 2013)] Glucose is 
enzymatically reduced to sorbitol by aldose reductase intracellularly which is then 
oxidised to fructose. Sorbitol penetrates cell membranes slowly. This increase in the 
osmotic potential of cells induces oedema and cell death.  
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Retinal capillary pericytes have a contractile role (Kelley C et al. 1987) and therefore 
their loss contributes to increased sheer forces due to the lack of deformability i.e. 
more stiff and less pulsatile (Davis MD 1992). Blood flow in the normal retina is 
maintained by autoregulation. The retinal blood vessels constrict or dilate in 
response to changes in local perfusion pressure and metabolic requirements (Alm et 
al. 1987). In diabetic subjects alterations in blood flow (hyper-perfusion due to 
hyperglycaemia) in the retina have been measured (Fallon TJ et al. 1987; Grunwald 
JE et al. 1990). In addition there in increased viscosity of blood in diabetic subjects 
and capillary closure contribute to these alterations (McMillan DE 1983). These 
alterations also lead to increased shear stress within the retinal vessels and 
consequent damage to the endothelium. Basement membrane thickening increases 
the rigidity of the retinal blood vessels and may contribute to the loss of 
autoregulation (Tooke JE 1989; Andreani D et al. 1991). 
  
Hyperglycaemia also causes retinal hyper perfusion (Grunwald JE et al. 1990) and 
rapid normalisation of high blood glucose levels may lead to worsening of DR in 
those with previous poor glycaemic control with evidence of diabetic retinopathy 
(Henricsson M et al. 1997). The sudden changes in retinal blood flow damage the 
abnormal retinal capillaries and thus it is advisable to gradually reduce glucose levels 
in poorly controlled diabetic subjects especially where there is evidence of DR 
present. 
 
57 
 
Thus to summarise chronic hyperglycaemia is a major initiator of diabetic vascular 
complications. Elevated glucose, via various mechanisms such as increased 
production of advanced glycation end products, activation of protein kinase C 
(Figure 1.24) stimulation of the polyol pathway and enhanced ROS generation, 
regulates vascular inflammation, altered gene expression of growth factors and 
cytokines, and platelet and macrophage activation, thus playing a central role in the 
development and progression of diabetic vascular complications (Yamagishi S and 
Imaizumi T 2005). The evidence shows that inhibition of different PKC isozymes is 
not sufficient to normalise vascular endothelial growth factor (VEGF)-induced 
barrier damage of retinal endothelial cells. However PKC-β inhibition prevents 
hyperglycemia-induced VEGF expression in retinal pericytes, suggesting that PKC 
inhibitors should be administered before increased VEGF expression is established 
in the diabetic retina. Though initial studies have indicated that treatment of diabetic 
patients with ruboxistaurin, a specific inhibitor of PKC-β, may reduce visual loss in 
patients with diabetic retinopathy, the overall benefit seems to be small (Deissler and 
Lang 2016). 
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Figure 1.24: Regulation of pathophysiological processes in Diabetic Retinopathy 
by protein kinase C (PKC) [Adapted from (Tarr JM et al. 2013)]. 
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DR is a multifactorial disease involving several pathological mechanisms, including 
increased oxidative stress, inflammation, the polyol pathway leading to sorbitol 
accumulation, production of advanced glycation end products (AGEs) and activation 
of the protein kinase C (PKC) pathway (Figure 1.25).  
 
These pathways can in turn activate the production of cytokines and many vasoactive 
factors, such as vascular endothelial growth factor (VEGF) and pigment epithelium-
derived factor (PEDF), which are vital in mediating the structural and functional 
changes of DR. Clinically significant DME can occur in the late stages of DR with 
NPDR or PPDR and is the most common cause of vision loss (Robinson R et al. July 
2012). 
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Figure 1.25: Key factors involved in the pathogenesis of DR and the clinical symptoms evident at different stages of DR (Robinson R 
et al. 2012).  
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1.3.1.1 Clinical evidence of Hyperglycaemia as a risk factor for diabetic 
retinopathy 
Overall hyperglycaemia as represented by HbA1c contributes to both initiating and 
promoting all these mechanisms and if hyperglycaemia is targeted and normalised 
then the cycle of damage can be prevented and risk of incidence and progression of 
DR will be significantly reduced. Both DCCT and UKPDS have stated that DR was 
not completely prevented, even in patients with near normal glycaemia, although no 
one achieved absolutely normal glucose profiles. The UKPDS demonstrated a 25% 
reduction in the rate of development of microvascular complications in the 
intensively-controlled group. It also showed that incidence [relative risk in the 
middle 1/3
rd
 (HbA1c 6.2 %-7.4%) was 1.4 and 2.5 in the top 1/3rd] and progression 
[relative risk in the middle 1/3
rd
 was 4.1 and 8.1 in the top 1/3
rd
 (HbA1c ≥ 7.5%)] of 
DR was strongly associated with HbA1c (Stratton IM et al. 2001). 
 
Investigating the possible association between hyperglycaemia and the presence of 
DR has, over the years, involved measurement of various metabolic indices, 
predominantly HbA1C (Stratton IM et al. 2006) and/or fasting plasma glucose (Miki 
E and Kikuchi M 1994). In the Diabetes Prevention Program (DPP), subjects with 
impaired glucose tolerance and recent onset T2DM were studied, and the 
investigators found a higher baseline HbA1c and systolic blood pressure (SBP) 
amongst those with DR, but no difference in insulin secretion (estimated by the 
Corrected Insulin Response, CIR methodology) (Diabetes Prevention Program 
Research Group 2007 ). Also the Kumamoto study showed that intensive glycaemic 
control utilising multiple daily insulin injection therapy in individuals with T2DM 
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delays the onset and the progression of DR. (Ohkubo Y et al. 1995). In 2005 
Shiraiwa et al. showed that postprandial hyperglycaemia (and postprandial hypo-
insulinaemia) were possible predictors for incident DR in Japanese T2DM subjects 
who were not on insulin treatment (Shiraiwa T et al. 2005a).  
 
Multiple factors are clearly involved.  The Action to Control Cardiovascular Risk 
Factors in Diabetes (ACCORD) trial assessed the effects of intensive glycaemic, 
lipid and hypertensive therapy on cardiovascular events and the progression of DR 
(ACCORD study group and Accord Eye Study Group 2010). Amongst these, 
intensive glycaemic control was noted to significantly reduce the risk of progression 
of DR after 4 years. In the Accord follow-on study, analysing T2DM subjects with 
established cardiovascular disease and duration of DM >10 years, the investigators 
showed that early intensive glycaemic control continued to reduce DR progression 
(ACCORD Study Group 2016). 
 
To try to establish the effect of the modification of these various parameters, the 
Steno-2 trial an intensified, multifactorial intervention of modifiable risk factors 
compared intensive to conventional treatments in persons with T2DM and 
microalbuminuria (Gaede P et al. 2003) and showed a 57% risk reduction of DR for 
individuals in the intensive treatment group over an 8-year period. The Steno-2 
follow up study went on to demonstrate a median of 7.9 years of gain of life at 
21.2 years of follow-up after 7.8 years of intensified, multifactorial, target-driven 
treatment of T2DM with microalbuminuria. This increase in lifespan was matched 
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by time free from incident cardiovascular disease (Gaede P et al. 2016). The 
Veterans Affairs Diabetes Trial (VADT) (Azad et al. 2014) similarly tested the 
hypothesis that intensive glycaemic control would be associated with better eye 
outcomes in subjects with poorly controlled DM and higher plasma C-peptide levels. 
The fasting C-peptide measured here has been used as a measure of pancreatic 
reserve and reflecting on to the glycaemic control. The incidence and progression of 
DR was assessed by grading seven-field stereoscopic fundus photographs at baseline 
and 5 years later in 858 of 1,791 participants of the study. Post adjustment for all 
covariates, risk of progression (but not incidence) of DR increased by 30% for each 
1% increase in baseline HbA1c. The incidence of DR was reduced by 67.2% with 
each 1 pmol/ml increment in baseline C-peptide. Baseline C-peptide was also an 
independent inverse risk factor for the progression of DR, with a reduction of 47% 
with each 1 pmol/ml increase in C-peptide. Thus the study demonstrated that poor 
glucose control at baseline was associated with an increased risk of progression of 
DR over 5 years. Importantly for the first time a higher C-peptide at baseline was 
associated with reduced incidence and progression of DR.  
 
Focusing more on blood glucose control, the ADVANCE trial (Zhu CH et al. 2013) 
evaluated the effects of intensive blood glucose control on microvascular 
complications in patients with T2DM by comparing the therapeutic effects of 
intensive and standard treatment in patients with T2DM. Direct ophthalmoscopy and 
seven-field stereoscopic retinal photography were used to examine the fundi at 
baseline, and repeated after 5 years of treatment. The severity of DR did not progress 
in subjects in the intensive group, but worsened in the standard group (P= 0.0006). 
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Thus intensive therapy proved to be able to maintain stable vision and proved that 
intensive control of blood glucose can diminish the incidence and/or slow the 
progression of DR in patients with T2DM. 
 
The association of hyperglycaemia and DR in established type 2 Diabetes Mellitus 
(T2DM) subjects is well accepted. However, the independent association between β-
cell status, insulin sensitivity and DR in newly diagnosed treatment naïve T2DM 
subjects remained previously unreported.  
 
1.3.2 β-cell function 
In the UKPDS, β-cell function was estimated based on the fasting glucose and 
insulin levels by the homeostasis model assessment HOMA-B (Matthews DR et al. 
1985) and demonstrated a strong relationship between DR and impaired β-cell 
function (Kohner EM et al. 1998). Since the increasing hyperglycaemia of T2DM is 
associated with progressive deterioration of β-cell function, (U.K. Prospective 
Diabetes Study Group 1995) it is possible that the assessment of β-cell function 
provides a better guide to the severity of DM than the measurement of FPG and 
glycosylated haemoglobin levels at a single clinic visit. [The lesser association of 
DR with these glycaemia indices might in part be because some subjects had already 
restricted their diet between the time when the diagnosis was suspected by their 
primary care physician and their first clinic visit]. The UKPDS also reported that the 
severity of DR at diagnosis of T2DM was related in both sexes to higher FPG, lower 
fasting serum insulin levels, and reduced β-cell function (HOMA-B). Increased 
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alcohol consumption was related to increased severity of DR in men and leaner 
women had more severe eye lesions (Kohner EM et al. 1998). A community based 
study in Taiwan has also demonstrated that both β cell dysfunction and IR (HOMA 
methodology) were associated with DR in established T2DM  patients (Tung TH et 
al. 2007).  
 
1.3.3 Insulin Resistance 
Rather than simply glucose level itself, Maneschi et al suggested in 1983 that 
increase in IR may contribute to the pathogenesis of DR (Maneschi F et al. 1983). 
Similarly, over the last decade, there have been several other reports associating IR 
with DR (Tung TH et al. 2007) (Katsumori K et al. 1995; Suzuki M et al. 2000; 
Nakano S  et al. 2003 ). 
 
Suzuki et al. measuring insulin sensitivity by euglycaemic glucose clamp method 
found that the frequency of advanced DR (PPDR and PDR) was more frequent in the 
IR group than in the insulin-sensitive group. Insulin sensitivity expressed as glucose 
utilization (glucose clearance) was also found to be significantly lower in T2DM 
subjects with DR compared to subjects without DR after adjustment for age, BMI, 
FPG, and known duration of diabetes. Furthermore, IR was more severe in those 
subjects with both DR and nephropathy; thus they concluded that IR associated with 
T2DM is closely associated with the progression of microangiopathies (Suzuki M et 
al. 2000).  
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Further on the consideration of insulin resistance, Katsumori et al. undertook a study 
to determine whether patients with IR syndrome (IRS - insulin resistance, 
hyperinsulinaemia, hyperglycaemia, obesity, dyslipidaemia, hypertension), were a 
high-risk population for macro- and microvascular diseases in Japanese T2DM and 
in subjects with borderline glucose-intolerance. The prevalence of late-stage DR 
(PDR/maculopathy) in the IRS group was significantly higher than that in the other 
group (12.3% vs. 2.4%, respectively, P<0.005). Macroalbuminuria, but not 
microalbuminuria, was also significantly higher in the IRS group (12.3% vs. 3.6%, P 
< 0.02). Thus they concluded that IRS preferentially increased the development of 
CAD, and was also involved in the progression of microvascular diseases including 
diabetic retinopathy (Katsumori et al. 1995). 
 
Not only is IR important for risk of development of retinopathy, Nakano et al 
measuring IR from the Glucose Infusion Rate (GIR) during an euglycaemic 
hyperinsulinaemic clamp study, demonstrated that a decrease in the GIR was 
associated with increasing severity of DR, neuropathy and nephropathy (Nakano S et 
al. 2003). They also demonstrated that IR is inversely correlated to urinary C-peptide 
secretion or pancreatic β-cell function thus suggesting that pancreatic β-cell function 
was unable to compensate for increased IR to maintain euglycaemia in T2DM 
subjects (Nakano S et al. 2003) as previously reported (Kahn SE et al. 1993). 
Genetic factors have also been shown to be involved in Insulin secretion and IR in 
T2DM (Ferrannini E 1998; Gerich JE 1998).  
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However, there is not complete agreement as to the role of IR as, in contrast to all 
the above studies, Stolk et al. when determining IR using the insulin to glucose ratio 
2 hours after an oral glucose load showed no difference in subjects with or without 
DR (Stolk RP et al. 1995). 
 
1.3.4  Hypertension 
Elevated BP enhances blood flow and leads to retinal capillary endothelial cell 
damage in eyes of people with DM (Kohner EM 1989). This has been further 
observed in clinical studies thus showing an association between hypertension and 
the presence and severity of DR in people with DM (Fujisawa T et al. 1999; Gillow 
JT et al. 1999). 
 
Hypertension has been associated with both the development and progression of DR 
(Klein R et al. 1984; Klein R et al. 1989b; Kohner EM et al. 1998; UK Prospective 
Diabetes Study Group 2004) within the UKPDS showing that the severity of DR at 
diagnosis of T2DM to be related to a higher systolic and diastolic BP (Kohner EM et 
al. 1998). The UKPDS, in a subset of hypertensive patients, showed that stringent 
BP control reduced the risk of developing macrovascular and microvascular 
complications of DM (Turner R et al. 1996) and that a 10 mm Hg decrease in 
updated mean SBP was associated with a 13% risk reductions of microvascular 
complications (P < 0.0001). Thus in patients with T2DM, the risk of diabetic 
complications has been strongly associated with raised BP and any reduction in BP 
is likely to reduce the risk of complications, with the lowest risk being in those with 
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SBP of <120 mmHg (Adler AI et al. 2000). The UKPDS has also reported that the 6-
year incidence and progression of retinopathy were both significantly related to BP 
(Kohner EM et al. 1996). 
 
In studying how hypertension may be a risk factor for diabetic complications, 
Rassam et al. demonstrated impairment in retinal vascular autoregulation in response 
to raised systemic BP in diabetic subjects, more so at an elevated blood glucose 
level, thus providing an additive mechanism for the detrimental effect of 
hypertension on DR (Rassam SM et al. 1995). The DPP, where subjects with IGT 
and recent onset T2DM were studied, also found a higher baseline SBP amongst 
those with DR (Diabetes Prevention Program Research Group 2007 ). This had built 
on data from the Santa Barbara County Diabetic Retinopathy Screening Feasibility 
Study where the mean SBP was found to be higher in patients with all types of DR 
with the relationship remaining significant when smokers and non smokers were 
separated although there was no significant difference noted in mean SBP between 
patients with severe DR (PPDR and PDR) and those with BDR (Lewis JM et al. 
1994).  
 
In contrast however, recently the Accord Eye Study Group has shown that intensive 
BP control does not reduce the rate of progression of DR (ACCORD study group 
and Accord Eye Study Group 2010). Of note in the Accord Eye Study Group, the 
target SBP was maintained at <140 mm Hg for the standard group and <120 mm Hg 
for the intensive group, however for the UKPDS the targets were <180 mm Hg and 
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<150 mm Hg respectively. This might be a possible explanation of the difference in 
outcomes. Thus the association of hypertension is reasonably well-established with 
DR though not all studies have found it to have the same importance as a risk factor. 
 
1.3.5 Dyslipidaemia and its treatment 
The contribution of dyslipidaemia (Chew EY et al. 1996; Cusick M et al. 2003) to 
the development and progression of DR is documented in the EURODIAB study 
where the serum total triglyceride concentration was significantly higher in those 
with moderate and severe non-NPDR and PDR in T1DM subjects than in those 
without DR (Sjolie AK et al. 1997). Similarly in the ETDRS elevated serum 
triglyceride was independently associated with the development of high risk PDR in 
both T1DM and T2DM subjects (Davis MD et al. 1998a). 
 
Cholesterol levels have also been implicated - in the WESDR study in subjects using 
insulin (irrespective of age at onset) a higher total serum cholesterol was associated 
with increased odds of having retinal hard exudates (Klein BE et al. 1999). Also the 
ETDRS estimated that there was twice the risk of having hard exudates at entry into 
the study and 1.5 times the risk of developing hard exudates during the 4 year study 
period if there was increased serum total cholesterol and low density lipoprotein 
cholesterol (LDL-cholesterol) at baseline/point of entry to the study, but not with 
other lipoprotein fractions and the total triglyceride levels (Chew EY et al. 1996). In 
contrast however, there was no relationship between total cholesterol and high 
density lipoprotein cholesterol (HDL-cholesterol) and the presence of DR (hard 
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exudates) in the older onset age group not requiring insulin therapy (Klein BE et al. 
1991). Cholesterol as also been studied as one of multiple risk factors and he 
STENO-2 study found a 67% significant reduction in DR in the intensive 
intervention group involving control of multiple risk factors, including glycaemic 
control, BP, cholesterol and microalbuminuria over 4 years, which was sustained at 8 
years (Gaede P et al. 1999; Gaede P et al. 2003). However these findings have not 
been universally consistent (Duncan LJ et al. 1968), Though this study with 
clofibrate showed a highly significant decrease in hard waxy exudates it did not 
cause appreciable improvement in visual acuity/improvement in vascular retinal 
lesions. The initial severity of the exudative lesions was also not related to the 
fasting serum cholesterol or triglyceride levels and there was further no correlation 
between the effect of clofibrate on exudates and serum lipids. The study however 
had modest numbers with twenty-three patients and twenty-five controls which 
might be a contributing factor to the outcome. 
 
Interestingly the use of fibrates has been shown in some studies to have a beneficial 
effect on retinal exudates (Harrold BP et al. 1969; Dorne PA 1977; Freyberger H et 
al. 1994; Keech AC et al. 2007; ACCORD study group and Accord Eye Study 
Group 2010). Treatment with fibrates in people with T2DM was independently 
associated with a reduced rate of progression to a first diagnosis of DR (Morgan CL 
et al. 2013) and macular oedema. Duncan et al. (Duncan LJ et al. 1968) also noted a 
highly significant decrease in hard waxy exudates (p ≤0.0001) in subjects treated 
with fibrates. The Fenofibrate Intervention and Event Lowering in Diabetes study 
(FIELD) reported that individuals with T2DM treated with fenofibrate, in addition to 
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therapies for hyperglycaemia and other risk factors for DR were less likely to need 
laser therapy than controls (Keech A et al. 2005). There was also less progression of 
pre-existing DR with fenofibrate. However, in individuals without DR at baseline 
there was no significant reduction in the development of DR (Keech AC et al. 2007).  
 
A retrospective matched cohort study found that treatment with fibrates was 
associated with a 20% reduction in the rate of first onset of DR (Morgan CL et al. 
2013), but this reduction in the onset of DR did not appear to be attributable to the 
lipid lowering effects of fibrates. Other nonlipid related mechanisms that may 
explain the effect of fibrates on DR include the anti-inflammatory, antioxidant and 
anti-VEGF properties of fibrates (Poynter ME and Daynes RA 1998; Delerive P et 
al. 1999). Fenofibric acid has also been reported to prevent the disruption of the 
retinal pigment epithelium cells, prevention of breakdown of the blood brain 
capillary barrier and down-regulation of vascular endothelial growth factor (VEGF) 
(Meissner M et al. 2004; Trudeau K et al. 2011; Villarroel M et al. 2011). In addition 
fibrates also possess neuroprotective properties (Bordet R et al. 2006). However, no 
data is available to indicate which features of DR progressed or whether any 
regression was seen. In interpreting these studies with their clinical implications 
(Wright and Dodson 2011), it must be noted that DR was not the primary endpoint 
by design, a tertiary endpoint in FIELD, and DR endpoints recorded in a sub study 
cohort of the ACCORD study population. Hence, the exact beneficial action of 
fenofibrate on DR remains to be elucidated.  
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1.3.6 Other risk factors   
1.3.6.1 Genetics 
Genetic and environmental factors both appear to affect the development of DR. 
Evidence indicating significant correlations between the severity of DR in family 
members has been reported in the DCCT study (The Diabetes Control and 
Complications Trial Research Group 1997) and by others (Alcolado 1998). An 
increased risk is seen in identical twins of affected probands (Leslie RD and Pyke 
DA 1982). Heritability has been estimated to be as high as 27% for any DR and 52% 
for PDR (Cho H and Sobrin L 2014) demonstrated by Looker et al. (Looker HC et 
al. 2007) and  Hietala et al. (Hietala K et al. 2008). There are current studies 
assessing genome-wide associations offering a better understanding to the genetic 
architecture of DR susceptibility (Liew et al. 2009; Cho H and Sobrin L 2014). DR is 
a however a polygenic disorder and linkage analyses, candidate gene association 
studies and genome-wide association studies (GWAS) performed till date hasn’t 
identified any widely reproducible risk loci for DR (Cho H and Sobrin L 2014). 
Combined analysis of data from multiple GWAS is emerging as an important next 
step to explain the unaccounted heritability. Important factors to future discovery of 
genetic underpinnings of DR are precise DR ascertainment, focus on more heritable 
disease forms (PDR), stringent selection of control participants with relation to 
diabetes duration, and methods that allow combining of existing datasets from 
various ethnicities to achieve sufficient sample sizes to detect variants with modest 
effect sizes.  
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1.3.6.2 Ethnicity 
Ethnic origin differences in the prevalence of DR have been a focal point of interest 
in recent research (Cheung et al. 2010). An association between ethnicity with the 
prevalence of DR, presence of any DR and also severe/referable stages of DR have 
previously been reported to be higher in non-Caucasian persons when compared with 
Caucasians by Ross et al. (Ross SA et al. 2007), Stolk et al. (Stolk RP et al. 2008) 
and Raymond et al. (Raymond NT et al. 2009). The studies did adjust for 
confounding variables. Though this variation in frequency may reflect true 
differences in prevalence, lack of uniformity in study designs, protocols for 
examination and documentation of DR may explain some of the reported differences. 
There also remains a possibility that differences in environmental and genetic risk 
factors as well as other covariates could have a marked impact on frequency. 
 
1.3.6.3 Smoking 
The reporting of the effect of smoking on the incidence of DR is varied. Walker at al. 
in a cross-sectional study of 193 adult patients demonstrated that smoking was 
related to DR in men but not in women, although in the latter group the prevalence 
of smoking was low (Walker JM et al. 1985). In a sample of 181 diabetics, a 
statistical association of smoking was also established with PDR (Paetkau ME et al. 
1977). Interestingly however the UKPDS reported in newly-diagnosed T2DM 
subjects that development of DR was strongly associated with not smoking. In those 
who already had DR, progression was also associated with not smoking (Stratton IM 
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et al. 2001). Thus smoking status was inversely related to the incidence and 
progression of DR.  
 
This was in variation to other published findings (Madsbad S et al. 1980; Owens D R 
et al. 1988; Lewis JM et al. 1994; Guillausseau PJ et al. 1998) which showed no 
association of DR with smoking. Some of these other studies were from a smaller 
population group (129 T2DM subjects) (Owens D R et al. 1988) and 163 subjects 
(Madsbad S et al. 1980) noting that no difference might not be truly reflective of a 
bigger population cohort as in the UKPDS trial. However Moss et al studied a larger 
cohort of diabetic subjects in USA and in these individuals baseline smoking history 
was categorized by status and pack-years smoked while diabetic. After controlling 
for known risk factors for the incidence and progression of DR, pack-years smoked 
was of borderline significance (P= 0.052) in predicting incidence of DR in younger-
onset subjects. Smoking was not associated with incidence in older-onset subjects or 
with progression or progression to PDR in any of the groups. (Moss SE et al. 1991). 
Moss et al further reported the association between cigarette smoking and the 
incidence and progression of DR by studying a large population-based cohort study 
who participated in baseline, 4-year, and 10-year examinations. Neither smoking 
status nor pack-years smoked showed significant associations with increased risk of 
DR. Thus cigarette smoking was not noted to be a risk factor for the long-term 
incidence of DR in these two studies of larger population cohort. (Moss SE et al. 
1996).   These studies supported the earlier work of Klein et al. in 1983 that showed 
that there was no association between smoking history and DR. There was also no 
established relationship between the risks or severity of DR and number of cigarettes 
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smoked daily, or the number of pack-years smoked while diabetic. Overall, these 
data suggest that there is no excess risk of DR in smokers or ex-smokers when 
contrasted with those who never smoked (Klein R et al. 1983). This does suggest 
that meta-analyses might be needed to clarify the exact relationship of DR with 
smoking status. 
 
In summary, although a majority of studies have not established a definitive 
relationship between smoking and incidence and progression of DR, it does not 
imply that persons with DM who smoke should not stop as cigarette smoking is a 
risk factor for other complications and associated conditions of DM, particularly 
cardiovascular and respiratory disease. 
 
1.4 Summary Hypothesis and Aims 
1.4.1 Summary  
To summarise, the mechanisms for the development of DR are multifactorial, inter-
related and complex. Genetic and environmental risk factors interact early on in the 
disease process to lead to the initial background changes. The effect of the various 
risk factors on the pathogenesis of DR evolves with the progression of the disease 
process. A complete and thorough understanding of the various risk factors 
contributing to the prevalence and incidence of DR will enable early intervention and 
thereby prevent the complication of DR, which can lead to visual impairment and  
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have an effect on day-to-day lifestyle. Timely and early interventions are imperative, 
in order to slow down or impede the development of sight threatening DR. 
 
1.4.2 Hypothesis 
The first research hypothesis was that along with the overall glycaemic exposure 
(routinely expressed by HbA1c), both the fasting and postprandial components of 
glycaemic exposure act in concordance and independently to affect the prevalence, 
incidence and progression of diabetic retinopathy. The second hypothesis was that β-
cell dysfunction (fasting and postprandial) is the basis of this overall dysglycaemia 
leading to diabetic retinopathy. 
 
1.4.3 Aims of the Thesis 
The aim of this thesis has been to assess the cross sectional and longitudinal 
relationships between the metabolic and clinical risk factors and DR in a group of 
newly diagnosed T2DM subjects. Data from standard meal tolerance tests and 
intravenous glucose tolerance tests in this group provides a unique insight into the 
dynamic secretory responses to meal and IV glucose stimuli. Subjects were studied 
at diagnosis of T2DM and at years 1, 2 and 5 years post diagnosis. 
 
The following were analysed: 
i) Prevalence of DR in newly diagnosed T2DM subjects (Chapter 3)  
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ii) Incidence of DR in the subjects with no DR at diagnosis followed up over a 5 
year period (Chapter 4) 
iii)  Progression of DR in the subjects with DR at diagnosis followed up over the 
5 year period (Chapter 5) 
 
This thesis examined the impact of the putative risk factors: HbA1c, fasting and 
postprandial glucose and insulin measured during the MTT and FSIVGTT on each 
of the above mentioned outcomes. In addition the relationship of fasting and 
postprandial β-cell responsiveness, Acute Insulin Response to IV glucose (AIRG), 
Insulin Sensitivity (SI), and Glucose Effectiveness (SG) was also estimated and 
compared against these outcomes. 
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2.1 Study design 
2.1.1 Study subjects 
661 newly diagnosed treatment naïve subjects, with T2DM (GAD antibody negative) 
were entered into the study. The subjects were originally referred by primary care 
physicians on clinical presentation and underwent Oral Glucose Tolerance Test 
(OGTT) or Fasting Glucose at the Biochemistry department, Llandough Hospital to 
confirm diagnosis as per WHO criteria (World Health Organisation 1985) (Table 
2.1). All study participants were investigated within 1-2 weeks following diagnosis 
of T2DM and prior to any intervention with either lifestyle advice and/or 
hypoglycaemic medications. The study was conducted between 1981 and 2007. 
Following
 
informed consent, subjects were assessed on one or two consecutive days 
at a metabolic unit during which they all had a general medical examination and 
underwent a standardised Meal Tolerance Test (MTT) on the 1
st
 day with a smaller 
group having in addition an Intravenous Glucose Tolerance Test (IVGTT) on the 2
nd
 
day. They all also had retinal photographs taken at this time. Ethical approval for the 
study was obtained from South Glamorgan/Bro Taf Local Research Ethics 
Committee.   
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Table 2.1: WHO criteria employed for diagnosis of Type 2 Diabetes Mellitus 
(World Health Organisation 1985) 
 
Type 2 Diabetes Mellitus 
Fasting and/or 
2 hours after 75gm oral glucose load 
Venous Plasma Glucose (mmol/L) 
≥ 7.8 
≥ 11.1 
Impaired Glucose Tolerance 
Fasting and/or 
2 hours after 75gm oral glucose load 
 
< 7.8 
≥ 7.8 and ≤ 11.1 
Normal Glucose Tolerance 
Fasting and/or 
2 hours after 75gm oral glucose load 
 
< 7.8 
< 7.8 
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Table 2.2: Inclusion and exclusion criteria for the study subjects 
 
Inclusion criteria 
The patient: 
 1 is aged       (30 – 70 years) 
either 2 has a fasting blood glucose of   (>7 mmol/L) 
or 3 has a random blood glucose of    (>11mmol/L) 
 4 is newly diagnosed 
 5 is Caucasian 
 
Exclusion criteria 
The patient  
 6 has not commenced treatment for diabetes 
 7 is not receiving treatment for hypertension 
 8 is not suffering from a severe concomitant disease 
 9 is not taking the following concomitant medication: 
  thiazide diuretics 
  any corticosteroids 
  hormone replacement therapy 
  anti-anginal drugs (e.g. beta blockers, calcium antagonists) 
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These subjects were followed up for a period of 5 years during which time they had 
further general medical reviews (clinical examination, biochemical and 
haematological screening) and metabolic and retinopathy assessment at 1, 2 and 5 
years. Detailed numbers of subjects studied over the study period is summarized in 
(Table 2.2). Some subjects were lost to follow up due to non-attendance, illness, 
relocation, transfer of care to GPs, and death. In addition subjects underwent routine 
annual reviews during the study period. Over the study period treatment consisted of 
diet, oral hypoglycaemic agents, insulin therapy or combination therapies as deemed 
necessary by the responsible health care professional. Regular contact was 
maintained with subjects and an appointment reminder system helped to minimise 
study dropouts. I was involved in the follow up studies of the subjects between 2008 
and 2010. 
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Table 2.3: Subjects studied over the study period  
642 subjects  
at diagnosis
• 661 T2DM subjects recruited at diagnosis
• 19 subjects had no Retinopathy data and were 
excluded from the analysis
544 subjects 
analysed at diagnosis 
– Chapter 3
• 98 subjects excluded at diagnosis as incomplete data 
on MTT
233 subjects 
analysed in Chapter 4
• 314 subjects at 5 years post diagnosis 
• 293 subjects had data at diagnosis and Years 1,2 and 5
• 60 subjects excluded as had DR at diagnosis or had 
inconsistent  grading over 5 years
41 subjects  analysed 
in Chapter 5
• Of these 233 subjects: 179 subjects had NDR (5 years), 
54 subjects developed DR over 5 years
19 subjects excluded 
in analyses of  data 
over 5 years.
• 17 subjects excluded as developed DR at Year 1 or 2 
but had no recorded evidence of DR at Year 5
• 2 subjects excluded with DR at Year 1 and 5 but had 
no evidence of DR at Year 0 and 2.
• 41 subjects with DR at diagnosis were analysed for 
progression of existent DR in Chapter 5.
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2.2 Clinical Methods 
2.2.1 Experimental protocol of metabolic challenge tests 
The T2DM subjects were admitted to the metabolic
 
unit at the University Hospital of 
Llandough following a 12-hour overnight fast and remained on bed rest throughout 
the morning of each of the study days. The subjects were advised to maintain normal 
diet and be rested for 3 days prior to the tests. 
 
Each subject’s height and weight were measured using a standard balance machine. 
Body Mass Index (BMI) was calculated (weight in kg/height in m
2
). Blood pressure 
was measured after 10 minutes rest in the supine position using a 
sphygmomanometer. A 17 gauge luer-lock venflon (Ohmeda AB, Helsingborg 
Sweden) was inserted into an anticubital fossa vein and fasting samples were taken 
for plasma glucose, HbA1 (1981-1995), HbA1c (1995 onwards), total serum 
cholesterol (TC), HDL-C and LDL-C cholesterol, total serum triglycerides (Tg), urea 
and creatinine concentrations In addition serum immuno-reactive insulin (IRI) 
(1981-1994), serum specific insulin (ELISA 1990 onwards), C-peptide were 
measured to assess β-cell function and Insulin Sensitivity (IS). 
 
The study extended over a long period of time during which certain assay changes 
occurred i.e. glycosylated haemoglobin and insulin assays. HbA1 measured in the 
early part of the study was converted to HbA1c utilising the formula  (HbA1c = 
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0.83HbA1 - 0.54) (Cull CA et al. 1997). The insulin assay is described in section 
2.2.5.  
 
2.2.2 The Meal Tolerance Test (MTT) 
All subjects underwent a standardized Meal Tolerance Test (MTT). This involved 
consuming a 500-kcal meal (15
 
gm Weetabix, 100 gm skimmed milk, 250 ml 
pineapple juice, 50 gm
 
white meat chicken, 60 gm wholemeal bread, 10 gm 
polyunsaturated
 
margarine) (58% carbohydrate, 23% fat, and 19% protein) (Owens 
DR et al. 1996). Subjects were required to consume the whole meal within
 
10 min (0 
to 10 minutes). All subjects remained resting in a supine position throughout the test 
period with no smoking allowed. Blood samples were taken at -30 and 0 (fasting) 
minutes and thereafter at frequent intervals up to 240 minutes, to estimate plasma
 
glucose, insulin, and C-peptide concentrations. The MTT, considered more 
physiological than an oral glucose tolerance test (OGTT), was a standardised mixed 
meal nutrient challenge, to determine the degree of glucose intolerance and 
pancreatic β-cell response. Approximately 30 seconds before a sample was due, the 
saline was stopped and approximately 2 mls of blood was withdrawn and 
subsequently discarded to remove all of the saline and diluted blood from the 
catheter. Following this a further 5 to 10 mls of blood was drawn for the sample to 
be assayed. This procedure has been previously validated. 
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2.2.3 The Insulin Modified Frequently Sampled Intravenous Glucose Tolerance 
Test (FSIVGTT) 
A smaller subgroup of subjects also underwent a ‘Frequently Sampled Intravenous 
Glucose Tolerance Test’ (FSIVGTT), (Bergman RN et al. 1981) to determine the 
state of insulin and glucose sensitivity, in addition to the β-cell response. This was 
carried out on the second day, again after an overnight fast, involving the 
intravenous administration of 0.3 gm of glucose per kg body weight given at 0 
minutes and infused over a 2-minute period. Thereafter, blood samples were taken at 
minute intervals up to 10 minutes. An  intravenous bolus of insulin (Actrapid; Novo 
Nordisk, Bagsvaerd, Denmark) was then injected at
  
20 minutes at a dose of 0.05
 
U/kg insulin and further blood samples were collected at 22, 23, 24, 25, 27, 30, 40, 
50, 60, 70, 80, 90, 100, 120 and 180 minutes (Owens DR et al. 1996). At each time 
point, measurements
 
of plasma glucose, c-peptide and insulin were made. Assays 
used are described in Section 2.2.5 
 
As for the MTT, the FSIVGTT involved the insertion of an indwelling intravenous 
cannula into an antecubital fossa vein in the forearm of the subject and connected
 
via 
a three-way tap to a slow-running saline infusion, to maintain
 
the patency of the 
cannula and allowing for repeated blood sampling with least inconvenience to the 
patient.  
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2.2.4 Assessment of retinopathy 
Both eyes were dilated using Tropicamide (1%) and retinal images were obtained 
through dilated pupils. Two 45° images were taken, one centred on the macula and 
the second a posterior pole image with the optic disc position one disc diameter from 
the edge of the image (Figure 2.1). For subjects presenting from 1981 to 1986, 
ophthalmoscopy and Polaroid images (Canon CR3-45NM) were employed. From 
1986 onwards, ophthalmoscopy and 35 mm colour transparencies (CR4-45NM 
retinal camera, Kodak Ektachrome EPR 64 film) were used. In 1994, the film was 
changed to Kodak Ektachrome EB 100.  Use of digital images was started around 
2000 with some overlap and was routinely used from 2002 onwards. 
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A)                                                                                                            B) 
 
 
 
Figure 2.1: Two standard retinal fields A) macular centred and B) nasal (Images from DRSSW) 
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The retinal images were graded by an experienced diabetologist with the highest 
grade for both eyes used for classification. All images were then regraded by a senior 
retinal grader against the newer DRSSW grading protocol and any differences were 
reconciled by reference to a second diabetologist and ophthalmologist to arrive at the 
final grading.  
 
Classification of DR was based on the Diabetic Retinopathy Screening Service for 
Wales (DRSSW) grading protocol (Table 2.3), which is an enriched version of the 
UK National DR grading protocol (Harding S et al. 2003).   
 
The retinal images were graded as showing: No DR (no diabetic retinopathy changes 
seen), Background DR (BDR): Mild, moderate and severe BDR including those with 
possible maculopathy (M1), Pre-Proliferative (PPDR), Proliferative DR (PDR) and 
Exudative Maculopathy (M2). 
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Table 2.4: Grading Protocol of Diabetic Retinopathy Screening Service for 
Wales (DRSSW)  
R0 No DR 
R1 Background DR (BDR) 
R1.1 Mild BDR 
 < 5 Mas > 1 DD from fovea  
 < 4 Hms > 1 DD from fovea 
 3 Mas < 1 DD from fovea 
 ≤ 3 MA < 1 DD from fovea with VA better than 6/12 
 exudates > 2 DD from fovea with or without CWS (< 5) 
R1.2 Moderate BDR 
 ≥ 5 MAs > 1 DD from fovea  
 ≥ 4 < 8 HMs > 1DD from fovea  
 > 3 MAs < 1 DD from fovea with VA > 6/12 
 Circinate or grouped exudates > 2 DD from fovea but within arcades 
 Questionable IRMA only in the presence of MA/HM  
R2 Severe BDR (PPDR) 
 ≥ 8 blot haemorrhages per eye (superior and inferior hemi-fields) 
 Venous irregularities, beading, reduplication, venous loops (but not on their own) 
 Definite IRMA 
With or without CWS (but not CWS on their own) 
R3 PDR/ADED 
 New vessels on disc (NVD) 
 New vessels elsewhere (NVE) 
 Pre-retinal haemorrhage 
 Vitreous haemorrhage 
 Pre-retinal fibrosis 
 Traction retinal detachment 
M0 No Maculopathy 
M1 
 
 
Possible Maculopathy 
 Exudates < 2 DD >1DD from fovea 
 > 3 Mas <1 DD from fovea with VA < 6/12 
 Hm < 2DD from fovea 
M2 Definite Maculopathy 
 Exudates < 1 DD from fovea 
 Retinal thickness changes < 1 DD from  
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No DR - no diabetic retinopathy; BDR - background diabetic retinopathy, mild, 
moderate and severe (PPDR - pre-proliferative diabetic retinopathy); PDR - 
proliferative diabetic retinopathy; ADED - advanced diabetic eye disease;  
MA - microaneurysm; Hm - haemorrhage; Ex - exudate; IRMA - intra-retinal 
microvascular abnormalities; CWS - cotton wool spots; DD – disc diameter; 
The various grades of DR have been illustrated in Chapter 1: Figures 1.14-1.18 
 
2.2.5 Assay methods  
Blood was taken into fluoride oxalate for measurement of glucose (YSI
 
2300, YSI, 
Hants, UK) and into lithium-heparin for measurement
 
of C-peptide and specific 
insulin (Andersen L et al. 1993).  
 
Glucose was assayed using 1) the glucose oxidase method (model
 
2300 Yellow 
Springs Analyzer, YSI, Inc., Yellow Springs, OH)
 
 with the intra-assay coefficient of 
variation <4%; 2) The Instrumentation Laboratories glucose oxidase assay (ILab 300 
plus clinical chemistry analyser) with the intra-assay coefficient of variation ≤ 2.5%. 
 
Specific insulin was measured using a 2-site immunochemiluminometric assay 
(ICMA); Invitron Ltd, Monmouth UK) comprising monoclonal capture and labelled 
antibodies. The intra-assay coefficient of variation was < 7.5%. 
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Although the majority of insulin samples were assayed using the specific insulin 
assay, some of the earliest collected samples were assayed using a less specific 
immunoreactive insulin (IRI) radioimmunoassay (Heding, 1972). Cross reactivity 
with intact proinsulin was approximately 60%, which resulted in a higher measured 
IRI concentration than for the measured ‘specific’ insulin.  
 
In order to enable the samples that were assayed using IRI only to be included in the 
final insulin analysis, a conversion factor was generated. 2290 samples were assayed 
using both the less specific IRI and the specific insulin assay. The resulting data 
were plotted and after removal of outliers, a regression equation was generated:  
Y = 1.1755X + 58.264, where Y = IRI and X = specific insulin, with R
2
 of 0.7472 
was rearranged to generate:  
Specific Insulin = (IRI – 58.264)/1.1755.  
As this equation had the potential to generate negative specific insulin values, after 
discussion with a statistician the regression line was altered to have an intercept of 
zero. The subsequent equation Y = 1.3819X with R
2
 of 0.7038 was rearranged to 
give:  
Specific insulin = IRI/1.3819.  
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C-peptide was measured using a 2 site assay (ICMA; Invitron Ltd, Monmouth UK) 
comprising polyclonal capture antibody and monoclonal labelled antibodies. The 
intra-assay coefficient of variation was < 8%. 
 
2.3 Metabolic data modelling
 
2.3.1 Baseline parameters  
Glucose, insulin and C-peptide levels: Fasting plasma glucose (FPG), plasma 
insulin (FPI) and plasma C-peptide levels were measured. The postprandial plasma 
glucose (PPG), plasma insulin (PPI) and postprandial plasma C-peptide were 
represented by the 120 minute values and the areas under the curve (AUC0-240mins) 
estimated up to 4 hours during the MTT.  
 
2.3.2 Homeostasis model assessment (HOMA) 
The Homeostasis Model Assessment (HOMA) estimates steady-state β-cell function 
(% B) and insulin sensitivity (% S), as percentages of a normal reference population. 
HOMA-B, HOMA-S and HOMA-IR (Insulin Resistance) were calculated employing 
only the fasting plasma glucose and specific insulin levels obtained at time 0 minutes 
during the MTT using the Homeostasis Model Assessment (HOMA; version 2.2.2) 
(Levy JC et al. 1998) Figure 2.2.  
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Figure 2.2 shows the HOMA model utilising the fasting plasma glucose and specific 
insulin levels obtained at time 0 minutes during the MTT to calculate steady state β-
cell function (% B) and insulin sensitivity (% S) and insulin resistance (IR). 
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2.3.3 CPR program 
The CPR (Calculating Pancreatic Response) program (Hovorka R et al. 1998)- 
(Figure 2.3) was used to quantify pancreatic ß-cell
 
responsiveness during the MTT. 
Fasting β-cell responsiveness (M0) is the ability of fasting glucose to stimulate 
insulin secretion and postprandial β-cell responsiveness (M1) is the ability of the 
postprandial glucose to increase insulin secretion in response to a meal. The M0 is 
the C-peptide response to fasting
 
glucose representing fasting prehepatic insulin 
secretion and the M1 is the C-peptide response to postprandial glucose representing 
the increase in prehepatic insulin secretion
 
in response to an increment in 
postprandial glucose (Hovorka R et al. 1998). 
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Figure 2.3 shows how the CPR program quantifies pancreatic ß-cell
 
responsiveness 
during the MTT. It takes into account the height, weight, age, sex, type of subject 
(normal/obese/T2DM) along with the glucose (mmol/L) and C-peptide (pmol/L) 
measurements at 30-minute intervals over a 4-hour period.  
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2.3.4 The minimal model (MINMOD) 
The acute ‘first phase’ insulin response to glucose (AIRG)
 
was calculated as the 
incremental area under the insulin curve from
 
0-10 minutes during the FSIVGTT 
(Kahn SE et al. 1993). 
 
The Minmod program (developed by Bergman and Pacini) using the software 
IS_CIBA (G Mehring, Novartis) was used (Figure 2.4). The minimal model analysis 
of FSIVGTT provided data on SI (ability of insulin to enhance the net glucose 
disappearance
 
from plasma) and SG (ability of glucose to promote its own disposal 
and a marker of insulin-independent component of glucose tolerance) (Bergman RN 
et al. 1985 ; Bergman RN et al. 1992).  
 
Both SI and SG are measures of insulin sensitivity;
 
the former measures insulin 
sensitivity at an incremental insulin
 
concentration, the latter at the basal insulin 
concentration. Thus SG reflects how much of the glucose pool is cleared per minute 
at basal insulin and SI demonstrates, how much 1 unit of insulin changes the glucose 
disposal (min
-1
 per mU/L). 
 
The Disposition Index (DI), a measure of the overall ability of the islet cells to 
secrete insulin normalised to the degree of insulin resistance, was calculated as DI = 
SI x AIRG  (Kahn SE et al. 1993).
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Figure 2.4: IS_CIBA sample analysis shows how plasma glucose and insulin levels 
measured at frequent intervals over 180 minutes is utilised by the program to 
calculate SI and SG. 
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2.4 Statistical Methods 
All analyses were carried out using SPSS 20 statistical computer software. P< 0.05 
has been taken to denote statistical significance throughout this thesis unless 
otherwise stated. 
 
The AUC was calculated using the “Trapezoidal rule” i.e. [(concentration at time1 x 
0.5) + concentration t2 + concentration t3 + concentration t4 ……+ (concentration tlast 
x 0.5)] x sample time interval. Its measured unit is concentration unit x time unit e.g.  
pmol/l x h or pmol.h/l. 
 
2.4.1 Data structure 
Data was collected on all the participant newly diagnosed Type 2 diabetic subjects. 
Demographic variables and blood chemistry variables were recorded. Other variables 
i.e. BMI (described in chapter 2.2.1) were calculated from these measures. 
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Table 2.5:  Clinical variables recorded during the study 
 
 
Recorded Variables Units 
  
Age  years 
  
Weight  kg 
Height m 
  
Blood Pressure  
Systolic blood pressure  mmHg 
Diastolic blood pressure  mmHg 
  
Plasma Lipids  
Total Cholesterol (TC) mmol/L 
High Density Lipoprotein Cholesterol (HDL-C) mmol/L 
Total Triglycerides (TG) mmol/L 
  
Renal function  
Creatinine  mmol/L 
Urea mmol/L 
  
Plasma Glucose  
Fasting Glucose (FPG) mmol/L 
Postprandial Glucose (PPG) (120 mins)  mmol/L 
Glycosylated Haemoglobin (HbA1) % (1981-1994) 
Glycosylated Haemoglobin (HbA1c) % (1995 onwards) 
  
Plasma C-peptide   
Fasting C-peptide (FCP) nmol/L 
Postprandial C-peptide (PCP) nmol/L 
  
Plasma Insulin  
Fasting Immuno-reactive Insulin (IRI, 0 mins)  pmol/L (1981-1994) 
Postprandial  Immuno-reactive Insulin (IRI, 120 mins)  pmol/L (1981-1994) 
Fasting Specific Insulin (0 mins)  pmol/L (1991 onwards) 
Postprandial  Specific Insulin (120 mins) pmol/L (1991 onwards) 
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Table 2.6: Categorical variables recorded during the study 
 
 
Categorical  Variables Coding 
  
Sex 0     Female 
 1     Male 
  
Smoking Status (SMOK) 0     non-smoker 
 1     ex-smoker 
 2     current smoker 
  
Family History (FH) 0     no family history 
 1     first degree relative with Type 2 Diabetes 
  
Treatment (at 1,2 and 5 years) 0     Diet 
 1     Oral Hypoglycaemics 
 2     Insulin or Combination therapy 
103 
 
 
Table 2.7: Derived variables calculated for study subjects  
 
 
Derived Variables Units 
  
BMI  kg.m
2
 
  
MTT derived   
AUC Glucose (0-240min)          mmol/L 
AUC C-peptide (0-240min)          nmol/L 
AUC Insulin (0-240min)  pmol/L 
M0 *10
-9
 pmol/kg/min 
M1  *10
-9
 pmol/kg/min 
HOMA-B  % 
HOMA-S % 
HOMA-IR  
  
FSIVGTT derived  
SI x 10
-4
  (microU/ml)
-1
.min
-1
 
SG x 10
-2
  min
–1
 
AIRG (0-10min)  microU/ml. min 
DI x 10
-2
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2.4.2 General statistical tests 
Descriptive analysis of the data with continuous and normally distributed data was 
recorded as mean ± standard deviation, (SD) and, when not normally distributed, 
represented by median and interquartile range (IQR). Normality was checked using 
qq plots. Categorical data has been presented as total numbers (n) and percentages 
(%). 
 
The Student's t-test has been used to compare the means of two groups and analysis 
of variance (ANOVA) employed to compare the means of more than two groups for 
normally distributed continuous data. Mann-Whitney U and Kruskal Wallis tests 
were used for non-normally distributed continuous variables and Pearson chi-
squared test was used for categorical data. P values of <0.05 were taken as 
statistically significant.  
 
We also calculated the average/mean of all the measured metabolic variables from 
diagnosis including variables at Years 1, 2 and 5 years post diagnosis (Chapter 4 and 
5).  These mean averaged metabolic variables of T2DM subjects have been defined 
as the follow-up indicator of diabetic control over 5 years. 
 
2.4.3 Univariate Logistic Regression Analyses 
A substantial numbers of tests were performed, to indicate differences between sub-
groups for the identification of possible important explanatory variables. This in 
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addition to univariate regression methods gave a smaller subset of variables for 
multivariable analysis. These designated putative risk factors were assessed using 
logistic regression methods for the presence or absence of DR (Binary outcome). 
The non-normally distributed variables were log transformed.  
 
Odds ratios with 95% CI have been used to denote the likelihood of an event 
occurring. An odds ratio equal to one occurs when the odds are the same in two 
groups and represents no association between the exposure and the disease 
(Kirkwood BR and Sterne JAC 2003). Odds ratios (OR) less than one are interpreted 
as the event being less likely to occur for an increase in the predictor variable, 
whereas odds ratios larger than one are interpreted as the event being more likely to 
occur. 
 
2.4.4 Multivariate Logistic Regression Analyses 
Multiple regression is a technique which analyses how dependant variables are 
influenced by predictor variables. Thus it is utilised to establish a prediction equation 
for the dependant variable from a number of predictor variables. All multivariate 
analyses were adjusted for age, gender, BMI and risk factors like SBP and TC which 
have previously been reported to have an association (Klein R et al. 1989b; Chew 
EY et al. 1996; UK Prospective Diabetes Study Group 2004) with DR. In our study a 
non-correlated subset of clinical and metabolic variables was determined based on 
statistical and clinical relevance 
.  
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Chapter 3 
Retinopathy at diagnosis 
in subjects with Type 2 
diabetes mellitus
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3.1 Introduction 
A relatively recent analysis based on the 2010 global estimate of persons with DM at 
285 million reported that approximately 93 million people had evidence of DR, 17 
million with proliferative DR, 21 million with diabetic macular oedema, and 28 
million with vision-threatening DR worldwide (Yau et al. 2012). In subjects with 
T2DM the prevalence estimates for DR ranged from 7 to 55.0% in the USA, 21.0 to 
52.0% in the UK and 18.8 to 65.9% in Scandinavia (Williams R et al. 2004).Thus 
screening, early detection of DR and treatment of known and modifiable risk factors 
is imperative. Approximately 17-18 % of subjects with T2DM have some lesions of 
DR at diagnosis, 40 to 60% after 20 years and approximately 10% developing sight-
threatening lesions related to either exudative maculopathy and/or proliferative DR 
after 20 years of known DM duration (Stefansson E et al. 2000).   
 
Various risk factors are associated with the development and progression of DR 
including hyperglycaemia (Zhang X et al. 2010), duration of DM (Zhang X et al. 
2010), hypertension and dyslipidaemia (Klein R et al. 1989b; Chew EY et al. 1996; 
UK Prospective Diabetes Study Group 2004). The UKPDS and DCCT, along with 
their 10-year follow-up, have demonstrated the benefits of early and sustained 
improvement in glycaemic control with respect to DR (The Diabetes Control and 
Complications Trial/Epidemiology of Diabetes Interventions and Complications 
Research Group 2000 Feb; Holman RR et al. 2008). Furthermore the UKPDS had 
shown that for every 1% decrease in HbA1c, there was a 37% risk reduction in 
microvascular complications in T2DM, predominantly DR and 14% reduction in all-
cause mortality (Stratton IM et al. 2006) . The ACCORD Eye Study Group has  
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shown that intensive glucose and lipid lowering, but not intensive blood-pressure 
control, reduces the rate of progression of DR (ACCORD study group and Accord 
Eye Study Group 2010). In the ACCORD follow-on study (ACCORDION) in 
T2DM subjects with established cardiovascular disease and duration of DM>10 
years re-affirmed that early intensive glycaemic control continued to reduce the risk 
of DR progression (ACCORD Study Group 2016).  
 
In individuals with T1DM, the DCCT  showed that the total glycaemic exposure 
(HbA1C and duration of diabetes) explained 11% of the variation in retinopathy risk 
in the complete cohort (The Diabetes Control and Complications Trial Research 
Group (DCCT) 1995) so that other factors may potentially explain the other 89% of 
the variation in risk among subjects independent of HbA1C. These will include 
environmental, genetic factors as well as glycaemic variation and other measures of 
glycaemia, on their own or through an inter-correlation with HbA1C.  
 
Investigating the possible association between hyperglycaemia and the presence of 
DR has over the years involved measurement of various metabolic indices, 
predominantly HbA1C and/or fasting plasma glucose (Miki E and Kikuchi M 1994; 
Stratton IM et al. 2006) with few examining dysglycaemia in more detail and very 
little reference to the role of β-cell function and insulin resistance. However, in 2005, 
Shiraiwa et al. suggested that postprandial hyperglycaemia and postprandial 
hypoinsulinaemia were predictors for incident DR in Japanese T2DM subjects who  
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were not on insulin treatment (Shiraiwa T et al. 2005a). The Diabetes Prevention 
Program (DPP) studied subjects with impaired glucose tolerance and recent onset 
T2DM, and found a higher baseline systolic blood pressure (SBP) and HbA1c 
amongst those with DR, but found no difference in insulin secretion (measured 30 
minutes post glucose challenge) as estimated by the Corrected Insulin Response 
(CIR) (Diabetes Prevention Program Research Group 2007 ) calculation. Their 
prevalence of DR was 8% in the subjects noted to be in the ‘pre-diabetic’ state and 
was 12% in the T2DM subjects within 3 years of diagnosis. In contrast a 
community-based study in Taiwan demonstrated that both β-cell dysfunction and 
increased insulin resistance (IR) (both measured by the HOMA methodology) were 
associated with the presence of DR in established T2DM patients (Tung TH et al. 
2007). Similarly, over the last decade, there have been other reports associating IR 
with DR (Katsumori K et al. 1995; Suzuki M et al. 2000; Nakano S  et al. 2003 ).  
 
3.2 Hypothesis and Aim of this analysis: 
The first research hypothesis was that along with the overall glycaemic exposure 
(routinely expressed by HbA1c), both the fasting and postprandial components of 
glycaemic exposure act in concordance and independently to affect the prevalence, 
of DR in newly diagnosed type 2 diabetic subjects. The second hypothesis was that 
β-cell dysfunction (fasting and postprandial) is the basis of this overall dysglycaemia 
leading to DR in these subjects. 
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The inter relationship between β-cell function, glucose effectiveness (SG), insulin 
sensitivity (SI), fasting and postprandial dysglycaemia, with the presence of DR in 
newly-diagnosed subjects with T2DM has not previously been reported. The aims of 
this study were to investigate the relationship between these and the presence of DR 
in newly-diagnosed previously-untreated T2DM.  
 
3.3 Methods 
In an attempt to minimise the number of confounding factors, such as duration of 
known T2DM and the use of different treatment modalities, we recruited only newly 
diagnosed and treatment- naïve T2DM subjects. 661 subjects were recruited at 
diagnosis. 19 subjects were excluded as they had no retinopathy data. A further 98 
subjects were excluded from the analysis as they had incomplete MTT data. Thus 
544 newly diagnosed treatment naïve subjects, with T2DM (Group A) were recruited 
into the study 1-2 weeks after diagnosis of DM prior to any intervention with either 
lifestyle advice and/or hypoglycaemic medications between 1981 and 2007.  
 
From 1991 onwards a subgroup of 201 subjects (Group B) additionally underwent a 
‘Frequently Sampled Intravenous Glucose Tolerance Test’ (FSIVGTT), following a 
second sequential overnight fast. The modified IVGTT was not used until part way 
through the study accounting for the smaller sample size. Once the modified IVGTT 
was used, most subjects (apart from those where the intravenous cannula failed etc.) 
underwent both tests.  
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The methods chapter (Chapter 2) states in detail the subject recruitment, 
experimental protocol, data analysis and basic statistical analysis. 
 
3.3.1 Statistical analysis 
Following the initial descriptive analysis and comparison of the means of the two 
groups, the designated putative risk factors were assessed using logistic regression 
methods with non-normally distributed variables [(FPG, FPI, PPG, PPI, AUCGlucose 
(0-240min), AUCInsulin (0-240min), HOMA B, M0, M1 and Sg)] log transformed. A non-
correlated subset of clinical and metabolic variables was determined based on 
statistical and clinical relevance. All multivariate analyses were adjusted for age, 
gender, BMI and putative risk factors systolic blood pressure and total cholesterol 
which have previously been reported to have an association (Klein R et al. 1989b; 
Chew EY et al. 1996; UK Prospective Diabetes Study Group 2004) with DR. The p 
value was calculated using the likelihood ratio test. All analysis were conducted 
using SPSS 20 with p < 0.05 taken as significant (two-tailed). Multivariate analysis 
was also conducted finally with the models including a parameter of -cell 
responsiveness/ -cell function and including a parameter of glycaemia, adjusting for 
the above mentioned variables.  
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3.4 Results 
 3.4.1 Baseline characteristics of subjects with type 2 diabetes at diagnosis (Table 
3.1) 
Of the 544 subjects (Group A), (393 male and 151 female, 2.6:1) with a mean age of 
54 (SD±10) years, 16.5% (90) had evidence of DR whereas the remaining 83.5% 
(454) had no DR at the time of presentation. Of those with DR, the majority 84.4% 
(76) had lesions of BDR (R1.1, R1.2 with or without M1), 15.6% (14) had PPDR 
(R2) and none displayed exudative maculopathy (M2) or PDR (R3). In the subgroup 
of patients (Group B, n= 201) who underwent FSIVGTT in addition to MTT, 15% 
(30) had DR comprising 12.5% (25) with BDR and 2.5% (5) PPDR with none 
having exudative maculopathy or PDR. The remaining 85% (171) of subjects had no 
evidence of DR.  
 
Baseline characteristics including age, weight, BMI, systolic and diastolic blood 
pressure, total cholesterol and HbA1c of the patients with DR and NDR in groups A 
and B are detailed in table 1. At baseline, group A subjects with DR were 
significantly leaner i.e. had a lower body weight (p= 0.02) compared to those 
without DR, although the difference in BMI did not reach significance (p= 0.06). 
Subjects with DR had a non-significantly higher HbA1c, (p= 0.06). Apart from 
weight, other baseline characteristics were not significantly different between those 
with or without DR (Table 3.1). 
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Table 3.1: Baseline characteristics for subjects with No Diabetic Retinopathy 
compared to those with Diabetic Retinopathy at time of diagnosis of T2DM. Group 
A: 544 subjects who underwent MTT, Group B: 201 subjects who underwent MTT 
and FSIVGTT 
 
Group A All 
subjects 
No Diabetic 
Retinopathy 
 
Diabetic 
Retinopathy 
 
p value 
(between  
NDR and 
DR)  
Number 544 454 90  
Age at presentation (years) 54 (10) 54 (10) 56 (11) 0.28 
Male Sex (%) 393 (72) 324 (71) 69 (77) 0.31 
Weight (kg) 88 (17) 88 (17) 85 (19) 0.02 
BMI (kg.m
2
) 30.2 (5.0) 30.4 (5.3) 29.6 (5.8) 0.06 
Systolic blood pressure (mmHg) 137 (19) 137 (20) 139 (18) 0.25 
Diastolic blood pressure (mmHg) 83 (11) 83 (11) 83 (11) 0.71 
Total Cholesterol (mmol/L) 5.4 (1.2) 5.5 (1.2) 5.2 (1.2) 0.08 
HbA1c (%) 7.7 (2.0) 7.7 (2.0) 8.0 (1.8) 0.06 
Group B 
All 
subjects 
No Diabetic 
Retinopathy 
 
Diabetic 
Retinopathy 
p value 
(between  
NDR and 
DR) 
Number 201 171 30  
Age at presentation (years) 55 (10) 55 (10) 55 (11) 0.79 
Male Sex 145 (72) 125 (73) 20 (67) 0.47 
Weight (kg) 90 (17) 91 (16.7) 86 (16.5) 0.16 
BMI (kg.m
2
) 31.2 (5.5) 31.3 (5.6) 30.6 (4.8) 0.54 
Systolic blood pressure (mmHg) 135 (19) 135 (18) 134 (19) 0.68 
Diastolic blood pressure (mmHg) 81 (10) 81 (10) 81 (10) 0.95 
Total Cholesterol (mmol/L) 5.4 (1.1) 5.4 (1.2) 5.4 (1.0) 0.77 
HbA1c (% ) 
 
7.6 (1.9)  7.6 (2.0)      
 
7.7 (1.5) 
 
0.80 
 
Data expressed as Means (± SD); Sex: Number (%); BMI = Body Mass Index 
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3.4.2 Comparative analysis of metabolic and hormonal data in subjects with 
type 2 diabetes with and without retinopathy at diagnosis (Tables 3.2 and 3.3) 
The metabolic variables during the MTT for group A subjects with or without DR 
are detailed in Table 3.2. Those subjects with DR in the fasting state had lower 
plasma insulin concentrations (p= 0.036), estimated -cell
 
responsiveness i.e. M0 (p= 
0.014) and -cell
 
function
 
i.e.
 ‘HOMA-B’ (p= 0.044), associated with higher fasting 
glucose levels (p= 0.021). In the postprandial state, individuals presenting with DR 
had significantly higher postprandial (2 hour) glucose (p= 0.023) with lower 
postprandial insulin levels (p= 0.001). T2DM subjects with DR had numerically 
lower but non-significant (p= 0.065) postprandial -cell
 
responsiveness [M1 {13.5 
(7.9-23.8) vs.16.9 (9.1-30.0)*10
-9
 pmol/kg/min}]. 
 
Over the 4 hour MTT study period, subjects with DR had significantly higher 
AUCGlucose (0-240min) (p= 0.023) and lower AUCInsulin (0-240 min) (p= 0.001) in 
comparison to those without DR (Table 2a). The glucose and insulin profiles and 
indices of -cell
 
responsiveness (M0 and M1) during the MTT in subjects with DR 
and NDR are illustrated in Figures 1a and b.   
 
The baseline characteristics and the metabolic responses in group B subjects with 
DR and NDR who underwent FSIVGTT are detailed in Table 3.3. Whereas insulin 
sensitivity (SI) was not significantly different between the two groups, the SG was 
significantly reduced in those with DR compared to those without DR (p= 0.012). 
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There was no difference in the AIRG and disposition index (DI) between those with 
or without DR.  
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Table 3.2: Comparison of the metabolic variables during the Meal Tolerance Test in 
subjects with No Diabetic Retinopathy and those with Diabetic Retinopathy at 
diagnosis of T2DM 
 
Group A 
No Diabetic Retinopathy 
(n=454) 
Diabetic Retinopathy 
(n=90) 
p value 
Fasting Glucose (mmol/L) 9.6 (7.6 - 12.7) 10.6 (8.5 – 13.8) 0.021 
Postprandial Glucose (mmol/L) (120 mins)  13.4 (9.8 - 17.3) 15.1 (11.1 - 18.1) 0.023 
AUC Glucose (0-240min) (mmol/L)           11.8 (9.0 – 15.4) 13.6 (9.8 - 16.3) 0.023 
Fasting Insulin (pmol/L) 61.8 (34.0 -99.0) 50.5 (33.9 – 86.36) 0.036 
Postprandial  Insulin (pmol/L) (120 mins)  278.5 (162.0 – 459.3) 189.0 (108.3  –  335.5) 0.001 
AUC Insulin (0-240min) (pmol/L) 199.2 (117.7 - 317.2) 130.5 (83.8-225.7) <0.001 
M0 (*10
-9
 pmol/kg/min) 5.3 (3.1-7.8) 3.7 (2.6-7.3) 0.014 
M1 (*10
-9
 pmol/kg/min) 16.9 (9.1-30.0) 13.5 (7.9-23.8) 0.065 
HOMA-B (%) 34.9 (19.1-60.3) 26.1 (14.7-48.2) 0.044 
HOMA-S (%) 59.7 (37.7-105.5) 78.7 (45.2-108.6) 0.094 
HOMA-IR 1.7 (0.9-2.7) 1.3 (0.9-2.2) 0.094 
 
Table 3.3: Comparison of metabolic variables following Frequently Sampled 
Intravenous Glucose Tolerance Test in subjects with No Diabetic Retinopathy and 
those with Diabetic Retinopathy at diagnosis  
 
Group B 
No Diabetic Retinopathy 
(n=171) 
Diabetic Retinopathy 
(n=30) 
p value  
SI x 10
-4
 [(microU/ml)
-1
.min
-1
] 0.8 (0.4-1.4) 0.9 (0.6-1.3) 0.610 
SG x 10
-2
 (min
–1
) 1.4 (1.2-1.7) 1.2 (0.8-1.6) 0.012 
AIRG (0-10min) (microU/ml. min) 111.4 (65.4-177.7) 94.8 (62.2-191.0) 0.703 
DI x 10
-2
 0.89 (0.39-1.53) 0.82 (0.51-1.70) 0.744 
 
Data expressed as median (1
st
 – 3rd Inter Quartile Range)  
FPG = Fasting Plasma Glucose; PPG = Post Prandial Glucose; AUC = Area Under 
the Curve 
SI = Insulin Sensitivity; SG = Glucose effectiveness; AIRG (0-10min) = Acute Insulin 
Response to glucose; DI = Disposition Index   
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Figure 3.1: Glucose and Insulin Profiles with β cell responsiveness in patients 
with and without diabetic retinopathy. 
 1a) Plasma glucose and insulin profile (mean ± SEM) during MTT in subjects with 
NDR (Filled squares) (n = 454) and those with DR (Open triangles) (n = 90) at 
diagnosis of T2DM. Significant difference between NDR and DR:  Fasting 
Glucose (p = 0.021),  Postprandial Glucose (p = 0.023),  Fasting Insulin (p 
= 0.036) and  Postprandial Insulin (p = 0.001).      
 
1b) Fasting (M0) (p = 0.014) and Post-prandial (M1) (p = 0.065) β cell 
responsiveness (mean ± SEM) during MTT in subjects with NDR and those with DR 
at diagnosis of T2DM. 
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3.4.3 Univariate and multivariate regression analysis (Tables 3.4 and 3.5)  
Fasting glucose (OR 2.23 [95% CI 1.038, 4.791] p = 0.04), postprandial glucose (OR 
2.09 [95% CI 1.063, 4.123] p = 0.033), AUCGlucose (0-240min) (OR 2.25 [95% CI 1.087, 
4.664] p= 0.029), fasting insulin (OR 0.76 [95% CI 0.585, 0.986] p = 0.039), 
postprandial insulin (OR 0.66 [95% CI 0.511, 0.863] p= 0.002) and AUCInsulin (0-
240min) (OR 0.61 [95% CI 0.453, 0.828] p= 0.001) show the contribution of fasting, 
postprandial and overall hyperglycaemic/insulinopaenic exposure in subjects leading 
to DR at diagnosis. However, in this group of subjects no significant relationship 
was observed for HbA1c (OR 2.3 [95% CI 0.900, 5.859] p = 0.082) with DR, when 
adjusted for the mentioned variables although the HbA1c was higher in subjects with 
DR. Each 1 mmol/L increase in fasting and postprandial glucose was associated with 
a two-fold increase the risk of DR. In addition each 1 pmol/L decrease in fasting and 
postprandial insulin was associated with increased risk of DR by 24% and 34% 
respectively.  
 
Based on the inter-group differences (Tables 2 and 3), univariate logistic regression 
was conducted which demonstrated that postprandial glucose, AUCGlucose (0-240min), 
postprandial insulin, AUCInsulin (0-240min), M0, HOMA-B and SG were significantly 
related to the presence of DR (Table 3.4).  
 
Factors independently associated with DR in multivariate logistic regression 
analyses when adjusted for age, sex, BMI, total cholesterol and systolic blood 
pressure are detailed in (Table 3.5). Measures of -cell function M0 (OR 0.66 [95% 
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CI 0. 0.484, 0.894] p= 0.007) and HOMA-B (OR 0.74 [95% CI 0.570, 0.958] p= 
0.022) were independently associated with DR along with SG (OR 0.20 [95% CI 
0.066, 0.602] p= 0.004), reflecting contribution of an “insulin-independent 
component of glucose tolerance”. 
 
When a parameter of -cell responsiveness/-cell function and a parameter of 
glycaemia (HbA1c/FPG/PPG) was included in multivariate logistic regression 
analyses adjusting for the above mentioned variables the parameters of -cell 
responsiveness/-cell function were significantly associated with the presence of DR, 
thus possibly reflecting that in this group of patients, failing -cell function is the 
driving force behind the total glycaemic exposure whether it be from FPG or PPG or 
HbA1c (Table 3.5).  
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Table 3.4: Univariate and multivariate logistic regression depicting variables independently associated with the presence of DR  
  Number Crude OR (95% CI) p Adjusted OR (95% CI) p OR (95% CI) p  
      
 
(for age and sex)  
 
(fully adjusted **) 
 HbA1c (%) 506 2.329 (0.931, 5.823) 0.071 2.515 (0.997, 6.346) 0.051 2.296 (0.900, 5.859) 0.082 
Fasting Glucose (mmol/L) 544 2.078 (0.982, 4.400) 0.056 2.238 (1.051, 4.765) 0.037 2.23 (1.038, 4.791) 0.040 
Postprandial Glucose (mmol/L) (120 mins)  543 1.944 (1.004, 3.763) 0.049 2.054 (1.058, 3.987) 0.033 2.093 (1.063, 4.123) 0.033 
AUC Glucose (0-240min) (mmol/L)           544 2.081 (1.021, 4.242) 0.044 2.196 (1.075, 4.487) 0.031 2.252 (1.087, 4.664) 0.029 
Fasting Insulin (pmol/L) 494 0.782 (0.607, 1.007) 0.057 0.784 (0.607, 1.012) 0.061 0.759 (0.585, 0.986) 0.039 
Postprandial  Insulin (pmol/L) (120 mins)  534 0.681 (0.526, 0.882) 0.004 0.686 (0.529, 0.890) 0.005 0.664 (0.511, 0.863) 0.002 
AUC Insulin (0-240min) (pmol/L) 534 0.625 (0.465, 0.840) 0.002 0.631 (0.468, 0.850) 0.002 0.612 (0.453, 0.828) 0.001 
M0 (*10
-9
 pmol/kg/min) 540 0.693 (0.514, 0.934) 0.016 0.697 (0.517, 0.940) 0.018 0.658 (0.484, 0.894) 0.007 
HOMA-B (%) 494 0.750 (0.582, 0.968) 0.027 0.745 (0.577, 0.963) 0.025 0.739 (0.570, 0.958) 0.022 
SG x 10
-2
 (min
–1
) 201 0.206 (0.069, 0.618) 0.005 0.211 (0.070, 0.642) 0.006 0.200 (0.066, 0.602) 0.004 
 
** adjusted for age, sex, BMI, SBP, TCh 
BMI = Body Mass Index, SBP = Systolic Blood Pressure; TCh = Total Cholesterol  
FPG = Fasting Plasma Glucose; PPG = Post Prandial Glucose; AUC = Area Under the Curve, SG = Glucose effectiveness 
 
122 
 
Table 3.5: Univariate and Multivariate logistic regression depicting variables independently associated with the presence of DR  
 
 
Number Crude OR (95% CI) 
 
Adjusted OR (95% CI) 
 
Adjusted OR (95% CI)  
a)     
 
(fully adjusted *) 
 
(adjusted for * and HbA1c ʘ)  
M0 (*10
-9
 pmol/kg/min) 540 0.693 (0.514, 0.934) 0.016 0.658 (0.484, 0.894) 0.007 0.647 (0.470 – 0.891) 0.008 
HOMA-B (%) 494 0.750 (0.582, 0.968) 0.027 0.739 (0.570, 0.958) 0.022 0.719 (0.550 – 0.940) 0.016 
 b)     
 
(fully adjusted *) 
 
(adjusted for * and FPG ©)  
M0 (*10
-9
 pmol/kg/min) 540 0.693 (0.514, 0.934) 0.016 0.658 (0.484, 0.894) 0.007 0.655 (0.482 – 0.891) 0.007 
HOMA-B (%) 494 0.750 (0.582, 0.968) 0.027 0.739 (0.570, 0.958) 0.022 0.739 (0.570 – 0.958) 0.022 
 c)     
 
(fully adjusted *) 
 
(adjusted for * and PPG ®)  
M0 (*10
-9
 pmol/kg/min) 540 0.693 (0.514, 0.934) 0.016 0.658 (0.484, 0.894) 0.007 0.655 (0.482 – 0.891) 0.007 
HOMA-B (%) 494 0.750 (0.582, 0.968) 0.027 0.739 (0.570, 0.958) 0.022 0.739 (0.570 – 0.958) 0.022 
 
* for age, sex, BMI, SBP, TCh   ʘ for age, sex, BMI, SBP, TCh, HbA1c 
© for age, sex, BMI, SBP, TCh, FPG  ® for age, sex, BMI, SBP, TCh, PPG 
BMI = Body Mass Index, SBP = Systolic Blood Pressure; TCh = Total Cholesterol, FPG = Fasting Plasma Glucose; PPG = Post Prandial 
Glucose
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3.5 Discussion 
Our analysis shows an independent association for the presence of DR with both 
fasting and postprandial hyperglycaemic and insulinopaenic responses to the MTT, 
as well as to the 4 hour (AUC (0-240min)) response to the meal. Thus our study shows 
both fasting and postprandial glycaemic exposure exhibit an independent association 
with DR. Although HbA1c was higher in the subjects with DR, it fails to reach 
significance (p= 0.06). Shiraiwa et al. studied Japanese T2DM subjects known to 
have DM but not on insulin treatment (Shiraiwa T et al. 2005a) and established 
postprandial hyperglycaemia but not HbA1c to be independently correlated with the 
presence of DR (Shiraiwa T et al. 2005a) and stated postprandial hyperglycaemia as 
a possible predictor for incident DR in their subjects. Contrary to our findings, two 
recent studies from the UK identified an independent association for the presence of 
DR with HbA1c and SBP in newly diagnosed T2DM within the first year of their 
diagnosis (Kostev K and Rathmann W 2012; Looker HC et al. 2012). The DPP study 
involving newly diagnosed T2DM subjects has also reported a higher HbA1c 
amongst those with DR (Diabetes Prevention Program Research Group 2007 ).  
 
Our findings have also demonstrated that the presence of DR is independently 
associated with reduced fasting and postprandial β-cell responsiveness, resulting in 
both fasting and postprandial hyperglycaemia. In this analysis there is an 
independent association of M0 and HOMA-B with presence of DR by measuring β 
cell functio(Hovorka R et al. 1998)n in response to a standardised meal challenge, 
employing both the CPR program (Hovorka R et al. 1998) and the HOMA 
methodologies. Similarly the relationship between DR with β cell function (HOMA-
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B) has been seen in a community-based study in Taiwan by Tung et al. (Tung TH et 
al. 2007) which involved patients with T2DM of varying duration, who were treated 
with lifestyle modifications and/or oral hypoglycaemic agents. They observed that 
those subjects with better preserved β-cell function were less likely to have DR. The 
association between fasting β-cell dysfunction and DR in established T2DM patients 
as reported by Tung et al (Tung TH et al. 2007) is in agreement with our findings in 
our newly-diagnosed, treatment naïve, T2DM subjects. The UKPDS has also 
reported that the severity of retinopathy at diagnosis of T2DM was related in both 
sexes to reduced β-cell function with lower serum insulin levels, higher fasting 
plasma glucose, systolic and diastolic blood pressure (Kohner et al. 1998). These 
findings contrasts with the DPP study involving newly diagnosed T2DM subjects, 
where no difference in insulin secretion estimated by the CPR was found (Diabetes 
Prevention Program Research Group 2007 ). This is possibly because the loss of the 
first phase insulin response was not captured in DPP as it was the 30 minute insulin 
that was measured. 
 
Glucose effectiveness (SG) represents the capacity of glucose, per se, to enhance 
glucose cellular uptake and to suppress endogenous glucose production and has been 
reported to be an important determinant of glucose metabolism (Best JD et al. 1996). 
The glucose transporter protein GLUT-1 is widely distributed on the plasma 
membrane of various body tissues contributing an important role in insulin-
independent glucose uptake (Ebeling P et al. 1988; Henriksen JE et al. 1994). Thus, 
in the presence of significant β-cell dysfunction and resultant insulinopaenia, a 
relatively poor SG will further worsen glycaemia. In addition, the insulin-
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independent component of glucose tolerance was reduced and independently 
associated with the presence of DR at diagnosis. This might explain our findings, 
where the newly diagnosed T2DM subjects with worse SG are more likely to present 
with DR. 
 
This analysis indicates significant contributions of β-cell dysfunction, fasting and 
postprandial hyperglycaemia/insulinopaenia and reduced glucose effectiveness to the 
presence of DR. Thus it adds to the evidence base of contributory factors towards 
development of diabetic retinopathy. Several epidemiological studies have 
confirmed the association between hyperglycaemia and the development of late 
diabetic complications (The Diabetes Control and Complications Trial/Epidemiology 
of Diabetes Interventions and Complication (DCCT/EDIC) Study Research Group 
2005; Holman RR et al. 2008). However most of the previous studies have employed 
the time-averaged mean levels of glycaemia measurement of HbA1c as a measure for 
glycaemic status. Over the last decade there has been increasing recognition that 
HbA1c is not a complete expression of the degree of hyperglycaemia and that other 
aspects of dysglycaemia contribute to the increased risk of diabetic complications 
and HbA1c was reported to account for 11% of the risk of retinopathy in the DCCT 
(The Diabetes Control and Complications Trial Research Group (DCCT) 1995). 
Recent research has also suggested that postprandial glucose levels and glucose 
variability, may confer additional risks for the development of micro- and macro 
vascular diabetic complications (Brownlee M and Hirsch IB 2006; Hanefeld M and 
Temelkova-Kurktschiev T 2002). 
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Mechanistically, this may be explained by reports that hyperglycaemia contributes 
towards DR by increasing the expression of several growth factors (e.g. platelet 
derived growth factor and vascular endothelial growth factors) by inducing apoptosis 
of retinal cells (Mizutani M et al. 1996; Barber AJ et al. 1998). Similarly 
physiological concentrations of insulin have been shown to rescue cultured optic 
nerve cells from apoptosis and to be necessary for survival of retinal ganglion cells 
in culture medium (Barber AJ et al. 2001). 
 
In our study we measured insulin sensitivity both by the MINMOD program 
(following FSIVGTT) and HOMA (following MTT) and found no difference 
between T2DM subjects presenting with DR compared to those without DR at the 
time of diagnosis. Our study cohort differed from other reports because it comprised 
both newly diagnosed, treatment naïve participants with T2DM, and thus lacked 
confounding effects of therapeutic interventions. By contrast, other cross-sectional 
studies have associated insulin sensitivity (assessed by euglycaemic clamp) with the 
presence or severity of DR (Katsumori K et al. 1995; Suzuki M et al. 2000; Nakano 
S  et al. 2003 ). The numbers of subjects and controls in those studies were modest 
and the subjects recruited had established T2DM that was being treated with a 
variety of hypoglycaemic agents, both oral agents and insulin preparations. It is 
therefore unclear whether the association that they found was entirely independent of 
the underlying confounders such as duration and treatment modalities.  
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Thus, in our cohort of newly diagnosed T2DM subjects, a leaner group of subjects, 
(which could be a manifestation of the relative insulinopaenia of subjects presenting 
with DR) with a reduced β cell secretory/responsiveness and hyperglycaemia, 
presented at diagnosis with DR.  These individuals did not have a significant 
contribution from diminished insulin sensitivity at the point of diagnosis. 
 
Whilst our study is limited by its cross-sectional design that makes it difficult to 
confirm a cause and effect relationship, the strength of our study lies in the 
recruitment of subjects at diagnosis. Thus, we were able to rule out confounding 
factors like duration of DM and treatment modalities. It also presents a detailed 
analysis of the metabolic response of a T2DM subject, emanating from a diminished 
fasting functional β-cell state, resulting in both fasting and postprandial 
dysglycaemia leading to DR but not being affected by an element of insulin 
insensitivity. An independent association for the presence of DR with HbA1c in 
subjects with newly diagnosed T2DM within the first year of their diagnosis 
(Diabetes Prevention Program Research Group 2007 ) (Kostev K and Rathmann W 
2012; Looker HC et al. 2012) is well- recognized. However, our study fails to show 
this association with chronic glycaemia as represented by HbA1c. A limitation of our 
study was that over its duration, because of developments in the measurement of 
HbA1c, we employed two different assays, which may account for this difference. 
However, our study provides a detailed analysis of the metabolic and hormonal 
responses to different carbohydrate challenges in our population of T2DM subjects. 
The DPP reported more than 12% of subjects with T2DM had DR within 
approximately 3 years of diagnosis (Diabetes Prevention Program Research Group 
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2007 ). 16.5% of our subjects with newly diagnosed T2DM, who presented with DR, 
were studied within 1-2 weeks of diagnosis, possibly indicating a slightly longer pre-
clinical period in our cohort. In our study, diagnosis of DM was not through a 
standardized or uniform screening program; therefore, duration of DM prior to the 
study is unknown and may have been substantial especially during the early part of 
this study.  
 
3.6 Summary 
In our population of newly diagnosed treatment-naïve T2DM subjects: 
 The prevalence of DR was noted to be associated with relatively worse 
fasting β-cell responsiveness and function with resultant relative 
insulinopaenia. 
  The contribution of the insulin independent (as manifested by reduced SG) 
component of glucose tolerance to the prevalence of DR was further noted. 
 Thus as a consequence of the above mentioned we have exhibited a 
contribution of both fasting and postprandial hyperglycaemia and 
hypoinsulinaemia to the prevalence of DR. 
 
Therefore, assessment of β-cell function may help to identify those subjects with 
T2DM at risk of developing DR who may benefit from early intensive treatment 
with current or newer therapies which help preserve β-cell function in order to 
achieve and maintain good diabetes control and limit progression to complications of 
DM.  
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4.1 Introduction  
In 2004 Williams and colleagues published a systematic review on the incidence of 
DR, PDR and maculopathy in T1DM, T2DM or mixed cohorts based on 153 articles 
(Williams R et al. 2004). The incidence of DR in individuals with T2DM was 66.9% 
over 10 years in the USA and 22.0% over 6 years in the UK. Identifying the risk 
factors involved in the development and progression of DR is important in order to 
be able to define strategies in an attempt to prevent visual impairment and blindness 
caused by this complication. Despite differences in methodologies and populations 
studied, a number of studies have demonstrated that the prevalence and incidence of 
DR are influenced predominantly by the duration and type of DM, glycaemic and 
blood pressure control, dyslipidaemia and the use of insulin (Appendix Table 1).  
Other less consistent risk factors include ethnicity, age of onset of diabetes, gender, 
pregnancy and genetic makeup (Stewart LL et al. 1993). In the 1970’s Kajinuma and 
colleagues also suggested that a past history of obesity during the preceding five year 
follow-up period increased the occurrence of DR (Kajinuma et al. 1983). 
 
From the perspective of risk factors the overall glycaemic exposure in DM seems to 
be the cornerstone for the development and progression of DR, compounded by the 
duration of DM and hyperglycaemia (Keen H et al. 2001; Yoshida Y et al. 2001; 
Tapp RJ et al. 2006; Perol J et al. 2012). Most studies have assessed glycaemic 
control using measures of glycosylated haemoglobin in the form of HbA1c (Klein R 
et al. 1995; Stratton IM et al. 2001; Voutilainen-Kaunisto RM et al. 2001; Yoshida Y 
et al. 2001) and FPG (Voutilainen-Kaunisto RM et al. 2001; Janghorbani M et al. 
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2003; Tapp RJ et al. 2006; Tapp RJ et al. 2008) with a lesser number including the 2 
hour PPG (Voutilainen-Kaunisto RM et al. 2001; Shiraiwa T et al. 2005b). In a 
group of Japanese subjects with T2DM, Takao et al. (Takao T et al. 2011) 
demonstrated that fasting plasma glucose variability when estimated (using standard 
deviation) over a prolonged period of time (27-44 years, mean 33 years) is an 
independent risk factor for PDR. Chen and colleagues further showed that T2DM 
subjects who had poor glycaemic control at or near the time of diagnosis and who 
remained poorly controlled over the subsequent four year follow-up period had a 
three times higher rate of development of diabetic retinopathy (31.0%) than those 
with better glycaemic control throughout the study (5.5%) (Chen MS et al. 1995).  
 
However, the relationship between indices of β-cell function, glucose effectiveness 
(SG) and insulin sensitivity (SI), with the progression to DR in newly diagnosed 
subjects with T2DM, reviewed over a prolonged period of time (up to 5years) 
remains inadequately addressed.  
 
4.2 Aim of analysis 
The aim of this analysis was to examine the association between β-cell function, 
glucose effectiveness (SG) and insulin sensitivity (SI) with the progression to DR in 
newly diagnosed and treatment naïve T2DM who had no evidence of DR at the time 
of diagnosis and who were observed for up to 5 years. 
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4.3 Methods 
Data was available on a total of 314 subjects at Year 5, with 293 having data at both 
diagnosis and Year 5. 179 subjects had no evidence of DR at baseline and 
throughout the study period. Of the remaining 114, a total of 60 subjects were 
excluded from analysis i.e. 41 subjects who had DR at Year 0, 17 subjects who 
developed DR at Year 1 or 2 but had no recorded evidence of DR at Year 5 and 2 
subjects with DR at Year 1 and 5 but with no evidence of DR at Year 0 and 2. 
  
Therefore, the number of subjects with NDR at diagnosis, who progressed to DR 
over the 5 year period, was 54 of whom 12 developed DR at Year 1, 15 developed 
DR at Year 2 and the remaining 27 first developed DR at Year 5. Data involving 233 
subjects have been included in the analyses involving 179 subjects who remained 
without DR and 54 who developed DR during course of the 5-year observation 
period. Thus, to monitor incidence, we compared those with NDR at baseline and 
throughout the 5 years (n= 179) with those subjects who developed DR during the 5-
year follow-up (n= 54). Subjects were examined at diagnosis, Year 1, Year 2 and 
Year 5 from diagnosis. The subject recruitment, experimental protocol, data analysis 
and basic statistical analysis are described in detail in Chapter 2. 
 
Appendix Table 2 shows the comparison of baseline characteristics of subjects who 
were not followed up over 5 years compared to those who were followed up over 5 years 
and shows that there was no significant difference in them. 
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4.3.1 Statistical analysis 
Following the initial descriptive analysis and comparison of the means of the two 
groups, a non-correlated subset of clinical and metabolic variables were determined, 
based on statistical and clinical relevance. The designated putative risk factors were 
assessed using logistic regression methods with non-normally distributed variables 
[(FPG, FPI, PPG, PPI, AUCGlucose (0-240min), AUCInsulin (0-240min), HOMA B, M0, M1 and 
Sg)] log transformed. All multivariate analyses were adjusted for age, gender, BMI 
and risk factors that included systolic blood pressure and total cholesterol, which 
have previously been reported to have an association with DR. All analysis were 
conducted using SPSS 20 with p<0.05 taken as statistically significant (two-tailed).  
 
We calculated the average/mean of all the measured metabolic variables from 
diagnosis, including variables at Years 1, 2 and 5 years post diagnosis and have 
defined them as the follow-up indicator of diabetic control over 5 years. 
 
4.4 Results 
4.4.1 Baseline characteristics of subjects with T2DM at 5 years post diagnosis: 
Data involving 233 subjects have been included in the analyses involving 179 
subjects who remained without DR and 54 who developed DR during the course of 
the 5-year observation periods. Of the 233 subjects (Group A) (145 male and 88 
female, 1.65:1) with a mean age of 54 (SD±9) years, 76.8% (179) never developed 
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DR with 23.2% (54) developing DR by 5 years after diagnosis. Of the ones who 
developed DR, BDR was seen in 12 (22%) after 1 year, 15 (28%) after 2 years and in 
27 (50%) after 5 years. Of those with DR at 5 years, the majority of 93% (50) had 
lesions of BDR including M1 with BDR. Only 1.7% (4) had exudative maculopathy 
and none progressed to PPDR or PDR (Figure 4.1). 
 
In the subgroup of 76 subjects (Group B) who underwent FSIVGTT at diagnosis in 
addition to a MTT, 76.3% (58) subjects had no evidence of DR at Year 5. In 
contrast, 23.7% (18) developed DR comprising predominantly of BDR 88.9% (16) 
with 11.1% (2) having exudative maculopathy. There were 6 subjects with BDR at 
Year 1 and 13 in Year 2.  
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Figure 4.1: Subjects with NDR at diagnosis who developed each level of DR at years 
1, 2 and 5. 
 
 
 
BDR: Background Diabetic Retinopathy 
M2: Definite Maculopathy 
137 
 
4.4.2 Comparison of baseline data for subjects with type 2 diabetes who did or 
did not develop DR at 5 years.  
Baseline characteristics including age, weight, BMI, systolic and diastolic blood 
pressure, total cholesterol and HbA1c of the patients with DR and NDR in Year 5 in 
groups A and B are detailed in Table 4.1. Group A subjects with DR at Year 5 
presented with a significantly higher HbA1c, (p= 0.017) at baseline. There was a trend 
to a greater percentage of males in the NDR group, but this was not statistically 
significant. Other baseline characteristics were not significantly different between 
those with or without DR at Year 5. In Group B, HbA1c was higher in those with DR 
at Year 5 but the difference did not reach statistical significance. None of the other 
baseline characteristics were significantly different between those with or without 
DR at 5 years from diagnosis 
 
There was no significant difference in the glycaemic parameters or β-cell function at 
diagnosis in the smaller subset of subjects who develop DR at Year 1, 2 and 5. 
However the subjects who develop DR earlier have lower measured fasting insulin 
levels at diagnosis. (Appendix Table 3) 
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Table 4.1: Baseline characteristics in subjects with No Diabetic Retinopathy 
(NDR) throughout 5 years since diagnosis compared to those who develop Diabetic 
Retinopathy (DR) by 5 years from diagnosis of T2DM. Group A: 233 subjects who 
underwent MTT, Group B: 76 subjects who underwent FSIVGTT 
 
Group A All 
subjects 
No Diabetic 
Retinopathy 
(NDR) 
Diabetic 
Retinopathy 
(DR) 
 Comparison of  
NDR and DR  
(p value) 
Number 233 179 54 - 
Age at presentation (years) 54 (9) 54 (10) 55 (8) 0.53 
Male Sex (%) 75 78 67 0.10 
Weight (kg) 88 (16) 88 (16) 88 (16) 0.78 
BMI (kg.m
2
) 30 (5) 30 (5) 30 (6) 0.48 
Systolic blood pressure (mmHg) 134 (18) 134 (17) 134 (18) 0.74 
Diastolic blood pressure (mmHg) 83 (10) 83 (10) 82 (10) 0.85 
Total Cholesterol (mmol/L) 5.5 (1.3) 5.5 (1.3) 5.7 (1.4) 0.20 
HbA1c (%) 8.2 (2.1) 8.1 (2.1) 8.8 (1.8) 0.017 
Group B All 
subjects 
No Diabetic 
Retinopathy 
 
Diabetic 
Retinopathy 
Comparison of 
NDR and DR  
(p value) 
Number 76 58 18 - 
Age at presentation (years) 54 (9) 53 (9) 56 (9) 0.27 
Male Sex 76 79 67 0.27 
Weight (kg) 91(17) 91(17) 91(19) 0.97 
BMI (kg.m
2
) 31 (6) 31 (5) 32 (7) 0.51 
Systolic blood pressure (mmHg) 133 (17) 133 (17) 133 (17) 0.95 
Diastolic blood pressure (mmHg) 81 (10) 81 (10) 80 (10) 0.56 
Total Cholesterol (mmol/L) 5.6 (1.2) 5.5 (1.2) 5.8 (1.1) 0.37 
HbA1c (%) 7.8 (2.1) 7.6 (2.2) 8.3 (1.9) 0.15 
 
Data expressed as Mean (± SD) or Number (%); BMI = Body Mass Index 
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The metabolic variables observed during the MTT for Group A subjects with or 
without DR during the 5 year period are detailed in Table 4.2a 
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Table 4.2a: Comparison in subjects who underwent a Meal Tolerance Test with No Diabetic Retinopathy throughout 5 years since 
diagnosis compared to those who develop Diabetic Retinopathy by 5 years from diagnosis of T2DM by their parameters at diagnosis. 
 
Group A 
No Diabetic Retinopathy 
(n=179) 
Diabetic Retinopathy 
(n=54) 
p value 
Fasting Glucose (mmol/L) 10.1 (7.8-13.3) 11.6 (9.6-13.6) 0.031 
Postprandial Glucose (mmol/L) (120 mins)  13.9 (10.2-17.7) 16.0 (13.3-18.1) 0.009 
AUC Glucose (0-240min) (mmol/L)           11.6 (8.6-14.6) 13.7 (11.2-15.6) 0.007 
HbA1c (%) 7.4 (6.4-9.6) 8.6 (7.8-10.0) 0.017 
Fasting Insulin (pmol/L) 61.2 (40.0-97.0) 56 (28-92) 0.177 
Postprandial  Insulin (pmol/L) (120 mins)  270 (145-428) 185 (94-391) 0.044 
AUC Insulin (0-240min) (pmol/L) 192 (106-303) 155 (68-270) 0.042 
M0 (*10
-9
 pmol/kg/min) 5.2 (2.7-7.8) 3.9 (1.9-7.0) 0.025 
M1 (*10
-9
 pmol/kg/min) 17.2 (10.4-28.5) 9.8 (6.9-15.5) <0.0001 
HOMA-B (%) 34 (16-60) 25 (11-43) 0.044 
HOMA-S (%) 59 (39-89) 72 (43-115) 0.191 
HOMA-IR 1.7 (1.1-2.6) 1.4 (0.9-2.4) 0.191 
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During the MTT, those with DR at Year 5, compared to those without DR, had at 
baseline a higher HbA1c (p= 0.017) and fasting glucose levels (p= 0.031) with a 
reduced (p= 0.025) basal ß-cell secretory function (M0) and non-significantly lower 
fasting insulin concentrations (p= 0.177), although the estimation of overall β-cell
 
function
 
(HOMA-B) was significantly reduced (p= 0.044) at diagnosis. In the 
postprandial state, individuals with DR at Year 5 had a highly significantly poorer 
estimated postprandial β-cell
 
responsiveness to the test meal i.e. M1 (p= 0.000) and 
lower postprandial insulin levels (p= 0.044) associated with a higher postprandial (2 
hour) glucose level (p= 0.009). 
 
Over the 4-hour MTT study period, subjects with DR had significantly higher 
AUCGlucose (0-240min) (p= 0.007) and lower AUC Insulin (0-240 min) (p= 0.042) in 
comparison to those without DR at Year 5 (Table 4.2a). 
 
The glucose and insulin profiles and indices of ß-cell
 
responsiveness (M0 and M1) 
during the MTT in subjects with DR and NDR are illustrated in Figures 4.2, 4.3 a 
and b. 
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Figure 4.2 a and b: Baseline (at diagnosis) Glucose and Insulin Profiles (mean ± 
SEM) in subjects with and without diabetic retinopathy at 5 years post diagnosis. 
Differences between NDR (n=179) and DR (n=54): Fasting Glucose (p= 0.031), 
2hr Postprandial Glucose  (p= 0.009), Fasting Insulin (p= 0.177) and 2hr 
Postprandial Insulin (p= 0.044). 
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Figure 4.3 a and b: Baseline (at diagnosis) Fasting (M0) and postprandial(M1) β-
cell responsiveness (mean±SEM) in subjects with and without diabetic retinopathy 
by 5 years post diagnosis. Significant differences between NDR and DR: Fasting 
(p= 0.025) and postprandial  (p= 0.000) β-cell responsiveness 
144 
 
The baseline (at diagnosis) β-cell responsiveness, insulin sensitivity in those subjects 
(group B) who underwent FSIVGTT and developed DR or remained NDR at Year 5 
are detailed in Table 4.2b. Whereas insulin sensitivity (SI) was not significantly 
different between the two groups, the AIRG (p= 0.024) and SG (p= 0.036) were 
significantly reduced in those with DR compared to those without DR at Year 5. 
There was no difference in the insulin sensitivity or DI between those with or 
without DR.  
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Table 4.2b: Comparison of metabolic variables following Frequently Sampled Intravenous Glucose Tolerance Test in subjects with No 
Diabetic Retinopathy throughout 5 years since diagnosis compared to those who develop Diabetic Retinopathy by 5 years from 
diagnosis of T2DM by their parameters at diagnosis. 
 
 
Group B 
No Diabetic Retinopathy 
(n=58) 
Diabetic Retinopathy 
(n=18) 
p value  
SI x 10
-4
 [(microU/ml)
-1
.min
-1
] 0.7 (0.4-1.5) 1.1 (0.6-1.8) 0.108 
SG x 10
-2
 (min
–1
) 1.6 (1.3-1.9) 1.3 (0.9-1.6) 0.036 
AIRG (0-10min) (microU/ml. min) 121.6 (64.6-192.9) 68.3 (43.7-113.6) 0.024 
DI x 10
-2
 64.6 (32.7-153.3) 71.6 (42.8-102.2) 0.735 
 
Data expressed as median (1
st
 – 3rd IQR)  
FPG = Fasting Plasma Glucose; PPG = Post Prandial Glucose; AUC = Area Under the Curve 
SI = Insulin Sensitivity; SG = Glucose effectiveness; AIRG (0-10min) = Acute Insulin Response to glucose; DI = Disposition Index   
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4.4.3 Univariate regression analysis  
Based on the inter-group differences (Table 2a and 2b), univariate logistic regression 
analysis was conducted, which demonstrated that HbA1c, fasting and postprandial 
glucose, AUCGlucose (0-240min), and SG were positively related to the development of DR 
by Year 5 whereas β-cell function/secretory capacity represented by M0, M1, HOMA-
B, postprandial insulin, AUC Insulin (0-240min), were negatively related to the appearance 
of DR within the 5-year observation period (Table 4.3). 
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Table 4.3: Univariate and Multivariate logistic regression depicting variables independently associated with development of Diabetic 
Retinopathy by 5 years from diagnosis of T2DM.  
  Univariate  Multivariate  
  Number Crude OR (95% CI) p OR (95% CI) p  
      
 
(fully adjusted **) 
 HbA1c (%) 233 4.27 (1.21, 15.13) 0.024 4.48 (1.26, 15.96) 0.021 
Fasting Glucose (mmol/L) 230 2.77 (1.01, 7.59) 0.047 2.78 (1.02, 7.64) 0.045 
Postprandial Glucose (mmol/L) (120 mins)  230 3.44 (1.34, 8.85) 0.011 3.44 (1.34, 8.86) 0.011 
AUC Glucose (0-240min) (mmol/L)           230 3.60 (1.34, 9.72) 0.011 3.62 (1.34, 9.76) 0.011 
Fasting Insulin (pmol/L) 224 0.77 (0.52, 1.13) 0.184 0.59 (0.36, 0.94) 0.027 
Postprandial  Insulin (pmol/L) (120 mins)  225 0.66 (0.45, 0.95) 0.026 0.66 (0.46, 0.96) 0.031 
AUC Insulin (0-240min) (pmol/L) 229 0.64 (0.43, 0.95) 0.028 0.53 (0.34, 0.83) 0.006 
M0 (*10
-9
 pmol/kg/min) 227 0.62 (0.41, 0.93) 0.022 0.59 (0.39, 0.91) 0.015 
M1 (*10
-9
 pmol/kg/min) 224 0.48 (0.33, 0.70) 0.000 0.46 (0.32, 0.68) 0.000 
HOMA-B (%) 224 0.70 (0.50, 0.98) 0.040 0.60 (0.41, 0.87) 0.007 
SG x 10
-2
 (min
–1
) 76 0.15 (0.27, 0.85) 0.032 0.15 (0.27, 0.85) 0.032 
 
** adjusted for age, sex, BMI, SBP, TCh: SBP = Systolic Blood Pressure; TCh = Total Cholesterol, BMI = Body Mass Index FPG = 
Fasting Plasma Glucose; PPG = Post Prandial Glucose; AUC = Area Under the Curve, SG = Glucose effectiveness 
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4.4.4 Multivariate regression analysis  
Factors associated with DR in univariate logistic regression analyses were adjusted 
for age and sex, BMI, total cholesterol and systolic blood pressure and are detailed in 
(Table 4.3). The p value was calculated using the likelihood ratio test.  
 
HbA1c (OR 4.48 [95% CI 1.26, 15.96] p = 0.021), fasting glucose (OR 2.78 [95% CI 
1.02, 7.64] p= 0.045), postprandial glucose (OR 3.44 [95% CI 1.34, 8.86] p= 0.011), 
AUCGlucose (0-240min) (OR 3.62 [95% CI 1.34, 9.76] p= 0.011), fasting insulin (OR 0.59 
[95% CI 0.36, 0.94] p= 0.027), postprandial insulin (OR 0.66 [95% CI 0.46, 0.96]  
p= 0.031) and AUC Insulin (0-240min) (OR 0.53 [95% CI 0.34, 0.83] p= 0.006) highlights 
the contribution of fasting, postprandial and overall hyperglycaemic and 
insulinopaenic status of subjects, when assessed at diagnosis, who subsequently at 5 
years had developed DR.  
 
Measures of β-cell secretory function i.e. M0 (OR 0.59 [95% CI 0.39, 0.91]             
p= 0.015), HOMA-B (OR 0.60 [95% CI 0.41, 0.87] p= 0.007) and M1 (OR 0.46 
[95% CI 0.32, 0.68] p= 0.000) are independently associated with the development of 
DR along with SG (OR 0.15 [95% CI 0.27, 0.85] p= 0.032), which reflects an insulin-
independent component of glucose tolerance. 
 
 In summary, each 1 mmol/L increase in fasting and postprandial glucose at 
diagnosis was associated with a two to three fold increase in the risk of DR by 5 
149 
 
years after diagnosis. Also each 1 pmol/L decrease in fasting and postprandial 
insulin was associated with increased risk of DR by 41% and 34% respectively.  
 
4.4.5 Comparative analysis of subjects with T2DM with and without DR at 5 
years with metabolic parameters at years 1, 2 and 5 since diagnosis 
The characteristics of patients at Years 1, 2 and 5 including age, weight, BMI, 
systolic and diastolic blood pressure, total cholesterol and HbA1c of the patients with 
DR and NDR in Year 5 in groups A are detailed in tables 4.4, 4.5 and 4.6.  
 
150 
 
 
Table 4.4: Year 1 characteristics of subjects with No Diabetic Retinopathy (NDR) 
throughout 5 years compared to those with Diabetic Retinopathy (DR) by 5 years of 
diagnosis of T2DM. Group A:  Subjects who underwent MTT. 
 
 
 All subjects NDR 
 
DR 
 
p value 
 
Number 
233 179 54  
Age at presentation (years) 55.0 (9.4) 55.0 (9.8) 56.0 (8.2) 0.661 
Male Sex (%) 175 (75) 139 (77.7) 36 (66.7) 0.075 
Weight (kg) 85.9 (16.2) 85.4 (16.4) 87.4 (15.3) 0.343 
BMI (kg.m
2
) 28.8 (6.5) 28.7 (6.0) 29.3 (8.1) 0.231 
Systolic blood pressure (mmHg) 131 (16) 130 (16) 133 (14) 0.238 
Diastolic blood pressure (mmHg) 80 (10) 79 (10) 81 (11) 0.224 
Total Cholesterol (mmol/L) 5.1 (1.1) 5.1 (1.1) 5.2 (1.0) 0.476 
HbA1c (%) 6.6  (1.2) 6.5 (1.1) 6.9 (1.4) 0.011 
 
Data expressed as Mean (± SD); Sex: Number (%); BMI = Body Mass Index 
(kg/m2) 
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Table 4.5: Year 2 characteristics of subjects with No Diabetic Retinopathy (NDR) 
throughout 5 years compared to those with Diabetic Retinopathy (DR) by 5 years of 
diagnosis of T2DM.  Group A: Subjects who underwent MTT. 
 
 
 All subjects NDR 
 
DR 
 
p value 
 
Number 
233 179 54  
Age at presentation (years) 56.0 (9.4) 56.0 (9.8) 57.0 (8.2) 0.661 
Male Sex (%) 175 (75) 139 (77.7) 36 (66.7) 0.075 
Weight (kg) 87.3 (16.6) 87.0 (16.6) 88.4 (16.6) 0.528 
BMI (kg.m
2
) 29.1 (6.9) 28.8 (6.8) 30.3 (7.3) 0.119 
Systolic blood pressure (mmHg) 129.3 (15.7) 128.6 (14.5) 131.7 (19.0) 0.461 
Diastolic blood pressure (mmHg) 78.3 (9.3) 78.0 (9.0) 79.3 (10.1) 0.386 
Total Cholesterol (mmol/L) 5.0 (1.1) 5.0 (1.1) 5.1 (1.0) 0.660 
HbA1c (%) 6.9 (1.5) 6.7 (1.4) 7.3 (1.5) 0.016 
 
Data expressed as Mean (± SD); Sex: Number (%); BMI = Body Mass Index 
(kg/m2)
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Table 4.6: Year 5 characteristics in subjects with No Diabetic Retinopathy (NDR) 
throughout 5 years compared to those with Diabetic Retinopathy (DR) by 5 years of 
diagnosis of T2DM. Group A: Subjects who underwent MTT. 
 
 
 All subjects NDR 
 
DR 
 
p value 
 
Number 233 179 54  
Age at presentation (years) 59.0 (9.4) 59.0 (9.8) 60.0 (8.2) 0.661 
Male Sex (%) 175 (75) 139 (77.7) 36 (66.7) 0.075 
Weight (kg) 85.1 (23.0) 85.0 (22.7) 85.4 (24.2) 0.528 
BMI (kg.m
2
) 29.1 (7.2) 29.0 (7.1) 30.0 (7.8) 0.163 
Systolic blood pressure (mmHg) 135.6 (17.3) 135.2 (16.8) 136.9 (18.8) 0.675 
Diastolic blood pressure (mmHg) 79.1 (10.1) 78.7 (10.5) 80.4 (8.8) 0.527 
Total Cholesterol (mmol/L) 5.2 (1.2) 5.2 (1.2) 5.1 (1.1) 0.604 
HbA1c (%) 7.5 (1.6) 7.4 (1.6) 8.0 (1.6) 0.009 
 
Data expressed as Mean (± SD); Sex: Number (%); BMI = Body Mass Index 
(kg/m2) 
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At Years 1, 2 and 5, group A subjects who developed DR at Year 5 presented with a 
significantly higher HbA1c, (p= 0.011, p= 0.016 and p= 0.009) (Tables 4.4, 4.5 and 
4.6). Other baseline characteristics were not significantly different between those 
with or without DR at Year 5. 
 
The metabolic variables in Year 1, 2 and 5 during the MTT for group A subjects 
with DR or no DR are detailed in Tables 4.7, 4.8 and 4.9. 
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Table 4.7: Comparison of the metabolic variables at 1 year post diagnosis of T2DM 
during the Meal Tolerance Test in subjects with No Diabetic Retinopathy (NDR) 
over 5 years from diagnosis of T2DM to those with Diabetic Retinopathy (DR) by 5 
years from diagnosis of T2DM 
 
 
 
 
NDR 
 
DR 
 
 
p value 
Number 179 54 - 
Fasting Glucose (mmol/L) 7.9 (6.9 – 8.9 ) 8.8 (7.6 – 10.7) 0.003 
Postprandial Glucose (mmol/L) (120 mins)  9.7 (7.8 – 12.1) 11.1 (9.5 – 13.7) 0.005 
AUC Glucose (0-240min) (mmol/L)           8.3 (7.2 – 10.2) 9.8 (8.1 – 11.1) 0.006 
Fasting Insulin (pmol/L) 64.6 (41.0 – 96.1) 63.0 (43.8 – 96.3) 0.965 
Postprandial  Insulin (pmol/L) (120 mins)  289.5 (177.8 – 443.3) 244.0 (155.0 – 396.5) 0.215 
AUC Insulin (0-240min) (pmol/L) 214.3 (134.8 – 313.8) 183.4 (113.0 – 289.5) 0.158 
M0 (*10
-9
 pmol/kg/min) 5.8 (3.8 – 9.5) 5.2 (3.9 – 7.2) 0.180 
M1 (*10
-9
 pmol/kg/min) 21.7 (12.7 – 34.7) 15.5 (11.5 – 29.9) 0.123 
HOMA-B (%) 51.2 (34.6 – 71.5) 39 (25.3 – 60.2) 0.051 
HOMA-S (%) 60.8 (41.4 – 97.0) 63.8 (42.9 – 90.4) 0.870 
HOMA-IR 1.7 (1.0 – 2.4) 1.6 (1.1 – 2.3) 0.870 
 
Data expressed as median (1
st
 – 3rd Inter Quartile Range)  
AUC = Area Under the Curve   
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Those with DR at Year 5, compared to those without, had a higher HbA1c (p= 0.001), 
a higher fasting glucose (p= 0.003) along with higher postprandial (2 hour) glucose 
(p= 0.005) in Year 1 (Table 4.7). Over the 4-hour MTT study period, subjects with 
DR had significantly higher AUCGlucose (0-240min) (p= 0.006) in comparison to those 
without DR at Year 5 (Table 4.7), 1 year post diagnosis. 
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Table 4.8: Comparison of the metabolic variables at 2 years post diagnosis of 
T2DM during the Meal Tolerance Test in subjects with No Diabetic Retinopathy 
(NDR) over 5 years from diagnosis of T2DM to those with Diabetic Retinopathy 
(DR) by 5 years from diagnosis of T2DM 
 
 
 
NDR DR 
 
p value 
Number 179 54 - 
Fasting Glucose (mmol/L) 8.0 (7.1 – 9.4) 8.7 (7.6 – 10.7) 0.113 
Postprandial Glucose (mmol/L) (120 mins)  10.0 (8.2 – 13.0) 11.7 (10.0 – 14.2) 0.005 
AUC Glucose (0-240min) (mmol/L)           8.6 (7.3 – 10.7) 9.9 (8.0 – 12.4) 0.017 
Fasting Insulin (pmol/L) 64.5 (40.0 – 91.8) 61.0 (33.0 – 106.5) 0.595 
Postprandial  Insulin (pmol/L) (120 mins)  281.0 (171.0 – 493.0) 259.0 (134.3 – 426.3) 0.234 
AUC Insulin (0-240min) (pmol/L) 208.0 (131.0 – 333.0) 186.0 (101.1 – 334.1) 0.312 
M0 (*10
-9
 pmol/kg/min) 6.4 (4.0 – 9.0) 5.7 (3.8 – 8.0) 0.444 
M1 (*10
-9
 pmol/kg/min) 23.2 (12.0 – 37.7) 17.5 (8.8 – 27.0) 0.009 
HOMA-B (%) 46.7 (31.4 – 74.1) 44.2 (27.2 – 71.2) 0.349 
HOMA-S (%) 60.7 (40.2 – 95.0) 65.3 (36.9 – 110.7) 0.617 
HOMA-IR 1.7 (1.1 – 2.5) 1.5 (1.0 – 2.7) 0.617 
 
Data expressed as median (1
st
 – 3rd Inter Quartile Range)  
AUC = Area Under the Curve
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Those with DR at Year 5, compared to those without, had a higher HbA1c (p=0.0016) 
in Year 2 (Table 4.8), with a lower estimated postprandial β-cell
 
responsiveness i.e. 
M1 (p= 0.009) and a higher postprandial (2 hour) glucose (p= 0.005) (Table 4.8).  
 
Over the 4-hour MTT study period, subjects with DR had significantly higher 
AUCGlucose (0-240min) (p= 0.017), in comparison to those without DR at Year 5 (Table 
4.8), 2 years post- diagnosis. A higher HbA1c (p= 0.009) at year 5 was the only 
remaining significant association with DR, 5 years post-diagnosis (Table 4.9)  
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Table 4.9: Comparison of the metabolic variables at 5 years post-diagnosis of 
T2DM during the Meal Tolerance Test in subjects with No Diabetic Retinopathy 
(NDR) over 5 years from diagnosis of T2DM to those with Diabetic Retinopathy 
(DR) by 5 years from diagnosis of T2DM 
 
 
 
NDR 
 
DR 
 
p value 
Number 179 54 - 
Fasting Glucose (mmol/L) 8.7 (7.5 – 11.1) 9.2 (7.9 – 11.6) 0.366 
Postprandial Glucose (mmol/L) (120 mins)  12.7 (9.8 – 15.3) 13.3 (10.7 – 16.3) 0.155 
AUC Glucose (0-240min) (mmol/L)           9.5 (7.4 – 12.7) 10.3 (7.9 – 13.7) 0.222 
Fasting Insulin (pmol/L) 61.4 (38.8 – 109.0) 65.6 (43.1 – 100.3) 0.849 
Postprandial  Insulin (pmol/L) (120 mins)  227.5 (173.7 – 426.0) 249.0 (119.8 – 458.0) 0.219 
AUC Insulin (0-240min) (pmol/L) 199.5 (118.1 – 312.7) 161.4 (84.6 – 304.0) 0.240 
M0 (*10
-9
 pmol/kg/min) 6.5 (4.0 – 8.7) 5.6 (2.6 – 8.3) 0.993 
M1 (*10
-9
 pmol/kg/min) 19.8 (12.1 – 31.4) 13.4 (7.3 – 19.0) 0.568 
HOMA-B (%) 42.3 (26.4 – 65.3) 41.8 (20.0 – 62.1) 0.623 
HOMA-S (%) 61.3 (34.6 – 99.4) 59.3 (39.0 – 90.3) 0.991 
HOMA-IR 1.6 (1.0 – 2.9) 1.7 (1.1 – 2.6) 0.991 
 
Data expressed as median (1
st
 – 3rd Inter Quartile Range)  
AUC = Area Under the Curve  
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4.4.6 Univariate regression analysis of Year 1, 2 and 5 Parameters 
Based on the inter-group differences (Tables 4.4 – 4.9) univariate logistic regression 
was conducted which demonstrated that after one year post-diagnosis of T2DM the 
HbA1c (p= 0.028), fasting glucose (p= 0.006), postprandial glucose (p= 0.006) and 
AUCGlucose (0-240min) (p= 0.011), were all significantly related to the development of 
DR by Year 5 (Table 4.10). Similarly, after 2 years post-diagnosis HbA1c (p= 0.011), 
postprandial glucose (p= 0.007), estimated postprandial β-cell
 
responsiveness i.e. M1 
(p= 0.011) and AUCGlucose (0-240min) (p= 0.011) lead to development of DR with no 
contribution from any of the measured parameters 5 years post-diagnosis (Table 
4.10),  
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Table 4.10: Univariate and Multivariate logistic regression depicting variables (Year 1 to 5) independently associated with development 
of Diabetic Retinopathy by 5 years from diagnosis of T2DM.  
  Univariate  Multivariate  
  Number Crude OR (95% CI) p OR (95% CI) p  
      (<0.05)  (fully adjusted **) (<0.05) 
Year 1 HbA1c (%) 228 7.29 (1.24 – 42.86) 0.028 6.20 (1.04 – 36.82) 0.045 
Year 1 Fasting Glucose (mmol/L) 217 7.85 (1.82 – 33.92) 0.006 7.71 (1.78 – 33.29) 0.006 
Year 1 Postprandial Glucose (mmol/L) (120 mins)  217 4.66 (1.56 – 13.93) 0.006 4.57 (1.52 – 13.69) 0.007 
Year 1 AUC Glucose (0-240min) (mmol/L)           218 5.12 (1.46 – 17.85) 0.011 5.00 (1.43 – 17.50) 0.012 
Year 1 HOMA-B (%) 191 0.60 (0.34 – 1.04) 0.069 0.49 (0.26 – 0.87) 0.016 
Year 2 HbA1c (%) 226 7.64 (1.61 – 36.31) 0.011 5.69 (1.16- 27.94) 0.032 
Year 2 Postprandial Glucose (mmol/L) (120 mins) 209 4.54 (1.52 – 13.56) 0.007 4.83 (1.60 – 14.64) 0.005 
Year 2 AUC Glucose (0-240min) (mmol/L)           210 3.90 (1.20 – 12.87) 0.024 4.15 (1.25 – 13.76) 0.020 
Year 2 M1 (*10
-9
 pmol/kg/min) 195 0.62 (0.43 – 0.90) 0.011 0.59 (0.41 – 0.86) 0.006 
Year 5 HbA1c (%) 120 1.93 (0.294 – 12.73) 0.493 1.81 (0.25 – 13.19) 0.560 
** adjusted for age, sex, BMI, SBP, TCh: SBP = Systolic Blood Pressure; TCh = Total Cholesterol, BMI = Body Mass Index 
FPG = Fasting Plasma Glucose; PPG = Post Prandial Glucose; AUC = Area Under 
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4.4.7 Multivariate regression analysis of Year 1, 2 and 5 Parameters 
Independently-associated risk factors for the development of DR in univariate 
logistic regression analyses were adjusted for age and sex, BMI, total cholesterol and 
systolic blood pressure (Table 4.10). The p value was calculated using the likelihood 
ratio test.  
 
At the end of the first year (Year 1), HbA1c (OR 6.20 [95% CI 1.04, 36.82] p= 
0.045), fasting glucose (OR 7.71 [95% CI 1.78, 33.29] p= 0.006), postprandial 
glucose (OR 4.57 [95% CI 1.52, 13.69] p= 0.007), AUCGlucose (0-240min) (OR 5.00 
[95% CI 1.43, 17.50] p= 0.012) demonstrate the contribution of continuing fasting, 
postprandial and overall hyperglycaemic exposure at Year 1 leading to DR by 5 
years. 
 
Similarly at the end of the second year (Year 2) HbA1c (OR 5.69 [95% CI 1.16, 
27.94] p= 0.032), postprandial glucose (OR 4.83 [95% CI1.60, 14.64] p= 0.005), 
AUCGlucose (0-240min) (OR 4.15 [95% CI 1.25, 13.76] p= 0.020), further confirmed the 
contribution of continuing fasting, postprandial and overall hyperglycaemic exposure 
at Year 2 leading to DR by 5 years. 
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Independent association with DR for measures of β-cell secretory capacity were seen 
at Year 1 i.e.
 
HOMA-B (OR 0.49 [95% CI 0.26, 0.87] p= 0.016) and at Year 2 M1 
(OR 0.59 [95% CI 0.41, 0.86] p= 0.006). 
 
4.4.8 Comparative analysis of subjects with T2DM with and without DR at 5 
years in relation to mean averaged metabolic variables over the 5 year study 
period since diagnosis of T2DM (Years 0, 1, 2 and 5)  
These mean values of T2DM subjects with DR and NDR by Year 5 are detailed in 
Table 4.11. 
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Table 4.11: Comparison of the mean averaged metabolic variables over a 5 year 
period (Years 0, 1, 2 and 5) during the Meal Tolerance Test in subjects with No 
Diabetic Retinopathy and those with Diabetic Retinopathy by 5 years post diagnosis 
of T2DM 
 
 
 
No Diabetic Retinopathy Diabetic Retinopathy 
 
p 
value 
Number 179 54 - 
Fasting Glucose (mmol/L) 9.1 (7.6 – 10.5) 9.5 (8.5 – 10.5) 0.116 
Postprandial Glucose (mmol/L) (120 mins)  11.8 (9.5 – 13.4) 13.0 (11.4 – 14.4) 0.007 
AUC Glucose (0-240min) (mmol/L)           9.6 (8.1 – 11.4) 10.5 (9.5 – 11.7) 0.015 
HbA1c 
(https://www.diabetes.org.uk/Documents/
Position%20statements/DiabetesUK_Facts
_Stats_Oct16.pdf) 7.0 (6.3 – 8.0) 7.6 (6.9 – 8.2) 
0.003 
Fasting Insulin (pmol/L) 63.5 (45.3 - 95.3) 67.1 (37.3 – 94.8) 0.957 
Postprandial  Insulin (pmol/L) (120 mins)  297.7 (202.1 – 468.3) 298.5 (156.0 – 426.8) 0.414 
AUC Insulin (0-240min) (pmol/L) 205.1 (146.7 – 315.3) 171.3 (98.4 – 318.1) 0.212 
M0 (*10
-9
 pmol/kg/min) 6.2 (4.4 – 8.2) 4.8 (3.5 - 7.1) 0.083 
M1 (*10
-9
 pmol/kg/min) 22.6 (15.8 – 31.5) 16.1 (10.6 – 22.6) 0.001 
HOMA-B (%) 44.4 (33.2 – 65.0) 42.1 (28.0 - 58.1) 0.257 
HOMA-S (%) 70.0 (45.2 – 99.2) 62.8 (46.8 -118.0) 0.873 
HOMA-IR 1.6 (1.2 - 2.5) 1.7 (1.0 - 2.5) 0.873 
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Those with DR at Year 5, compared to those without, had a significantly higher 
mean averaged HbA1c (p= 0.003) over 5 years since diagnosis, and a higher mean 
averaged postprandial (2 hour) glucose (p= 0.007) over 5 years. Over the 4-hour 
MTT study period, subjects with DR had significantly higher mean averaged 
AUCGlucose (0-240min) (p= 0.0015) in comparison to those without DR at Year 5 (Table 
4.11) over 5 years post diagnosis. There was no significant difference in the mean 
averaged Insulin levels between the two groups. Those with DR by Year 5, 
compared to those without were also associated with a lower mean averaged 
estimated postprandial β-cell
 
responsiveness i.e. M1 (p= 0.001).  
 
4.4.9 Univariate regression analysis of Mean averaged metabolic parameters 
over 5 years 
Based on the inter-group differences (Table 4.11), univariate logistic regression was 
conducted, which demonstrated that the cumulative HbA1c (p= 0.004), postprandial 
glucose (p= 0.022) and AUCGlucose (0-240min) (p= 0.023) over 5 years post-diagnosis of 
T2DM were significantly related to the development of DR by Year 5 (Table 4.12). 
Estimated postprandial β-cell responsiveness i.e. M1 (p= 0.001) over the 5 years was 
also highly significantly related to the development of DR. 
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Table 4.12: Univariate and Multivariate logistic regression depicting variables independently associated with development of Diabetic 
Retinopathy by 5 years from diagnosis of T2DM. All parameters are mean average values measured over diagnosis, Year 1, 2 and 5 
years post diagnosis. 
 
  Univariate  Multivariate  
  Number Crude OR (95% CI) p OR (95% CI) p  
      
 
(fully adjusted **) 
 Mean HbA1c (%) 233 1.51 (1.14 – 2.01) 0.004 1.48 (1.12 – 1.97) 0.008 
Mean Fasting Glucose (mmol/L) 230 1.15 (0.96 – 1.38) 0.143 1.13 (0.93 – 1.36) 0.227 
Mean Postprandial Glucose (mmol/L) (120 mins)  230 1.15 (1.02 – 1.30) 0.022 1.15 (1.02 – 1.30) 0.023 
Mean AUC Glucose (0-240min) (mmol/L)           230 1.17 (1.02 – 1.35) 0.023 1.18 (1.02 – 1.36) 0.027 
Mean M0 (*10
-9
 pmol/kg/min) 227 0.89 (0.78 – 1.02) 0.100 0.81 (0.68 – 0.96) 0.014 
Mean M1 (*10
-9
 pmol/kg/min) 224 0.93 (0.89 – 0.97) 0.001 0.93 (0.86 – 0.97) 0.001 
Mean HOMA-B (%) 224 0.10 (0.98 – 1.01) 0.505 0.99 (0.97 – 1.01) 0.207 
Mean HOMA-S (%) 224 1.00 (0.10 – 1.01) 0.779 1.01 (1.00 – 1.01) 0.124 
** adjusted for age, sex, BMI, SBP, TCh: SBP = Systolic Blood Pressure; TCh = Total Cholesterol, BMI = Body Mass Index 
FPG = Fasting Plasma Glucose; PPG = Post Prandial Glucose; AUC = Area Under the Curve
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4.4.10 Multivariate regression analysis of Mean averaged metabolic parameters 
over 5 years 
Factors independently associated with DR in univariate logistic regression analyses 
when adjusted for age and sex, BMI, total cholesterol and systolic blood pressure are 
detailed in (Table 4.12). Measures of β-cell function – M0 (OR 0.81 [95% CI 0.68, 
0.96] p= 0.014) and M1 (OR 0.93 [95% CI 0.86, 0.97] p= 0.001) show independent 
association with DR. HbA1c (OR 1.48 [95% CI 1.12, 1.97] p= 0.008), Postprandial 
glucose (OR 1.15 [95% CI 1.02, 1.30] p= 0.023), AUCGlucose (0-240min) (OR 1.18 [95% 
CI 1.02, 1.36] p= 0.027), show the contribution of postprandial and overall 
hyperglycaemic exposure over 5 years in subjects leading to DR by 5 years when 
adjusted for the mentioned variables (Table 4.12).   Figures 4.4a and 4.4b illustrate 
the mean Fasting, Postprandial and AUC Glucose and Insulin Profiles and mean 
HbA1c over the 5 year study period (Years 0, 1, 2, and 5)  in patients with and 
without diabetic retinopathy by 5 years post-diagnosis of T2DM. 
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Figure 4.4 a and 4.4b: Mean Fasting (FPG), Postprandial (PPG), AUC Glucose (0-
240 min), Mean HbA1c and Mean Fasting Insulin (FPI), Postprandial (PPI) and 
AUC Insulin (0-240 min) Profiles (mean ± SEM) combined over the 5 year study 
period in subjects with and without diabetic retinopathy by 5 years post-diagnosis 
of T2DM. 
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Figure 4.5 a and 4.5 b illustrate the mean HOMA-B and S and mean fasting and 
postprandial β-cell responsiveness over 5 years with in patients with and without 
diabetic retinopathy by 5 years post-diagnosis of T2DM. 
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Figure 4.5 a and 4.5 b: Mean HOMA-B and S and Mean fasting (M0) and 
postprandial (M1) β-cell responsiveness (mean±SEM) over 5 years in subjects with 
and without diabetic retinopathy by 5 years post diagnosis of T2DM. 
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4.5 Discussion  
Our analysis indicates a strong and independent association between incident DR 
and glycaemic control at the time of diagnosis represented by HbA1c, fasting and the 
2-hour postprandial hyperglycaemia, as well as the overall 4-hour glucose (AUC(0-
240min)) response to the standardised test meal. We have further shown that calculated 
measures of β-cell
 
function during fasting (M0) and HOMA-B and in response to the 
test meal (M1), conducted at the time of diagnosis, were independently associated 
with DR along with SG, which reflects the contribution of an “insulin-independent 
component of glucose tolerance”. These findings suggest that by the time of 
diagnosis of T2DM, subjects have lost a substantial part of their β-cell function, and 
are at a greater risk of developing DR in a further 5 years time. In addition, the data 
emphasise the contribution of both postprandial and overall glycaemic exposure over 
the 5-year follow up period to the development of DR i.e. the cumulative effect of 
poor glycaemic control and β-cell dysfunction. The degree of dysglycaemia is 
related to a lower fasting and postprandial β-cell responsiveness at diagnosis leading 
to the postprandial and overall glycaemic exposure over the 5-year study period. 
 
In our study, involving patients who were newly-diagnosed with T2DM, those who 
went on to develop DR by 5 years had a significantly higher baseline HbA1c (8.6%) 
compared to those who did not (7.4%). This association remained significant on 
multivariate logistic regression after adjusting for age, sex, BMI, SBP and total 
cholesterol. Thus for every 1% rise in HbA1c at diagnosis, there was a four times 
greater likelihood of developing DR in the 5 years follow-up. There was also a 
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significant and independent association between the HbA1c level at Years 1 and 2 
and the 5-year mean HbA1c with the development of DR over the 5-year observation 
period. However, although the HbA1c at Year 5 showed a significant univariate 
association, once adjusted for the above-mentioned variables, it did not retain its 
significance. 
 
Similar to our study, in which 23.2% of the subjects developed DR over 5 years, the 
UKPDS who also recruited newly diagnosed subjects with T2DM showed that their 
study participants had a DR incidence of 22% over 5 years (Stratton IM et al. 2001). 
They had also demonstrated that glycaemic control at diagnosis and overall 
glycaemic exposure were significant contributory factors to the incidence of DR. The 
Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) also reported 
that in individuals with both younger and older onset DM over 6 years, glycaemic 
control, as measured by glycosylated haemoglobin, was associated with an increased 
risk of development of DR (Klein R et al. 1995).  However in contrast to our 
findings, they did not find a relationship between DR incidence and β-cell function, 
as defined by plasma C-peptide measurement. Our study is also consonant with that 
of Yoshida et al. studying T2DM subjects with no DR at the initial visit where they 
also found a significant contribution of baseline overall glycaemic exposure (HbA1c) 
and duration of DM (Yoshida Y et al. 2001) to the development of DR.  This is a 
robust finding as Looker et al. (Looker HC et al. 2003) studying the Pima Indians 
found a slightly lower cumulative incidence than ourselves at 16.8% but overall 
glycaemia was again found to have a significant contribution. In addition, more 
recent studies also have confirmed the role of HbA1c in the incidence of DR 
172 
 
(Semeraro F et al. 2011) (Rudnisky CJ et al. 2012). In 130 Korean patients with 
T2DM who had NDR at baseline, age, known duration of DM, mean FPG, and HbA1 
levels during the follow-up period of 5.3 years were higher in the patients who 
developed DR. Cox proportional hazards analysis established mean HbA1 as the only 
independent risk factor for the development of DR (Kim HK et al. 1998).  
 
In the Verona Diabetes Study, by the time of the second eye examination (4-5 years 
follow up) 124 patients had either developed new DR (79 patients) or progressed to a 
more severe degree of DR (45 patients). By multivariable logistic regression 
analysis, the development of DR was independently predicted by the average 
glycaemia over time, expressed as glycated haemoglobin or mean FPG (Zoppini G et 
al. 2009). These results suggest that in elderly T2DM subjects, the magnitude of 
hyperglycaemia independently predicts the development of DR. A Taiwanese study 
also showed that glycaemic control as measured by mean FPG and mean HbA1c was 
significantly related with the incidence of DR over a 4-year study period (Chen MS 
et al. 1995). Therefore the analysis of our study supports the association of both 
baseline and overall glycaemic exposure and the development of DR.  
 
Both the fasting and postprandial hyperglycaemic and insulinopaenic responses 
during a standardised MTT, as well as the overall 4-hour (AUC (0-240min)) response to 
the meal at the time of diagnosis, are strongly related to the development of DR by 5 
years. In our study, the FPG at diagnosis, and at one year post-diagnosis, had an 
independent association with the development of DR by 5 years in our T2DM 
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subjects. FPG at Year 2 and 5 and Mean FPG although higher in subjects with DR 
compared to those without, did not reach statistical significance. FPI at diagnosis 
was higher in subjects without DR and after adjusting for the above mentioned 
variables showed a significant contribution to the development of DR. FPI at year 1, 
2, 5 and the mean FPI for the 5 years showed no association with the development of 
DR. The contribution of fasting insulinopaenia at diagnosis contributing 
independently to incident DR has not been documented before. Thus this is reflective 
of a failing fasting β-cell function leading to an insulinopaenic milieu and leading to 
a higher fasting hyperglycaemic exposure causing development of DR. 
 
In the same vein as our study, an epidemiological study from Mauritius showed 
baseline FPG to contribute independently to a 6 year incidence of DR (Tapp RJ et al. 
2006). In their newly-diagnosed DM subjects at baseline, the incidence of NPDR 
was 19.1% with no incident cases of PDR. Their 6-year incidence of DR of 23.8% 
(sight-threatening in 0.4%) was very much in line with our 5-year incidence of 
23.2%. The Atherosclerosis Risk in Communities (ARIC) study (studying DM 
subjects aged 45-64 years from USA with a 3 year DR incidence of 10.1%) (Wong 
TY et al. 2007) and the Blue Mountains Eye Study (studying an older Australian 
population-based cohort over 5 year) (Cikamatana et al. 2007) both similarly showed 
the association of baseline FPG with incident DR. Baseline FPG similarly showed 
significant contribution to incident DR in other international studies including a 4 
year study in Iran (Manaviat MR et al. 2008) and Japan (Araki et al. 1993). A 
slightly longer study involving Oklahoma Indians with a mean follow-up time of 
12.7 years reported a fasting plasma glucose level >11.1 mmol/L (200 mg/dl) 
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increased the risk of DR 3.6 times that for a level <7.8 mmol/L (140 mg/dl) (Lee ET 
et al. 1992). 
 
A data-pooling analysis of nine studies from five countries with 44,623 participants 
aged 20-79 years with gradable retinal photographs was published by Colagiuri. 
They demonstrated glycaemic thresholds for DR from receiver-operating 
characteristic curve analyses to be 6.6 mmol/l for FPG, 13.0 mmol/l for 2-hour PPG, 
and 6.4% for HbA1c (Colagiuri et al. 2011). Massin et al. also reported the positive 
predictive values for DR, increasing sharply from 108 mg/dl (6.0 mmol/L) for FPG 
and from 6.0% for HbA1c levels and propose these thresholds to identify those at 
risk of DR 10 years later (Massin P et al. 2011). These two studies further 
consolidate the importance of achieving a FPG around 6.0-6.6 mmol/L to minimise 
the risk of DR. 
 
On a slightly different note, a study in T2DM Japanese subjects showed that long-
term fasting plasma glucose variability (CV-FPG) was a risk factor for PDR 
independent of the mean FPG or HbA1c in people with T2DM. PDR development 
was also significantly associated with HbA1c more than 5 years earlier and with the 
mean FPG more than 10 years earlier (Takao T et al. 2011). This study has indicated 
that FPG variability is an additional risk factor independent of the mean FPG or 
HbA1c for the development of PDR in people with T2DM. This is consistent with 
their previous report that FPG variability is a risk factor independent of the mean 
FPG or HbA1c for the development of mild moderate and severe NPDR in these 
175 
 
same subjects (Takao T et al. 2010). These observations support a legacy effect and 
are consistent with the results of the DCCT/EDIC (White NH et al. 2008) and 
UKPDS 80 (Holman RR et al. 2008). On a similar note, although our study does not 
establish an association of mean FPG over a period of 5 years with DR, the 
independent association of FPG at diagnosis and Year 1 with development of DR by 
5 years post diagnosis is reflective of a delayed effect of good early glycaemic 
control. 
 
In our study, we found that the 2 hour PPG following a standardised meal at the time 
of diagnosis, 1 and 2 years post diagnosis and the mean PPG over 5 years all have an 
independent association with the development of DR by 5 years. The difference in 
the 5-year PPG however, although noted to be higher in subjects with DR, compared 
to those without DR, fails to reach statistical significance. PPI at baseline indicated a 
significant contribution to the development of DR by 5 years. However, the PPI at 
years 1, 2, 5 and the mean FPI over the 5 years observation period did not shown any 
association with the development of DR in our population of T2DM subjects.  This 
post-prandial insulinopaenic and glycaemic effect is important as the relevance of 
the postprandial glycaemic exposure has not been extensively documented before. 
However, Shiraiwa et al. in the past decade has shown an independent correlation of 
postprandial plasma glucose and insulin with the progression of DR in T2DM 
Japanese subjects surveyed over a 5-year period. PPG was shown to be a stronger 
predictor than HbA1c in their subjects (Shiraiwa T et al. 2005b). Ohkubo et al. has 
also proposed that achieving a glycaemic threshold of HbA1c< 6.5%, FPG< 110 
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mg/dl and 2 hour PPG< 180 mg/dl would prevent the onset and progression of 
diabetic microangiopathy (Ohkubo Y et al. 1995). 
 
As in our study Voutilainen-Kaunisto et al. examined newly-diagnosed T2DM 
subjects over 10 years in a prospective study in Finland, grading DR using 45° 
fundal photographs at diagnosis baseline and after 5 and 10 years. Their frequency of 
DR increased sharply after 5 years with 55% of subjects showing evidence of DR at 
10 years. In these subjects, (Voutilainen-Kaunisto RM et al. 2001) FPG, 2-hour PPG 
and HbA1c at 5 years but not baseline, predicted development of DR at the 10-year 
follow-up. In contrast to our study,  their fasting insulin and fasting C-peptide levels 
failed to show an association with DR development (Voutilainen-Kaunisto RM et al. 
2001). Our findings noting an association between the incidence of DR and FPG, 2 
hour PPG and HbA1c, 5 years prior to its development reflects a similar contribution 
of metabolic memory.  They further demonstrated that their risk for developing DR 
was 7.7 times greater with elevated PPG levels compared with 4.2 times for elevated 
FPG (4
th
 quartile values compared to 1
st
 quartile glucose values). Our study 
establishes a greater contribution of postprandial and overall glycaemic exposure to 
the development of DR than FPG, which is concordant with the Finnish study. A 
similar 10-year study in Pima Indian adults also showed development of DR to be 
directly related to higher FPG and 2-hour PPG (Gabir MM et al. 2000). 
 
The analysis of our study further reports that the AUC Glucose (0-240min) at the time of 
diagnosis and 1 and 2 years post-diagnosis and Mean AUC Glucose (0-240min) over a 5-
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year follow-up period have an independent association with the development of DR 
over this period of time. AUC Glucose (0-240min) at Year 5, although higher in subjects 
with DR, fails to reach statistical significance. AUC Insulin (0-240min) at diagnosis also 
showed a significant contribution to the development of DR by 5 years, but AUC 
Insulin (0-240min) at years 1, 2, 5 and Mean AUC Insulin (0-240min) showed no association 
with the development of DR. This shows that the glycaemic exposure over 4 hours, 
measured during the MTT, has a significant contribution to the development of DR. 
This glycaemic exposure shows a contribution from both the fasting and postprandial 
glycaemic insult on the microvasculature.  
 
In our study, newly-diagnosed T2DM subjects who went on to develop DR by 5 
years had a significantly lower fasting and postprandial β-cell responsiveness and 
function at diagnosis and also a significantly lower mean fasting and postprandial β-
cell responsiveness over this 5-year time period. A significant contribution was also 
noted from a lower fasting β-cell function at Year 1 and lower postprandial β-cell 
responsiveness at Year 2 to the development of DR. There was no noted association 
with any parameters of insulin resistance/sensitivity. 
 
Whereas we have studied β-cell function prospectively and early in the course of 
known disease, Suzuki et al retrospectively studied the role of pancreatic β-cell 
insulin secretory capacity (24-hour urinary C-peptide) in the development of PDR in 
T2DM subjects with a known duration of DM of >10 years. The incidence of PDR 
during the follow-up period (~10 years) was highest in the group with the lowest 24-
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hour urinary C-peptide concentration. These data are consistent with the view that 
low pancreatic β-cell insulin secretory capacity may be a risk factor for the 
development of PDR (Suzuki K et al. 1989).  
 
In our study the AIRG and SG were significantly reduced in those with DR compared 
to those without DR at Year 5 but there was no difference in the insulin sensitivity or 
DI between those with or without DR. The independent association of the insulin-
independent (as manifested by reduced SG) component of glucose tolerance to the 
incidence of DR has not been noted before. 
 
Our analysis also established an independent association of M0, HOMA-B  and M1 
with incidence of DR by measuring β-cell function in response to a standardised 
meal challenge, employing both the CPR program (Hovorka R et al. 1998) and the 
HOMA methodologies. This analysis of newly-diagnosed T2DM subjects indicates 
that a lower fasting and postprandial β-cell responsiveness at diagnosis and over the 
5-year study period are a basis for increased fasting, postprandial and overall 
glycaemic and insulinopaenic exposure, and all contribute significantly to the 
development of DR. The fasting and postprandial insulinopaenia at diagnosis in 
subjects who go on to develop DR is a reflection of a failing β-cell function at 
diagnosis and, despite the introduction of therapeutic intervention subsequently, do 
have an effect on the incidence of DR. In our data there is no noted effect of 
antihypertensive or insulin use over the 5 years on development of DR by Year 5. 
However, our subjects on oral hypoglycaemic medications at Year 1, 2 and 5 have a 
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significantly greater chance of developing DR by Year 5. A similar significant 
association was noted with uses of lipid-lowering medication at Year 5 in our 
subjects. There was however no difference in the outcome on the basis of use of 
Metformin or Sulphonylurea in our subjects. 
 
The long-term contribution of the postprandial component in our study (mean PPG) 
is stronger than the mean FPG on the development of DR. Of note is that most 
parameters of glycaemic control and β-cell secretory status at diagnosis, and soon 
after, appear to be the main contributors to the development of DR, with no 
significant contribution from the HbA1c and other glycaemic parameters at year 5. 
This is compatible with the early history of glycaemic exposure leading to a delayed 
effect in the development of DR. In addition, the insulin-independent component of 
glucose tolerance at diagnosis was reduced and independently associated with the 
incidence of DR by 5 years in newly-diagnosed T2DM subjects.  
 
As mentioned previously, in our study the pre-diagnostic duration of DM might be 
slightly longer than other studies, which is possibly reflected in the slightly greater 
percentage of subjects presenting with DR. Following treatment introduction, the 
percentage of subjects on OHG agents developing DR is significantly higher, thus 
reflecting possibly a more advanced/severe stage of the disease process. The 
numbers of subjects on insulin were limited and therefore it is not possible for this to 
have a meaningful association with the outcome. Therefore, the need to diagnose 
T2DM as early as possible in order to intervene and lower the glycaemic exposure is 
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paramount, as Colagiuri has demonstrated glycaemic thresholds for diabetes-specific 
retinopathy to be about 6.4%. 
 
4.6 Summary 
In this chapter, our study of newly diagnosed T2DM subjects indicates that most 
parameters of glycaemic control and β-cell secretory status at diagnosis and over the 
5-year period of observation appear to be the main contributors to the development 
of DR.  We have shown that: 
 The factors that contribute significantly to the development of DR include a 
lower fasting and postprandial β-cell responsiveness at diagnosis and over the 
5-year study period. 
 The significant contribution of the increased postprandial and overall 
glycaemic exposure over the first 5 years from diagnosis.  
 The fasting and postprandial insulinopaenia at diagnosis in subjects who go 
on to develop DR is a reflection of a failing β-cell function at diagnosis.  
 The early history of a lower glycaemic exposure not leading to DR 
development by 5 years in our study is indicative of better early glycaemic 
milieu at diagnosis leading to a long-term risk reduction for DR. 
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Chapter 5 
Follow-up at 5 years of 
subjects with type 2 
diabetes with retinopathy 
at diagnosis
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5.1 Introduction 
In the previous chapters (Chapters 3 and 4), the relevance of β-cell dysfunction, 
fasting, postprandial and overall glycaemia has been demonstrated on the prevalence 
and incidence of DR in newly diagnosed subjects with T2DM without DR at 
diagnosis over the 5-year follow-up study. In this chapter the influence of similar β-
cell and metabolic indices on the future course of existing DR in newly-diagnosed 
subjects with T2DM over the same follow-up time period of 5 years is examined. 
The relationship between HBA1c (Klein R et al. 1995; Kim HK et al. 1998; Looker 
HC et al. 2003) and FPG (Lee ET et al. 1992; Chen MS et al. 1995; Cikamatana et 
al. 2007; Zoppini G et al. 2009) on DR progression is well documented with the 
contribution of PPG more recently recognised (Voutilainen-Kaunisto RM et al. 
2001; Shiraiwa T et al. 2005b) although not widely reported. However, the 
contribution of fasting and postprandial β-cell function is rarely reported.  
 
5.2 Aim of the study 
The aim of this chapter is to analyse the association between (a) β-cell function, (b) 
insulin sensitivity, (c) glycaemic status (HbA1c, fasting and postprandial glucose and 
insulin) and the future of DR over a 5-year period in newly-diagnosed and treatment-
naïve type 2 diabetic subjects with DR at diagnosis   
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5.3.1 Subjects and Methods 
Of the 293 subjects who had data over the 5 years from diagnosis i.e. at baseline, 
Year 1, Year 2 and Year 5, 41 subjects had evidence of DR at diagnosis and will be 
the subject of the analysis presented in this chapter. The data on 233 subjects with no 
DR at diagnosis has been detailed in the preceding chapter (Chapter 4).  
 
The subject recruitment, experimental protocol, data analysis and basic statistical 
analysis are described in detail in chapter 2. 
 
5.4 Results  
5.4.1: Grades of DR over the 5-year study period 
The grades of DR for the 41 subjects over the 5-year study period are detailed in 
table 5.1. 
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Table 5.1: Grades of DR over the 5 years 
 
 Diagnosis Year 1 Year 2 Year 5 
NDR  10 10 7 
BDR 31 17 19 19 
Maculopathy 7 4 6 9 
PPDR 3 4 3 3 
PDR - 1 2 3 
Missing data - 5 1 - 
Total 41 36 (5) 40 (1) 41 
 
NDR: No DR, BDR: Background DR, PPDR: Preproliferative DR, PDR: 
Proliferative DR. 
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As the number of subjects within each grade was small, they were classified into two 
severity categories of DR (Table 5.2) as per the European Field Guide (Kohner EM 
and Porta M 1990). 
i) Non-Sight Threatening Diabetic Retinopathy (NSTDR), which included 
Background Diabetic Retinopathy (BDR) and Pre-proliferative Diabetic 
Retinopathy (PPDR), 
ii) Sight Threatening Diabetic Retinopathy (STDR), which included 
Proliferative Diabetic Retinopathy (PDR) and Definite Maculopathy 
(M2). 
187 
 
 
Table 5.2: Categories of DR over the 5 years 
 
 Diagnosis Year 1 Year 2 Year 5 
NDR  10 10 7 
NSTDR 34 21 22 22 
STDR 7 5 8 12 
Missing data - 5 1 - 
Total 41 36 (5) 40 (1) 41 
 
NDR: No DR, NSTDR: Non-Sight Threatening Diabetic Retinopathy, STDR: Sight 
Threatening Diabetic Retinopathy 
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They were also further sub-classified according to whether the categories of: 
 
i) DR remained same over 5 years – “Same”  (n = 25) 
ii) DR progressed same over 5 years – “Progressors” (n = 7) and  
iii) DR regressed over 5 years – “Regressors” (n = 9) 
 
Of the 25 subjects who maintained the same status in relationship to NSTDR/STDR: 
18 subjects had BDR, 2 had PPDR and 5 had maculopathy. [Of the18 subjects who 
had BDR 17 remained unchanged with 1 developing PPDR by Year 5; 2 with 
PPDR– 1 remained PPDR and 1 regressed to BDR by Year 5; 5 with Maculopathy– 
3 remained unchanged and 2 developed PDR by Year 5] 
 
Of the 9 “Regressors”: 7 subjects with BDR at diagnosis had NDR at Year 5 and 2 
subjects with Maculopathy at diagnosis reverted to BDR and PPDR at year 5. 
 
Of the 7 “Progressors”: there were 6 subjects with BDR and 1 with PPDR and they 
progressed to develop Maculopathy (6) and PDR (1) over the 5-year study period. 
 
The 41 subjects were studied at diagnosis, Year 1, 2 and 5 and for the total exposure 
over the 5-year follow-up period for the purpose of comparing these 3 groups of 
subjects. 
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5.4.2 Baseline characteristics of subjects with T2DM and DR at the time of 
diagnosis followed up over a 5-year period  
The baseline characteristics of subjects with T2DM and DR at the time of diagnosis 
who were followed up over a 5-year period according to the evolution of their DR 
are represented in Table 5.3. 
 
Of the 41 subjects (34 male and 7 female) with a mean age of 54 (SD ± 8) years, 25 
(61%) remained at the same stage of DR over the 5 years, 9 (22 %) regressed, and 7 
(17 %) progressed from their baseline level of DR.  
 
At baseline, subjects who progressed by Year 5 presented with a significantly higher 
HbA1c, (p= 0.00) (Table 5.3). Other baseline characteristics were not significantly 
different between the 3 groups. However there was a distinct trend that the 
progressors were leaner with a lower weight and BMI and also had a higher diastolic 
BP, but these parameters did not reach statistical significance.  
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Table 5.3: Baseline characteristics of subjects with Diabetic Retinopathy whose grade of DR regressed over the 5 year time period 
since diagnosis compared to those whose grades of DR remained same or progressed. 
 
 
 All 
subjects Regressors Same Progressors 
p value 
(between groups)  
Number (%) 41 (100) 9 (22) 25 (66) 7 (17) - 
Age at presentation (years) 54 (8) 57 (10) 53 (8) 55 (8) 0.489 
Male Sex (%) 34 (83) 8 (89) 20 (80) 6 (86) 0.812 
Weight (kg) 82 (17) 90 (23) 81 (14) 73 (18) 0.290 
BMI (kg.m
2
) 29 (6) 31 (7) 29 (5) 26 (5) 0.207 
Systolic blood pressure (mmHg) 137 (17) 143 (16) 133 (15) 143 (23) 0.400 
Diastolic blood pressure (mmHg) 85 (12) 86 (12) 82 (10) 93 (16) 0.226 
Total Cholesterol (mmol/L) 5.4 (1.4) 6.1 (2.0) 5.2 (1.2) 5.3 (1.1) 0.629 
HbA1c (%) 8.5 (1.7) 6.7 (1.5) 8.6 (1.5) 10.1 (0.8) 0.000 
 
Data expressed as Mean (± SD) or Number (%); BMI = Body Mass Index 
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5.4.3 Comparative analysis of the metabolic parameters at diagnosis for the 
three groups of subjects with type 2 diabetes mellitus and diabetic retinopathy.  
The metabolic variables during the MTT at baseline, for the subjects who remained 
at the same stage of DR, progressed or regressed by 5 years after diagnosis are 
detailed in Table 5.4. Those who progressed by Year 5, compared to those who did 
not, had a higher HbA1c (p= 0.000), a lower estimated fasting β-cell
 
responsiveness 
i.e. M0 (p= 0.003) and β-cell
 
function
 
i.e.
 ‘HOMA-B’ (p= 0.001). The progressors 
had the lowest β-cell responsiveness and function followed by the subjects who 
remained at the same category, with the regressors having the highest β-cell 
responsiveness and function at diagnosis. The lower fasting insulin concentrations 
(p= 0.036) resulted in a higher fasting glucose (p= 0.003) at diagnosis in the 
progressors compared to the other categories. 
 
In the postprandial state, those individuals whose DR progressed by Year 5, 
compared to those who did not progress had a lower estimated postprandial β-cell 
responsiveness i.e. M1 (p= 0.012) associated with a higher postprandial (2 hour) 
glucose (p= 0.036) and lower postprandial insulin levels (p= 0.006). The progressors 
again had the lowest estimated postprandial β-cell responsiveness followed by the 
subjects who remained at the same category, with the regressors having the highest 
postprandial β-cell responsiveness at diagnosis. This is appropriately reflected in the 
trends exhibited by the postprandial glucose and insulin. 
192 
 
 
Over the 4-hour MTT study period, subjects who progressed had a significantly 
higher AUCGlucose (0-240min) (p= 0.001) and lower AUC Insulin (0-240 min) (p= 0.018) in 
comparison to those who remained at the same level of DR or whose DR regressed 
over the 5-year period (Table 5.4). 
 
 The plasma glucose, HbA1c, insulin profiles during the MTT and indices of β-cell
 
responsiveness (M0 and M1) and HOMA B and S in subjects with existent DR at 
diagnosis and according to progression or not are illustrated in Figures 5.1 a, b, 5.2 
and 5.3. 
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Table 5.4: Comparison in subjects with Diabetic Retinopathy whose grade of DR remains same throughout 5 years since diagnosis 
compared to those whose grades of DR Regressed or Progressed by 5 years from diagnosis of T2DM by their parameters at diagnosis 
 
 Regressors Same Progressors p value 
Number 9 25 7  
Year 0 Parameters     
Fasting Glucose (mmol/L) 9.2  (7.5 - 12.3) 12.5 (10.1 - 14.7) 16.0 (14.3 - 17.5) 0.003 
Postprandial Glucose (mmol/L) (120 mins) 12.1 (10.2 - 16.6) 16.2  (13.7 - 17.7) 20.9 (16.9 - 23.2) 0.015 
AUC Glucose (0-240min) (mmol/L)           9.3 (8.0 - 12.6) 13.9 (11.3 - 16.2) 19.2 (15.5 - 20.0) 0.001 
HbA1c (%) 6.5 (6.1 - 7.9) 8.8 (7.1 - 9.8) 10.2 (9.3 - 10.8) 0.000 
Fasting Insulin (pmol/L) 65.0 (40.3 - 93.8) 44.0 (33.5 - 75.5) 32.0 (21.5 - 43.1) 0.036 
Postprandial  Insulin (pmol/L) (120 mins) 358.0 (146.5 - 744.8) 162.0 (106.8 - 226.0) 103.3 (79.0 - 133.5) 0.006 
AUC Insulin (0-240min) (pmol/L) 220.7 (99.0 - 499.7) 121.0 (88.8 - 154.7) 87.8 (59.8 - 102.6) 0.018 
HOMA-B (%) 43.6 (20.9 - 67.8) 19.6 (13.6 - 28.1) 10.0 (6.7 - 15.5) 0.001 
HOMA-S (%) 56.5 (42.2 - 92.8) 76.6 (44.5 - 110.2) 102.6 (52.1 - 132.2) 0.244 
HOMA-IR 1.8 (1.1 - 2.4) 1.3  (0.9 - 2.3) 1.0 (0.8 - 1.9) 0.244 
M0 (*10
-9
 pmol/kg/min) 6.8 (3.9 - 10.4) 3.4 (2.8 - 4.6) 2.4 (0.6 - 3.2) 0.003 
M1 (*10
-9
 pmol/kg/min) 29.5 (14.5 - 41.6) 11.3 (8.9 - 19.0) 7.3 (1.5 - 12.8) 0.012 
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Figure 5.1 a: Plasma Glucose [Fasting (FPG), Postprandial (PPG) and AUC (0-
240min) (Area under the Curve) during MTT] and HbA1c at diagnosis (mean±SEM) 
in subjects with Diabetic Retinopathy at diagnosis who regressed, remained at the 
same stage or progressed by 5 years post diagnosis. 
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Figure 5.1 b: Plasma Insulin Profiles [Fasting (FPI), Postprandial (PPI) and 
AUC (0-240min) (Area under the Curve) during MTT] at diagnosis (mean±SEM) in 
subjects with Diabetic Retinopathy at diagnosis who regressed, remained at the 
same stage or progressed by 5 years post-diagnosis. 
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Figure 5.2: β-cell function (HOMA B) and Insulin sensitivity (HOMA S) 
(mean±SEM) in subjects with Diabetic Retinopathy at diagnosis who regressed, 
remained at the same stage or progressed by 5 years post diagnosis. 
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Figure 5.3: Fasting and postprandial β-cell responsiveness (M0 and M1) 
(mean±SEM) in subjects at diagnosis (subjects with diabetic retinopathy at 
diagnosis) who regressed, remained at the same stage or progressed by 5 years   
post diagnosis. 
196 
 
 
5.4.4 Univariate regression analysis  
Based on the inter-group differences (Table 5.4) univariate logistic regression was 
undertaken. It demonstrated that HbA1c and AUCGlucose (0-240min) was significantly 
higher in the progressors compared to those who remained at the same category and 
had a positive/direct relationship. Postprandial insulin, AUC Insulin (0-240min), M0, 
HOMA-B and M1 were all significantly lower in the progressors compared to those 
who remained in the same category and had a negative/inverse relationship.  
 
It also showed that in subjects whose grade of DR progressed, compared to those 
whose grade regressed, there was a significant positive/direct association with 
HbA1c, fasting glucose, postprandial glucose and AUCGlucose (0-240min), It also exhibited 
a significant negative/inverse relationship with the fasting insulin, postprandial 
insulin, AUC Insulin (0-240min), M0, HOMA-B and M1 (Table 5.5). 
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Table 5.5: Univariate and Multivariate logistic regression depicting variables independently associated with progression or regression 
of Diabetic Retinopathy by 5 years from diagnosis of T2DM.  
 
  Univariate Analysis Univariate Analysis Multivariate Analysis Multivariate Analysis 
 
Crude OR  
(95% CI) p 
Crude OR  
(95% CI) p  
OR (95% CI) 
(Adjusted) ** p 
OR (95% CI) 
(Adjusted) ** p 
Year 0 Parameters  
Regressors  
vs. Same  
 
Regressors  
vs. Progressors 
 
Regressors  
vs. Same   
Regressors  
vs. Progressors  
HbA1c (%) 2.75 (1.23, 6.14) 0.014 8.10 (2.25, 29.17) 0.001 - - - - 
Fasting Glucose (mmol/L) 1.40 (1.00, 1.87) 0.059 2.12 (1.28, 3.54) 0.004 2.41 (1.11, 5.23) 0.027 3.74 (1.53, 9.16)  0.004 
Postprandial Glucose (mmol/L)  1.19 (0.95, 1.48) 0.124 1.58 (1.13, 2.20) 0.007 1.66 (1.03, 2.68) 0.039 2.23 (1.26, 3.93) 0.006 
AUC Glucose (0-240min) (mmol/L)           1.39 (1.05, 1.85) 0.023 2.09 (1.34, 3.25) 0.001 2.05 (1.10, 3.81) 0.023 3.12 (1.50, 6.51) 0.002 
Fasting Insulin (pmol/L) 0.99 (0.97, 1.01) 0.190 0.93 (0.88, 1.00) 0.035 0.99 (0.96, 1.02) 0.530 0.93 (0.87, 1.00) 0.064 
Postprandial  Insulin (pmol/L)  0.99 (0.99, 1.00) 0.033 0.97 (0.95, 0.99) 0.025 0.97 (0.94, 1.01) 0.114 0.95 (0.91, 0.99) 0.025 
AUC Insulin (0-240min) (pmol/L) 0.99 (0.98, 0.99) 0.035 0.96 (0.93, 0.99) 0.022 0.98 (0.96, 1.01) 0.122 0.94 (0.89, 0.99) 0.011 
M0 (*10
-9
 pmol/kg/min) 0.71 (0.52, 0.97) 0.032 0.26 (0.10, 0.67) 0.005 0.33 (0.11, 1.02) 0.054 0.09 (0.02, 0.48) 0.005 
M1 (*10
-9
 pmol/kg/min) 0.92 (0.86, 0.99) 0.022 0.82 (0.69, 0.96) 0.017 0.90 (0.81, 1.00) 0.055 0.80 (0.66, 0.98) 0.031 
HOMA-B (%) 0.96 (0.92, 0.99) 0.046 0.75 (0.61, 0.93) 0.008 0.89 (0.79, 1.00) 0.053 0.66 (0.49, 0.91) 0.010 
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5.4.5 Multivariate regression analysis  
Factors associated with DR in univariate logistic regression analyses when adjusted 
for age and sex, BMI, total cholesterol and systolic blood pressure are detailed in 
(Table 5.5). The p value was calculated using the likelihood ratio test.  
 
Fasting glucose: Regressors vs. Same - OR 2.41 [95% CI 1.11, 5.23] p= 0.027), 
Regressors vs. Progressors - OR 3.74 [95% CI 1.53, 9.16] p= 0.004). Postprandial 
glucose: Regressors vs. Same - OR 1.66 [95% CI 1.03, 2.68] p= 0.039), Regressors 
vs. Progressors - OR 2.23 [95% CI 1.26, 3.93] p= 0.006). AUCGlucose (0-240min): 
Regressors vs. Same - OR 2.05 [95% CI 1.10, 3.81] p= 0.023), Regressors vs. 
Progressors - OR 3.12 [95% CI 1.50, 6.51] p= 0.002). The data show a significant 
contribution of dysglycaemia to the evolution of the various stages of DR in type 2 
diabetic subjects who present with DR at diagnosis (Table 5.5).  
 
Postprandial insulin (OR 0.95 [95% CI 0.91, 0.99] p= 0.025) and AUC Insulin (0-240min) 
(OR 0.94 [95% CI 0.89, 0.99] p= 0.011) also show the contribution of a deficient 
insulin secretory response to a standard meal at the time of diagnosis. This led to 
fasting and postprandial hyperglycaemia resulting in progression of DR by 5 years, 
in contrast to those who regressed when adjusted for the mentioned variables (Table 
5.5).  
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Measures of β-cell function M0 (OR 0.09 [95% CI 0.02, 0.48] p= 0.005), HOMA-B 
(OR 0.66 [95% CI 0.49, 0.91] p= 0.010) and M1 (OR 0.80 [95% CI 0.66, 0.98] p= 
0.031) show independent association with progression of DR compared to those who 
regressed. However the difference between regressors and those who remained at the 
same category was not statistically significant. 
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5.4.6 Comparative analysis of subjects with type 2 diabetes mellitus (with 
diabetic retinopathy at diagnosis) at years 1, 2 and 5 from diagnosis 
Demographic characteristics at years 1, 2 and 5 including age, weight, BMI, systolic 
and diastolic blood pressure, total cholesterol and HbA1c of the subjects who 
remained at the same stage of DR, progressed or regressed by 5 years after diagnosis 
were not significantly different between the 3 groups.  (Appendix Table 2 to 4)  
 
The Years 1 and 2 metabolic variables during the MTT for the subjects who 
remained at the same stage of DR, progressed or regressed by 5 years after diagnosis 
are detailed in Table 5.6. Those who progressed by Year 5, compared to those who 
did not, had a lower estimated fasting β-cell responsiveness at Year 1 M0 (p= 0.001) 
and Year 2 M0 (p= 0.008) and a lower estimated postprandial β-cell
 
responsiveness 
at Year 1 M1 (p= 0.012), causing a higher Year 2 fasting glucose (p= 0.020) and a 
higher Year 2 postprandial (2 hour) glucose (p= 0.049) (Table 5.6). Year 1, fasting 
and postprandial glucose show a similar trend but failed to attain statistical 
significance. 
 
Over the 4-hour MTT study period, subjects who progressed had significantly higher 
Year 1 AUCGlucose (0-240min) (p= 0.024) and Year 2 AUCGlucose (0-240min) (p= 0.032) in 
comparison to those who remained the same or regressed by Year 5 (Table 5.6). 
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Table 5.6: Comparisons by metabolic parameters, 1 and 2 years post-diagnosis between subjects with Diabetic Retinopathy whose 
grade of DR remained the same throughout 5 years from diagnosis compared to those whose DR grades Regressed or Progressed by 5 
years post-diagnosis  
 
 Regressors Same Progressors  
Year 1 and 2 Parameters Median (IQR) Median (IQR) Median (IQR) p  value 
Number 9 25 7  
Yr 1 Fasting Glucose (mmol/L) 7.1 (6.8 – 7.3) 7.9 (6.9 – 9.0) 9.1 (7.4 – 12.9) 0.079 
Yr 1 Postprandial Glucose (mmol/L) 9.7 (7.6 – 11.1) 11.4 (9.4 – 13.2) 12.5 (11.4 – 17.4) 0.056 
Yr 1 AUC Glucose (0-240min) (mmol/L)           7.5 (6.9 – 9.5) 9.2 (8.3 – 10.0) 10.8 (10.2 – 15.6) 0.024 
Yr 1 HbA1c (%) 6.1 (5.2  6.7) 6.6 (5.7 – 7.2) 6.0 (5.3 – 8.3) 0.371 
Yr 2 Fasting Glucose (mmol/L) 6.9 (6.1 – 8.4) 8.8 (7.8 – 10.4) 9.6 (9.2 – 12.4) 0.020 
Yr 2 Postprandial Glucose (mmol/L) 10.0 (9.0 – 12.7) 13.1 (10.0 – 15.3) 14.7 (12.8 – 16.3) 0.049 
Yr 2 AUC Glucose (0-240min) (mmol/L)           8.3 (6.7 – 10.2) 10.3 (8.3 – 12.8) 12.2 (10.9 – 15.0) 0.032 
Yr 2 HbA1c (%) 6.3 (5.0 – 6.8) 6.7 (6.2 – 7.6) 5.7 (5.6 – 8.3) 0.226 
Yr 1 M0 (*10
-9
 pmol/kg/min) 10.2 (7.0 – 13.0) 5.9 (4.2 – 8.5) 2.8 (1.5 – 4.1) 0.001 
Yr 1 M1 (*10
-9
 pmol/kg/min) 30.1 (20.6 – 53.5) 21.8 (12.3 – 28.1) 8.9 (2.0 – 27.0) 0.044 
Yr 2 M0 (*10
-9
 pmol/kg/min) 8.6 (6.0 – 14.0) 4.5 (2.6 – 6.9) 3.0 (1.3 – 4.8) 0.008 
Yr 2 M1 (*10
-9
 pmol/kg/min) 32.7 (20.0 – 57.5) 17.3 (10.7 – 30.8) 15.2 (3.0 – 26.4) 0.115 
Data expressed as median (1
st
 – 3rd IQR), AUC = Area Under the Curve
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5.4.7 Univariate and Multivariate regression analysis of Year 1, 2 and 5 
Parameters 
Based on the inter-group differences (Table 5.6), univariate logistic regression was 
conducted. This demonstrated that Year 2 fasting glucose (p= 0.029), Year 1 M0 (p= 
0.016), and Year 2 M0 (p= 0.039) were significantly related to regression of DR 
compared to those who remained at the same grade of DR by Year 5 (Table 5.7). It 
also showed that subjects whose grade of DR progressed, compared to those whose 
grade regressed, had a significant relationship at Year 1 of AUCGlucose (0-240min) (p= 
0.028) and M0 (p= 0.018). Also at Year 2 assessment, fasting glucose (p= 0.018), 
postprandial glucose (p= 0.042) and AUCGlucose (0-240min) (p= 0.022) were significantly 
related (Table 5.7)  
 
Factors associated with DR in univariate logistic regression analyses when adjusted 
for age, sex, BMI, total cholesterol and systolic blood pressure showed that  none of 
the metabolic factors had any significant contribution to the afore-mentioned 
outcome. 
 
203 
 
Table 5.7: Univariate logistic regression depicting variables independently associated with progression or regression of Diabetic Retinopathy 
by 5 years from diagnosis of T2DM 
 
 
Univariate analysis 
 
Univariate analysis 
 
 
Crude OR (95% CI) p Crude OR(95% CI) p 
Year 1 and 2 Parameters Regressors vs. Same 
 
Regressors vs. Progressors 
 Yr 1 AUC Glucose (0-240min) (mmol/L) 1.69 (0.93, 3.09) 0.087 3.87 (1.16, 12.96) 0.028 
Yr 2 Fasting Glucose (mmol/L) 2.13 (1.08, 4.19) 0.029 2.64 (1.19, 5.90) 0.018 
Yr 2 Postprandial Glucose (mmol/L) 1.30 (0.96, 1.75) 0.086 1.61 (1.02, 2.53) 0.042 
Yr 2 HbA1c (%) 2.16 (0.99, 4.73) 0.054 1.92 (0.71, 5.22) 0.203 
Yr 2 AUC Glucose (0-240min) (mmol/L) 1.55 (0.99, 2.42) 0.056 1.92 (1.10, 3.36) 0.022 
Yr 1 M0 (*10
-9
 pmol/kg/min) 0.65 (0.46, 0.92) 0.016 0.18 (0.04, 0.74) 0.018 
Yr 1 M1 (*10
-9
 pmol/kg/min) 0.95 (0.91, 1.00) 0.065 0.89 (0.78, 1.00) 0.052 
Yr 2 M0 (*10
-9
 pmol/kg/min) 0.76 (0.59, 0.99) 0.039 0.55 (0.32, 0.93) 0.026 
Yr 2 M1 (*10
-9
 pmol/kg/min) 0.96 (0.92, 1.01) 0.098 0.93 (0.85, 1.02) 0.118 
 
       (AUC = Area Under the Curve) 
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5.4.8 Comparative analysis of subjects with type 2 diabetes mellitus at diagnosis 
(with diabetic retinopathy) utilising the means of all metabolic parameters over 
the 5-year study period 
We calculated the average/mean of all the measured metabolic variables from 
diagnosis including variables at Years 1, 2 and 5 years post-diagnosis.  These mean 
averaged metabolic variables of T2DM subjects have been defined as the follow-up 
indicator of diabetic control over 5 years. These mean metabolic values of T2DM 
subjects, whose stage of DR remained the same, progressed or regressed by Year 5 
are detailed in Table 5.8. 
 
Those who progressed by Year 5, compared to those who did not, had a significantly 
higher mean averaged fasting plasma glucose (p= 0.010), higher mean averaged 
postprandial (2 hour) glucose (p= 0.024) and a lower mean averaged estimated 
fasting i.e. M0 (p= 0.005) and postprandial β-cell
 
responsiveness i.e. M1 (p= 0.015) 
over 5 years post-diagnosis of T2DM.  
 
5.4.9 Univariate and Multivariate regression analysis of Mean averaged 
metabolic parameters over 5 years 
Based on the inter-group differences (Table 5.8) univariate and multivariate logistic 
regression was conducted on the significant variables but did not show any 
significant contribution to the measured outcome. 
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Table 5.8: Comparison of the mean averaged metabolic variables over a 5-year period (Year 0, 1, 2 and 5) during the Meal Tolerance 
Test (subjects with Diabetic Retinopathy) whose grade of DR remained the same throughout 5 years from the time of diagnosis 
compared to those whose grades of DR Regressed or Progressed by 5 years from diagnosis of T2DM 
 
 Regressors Same Progressors  
Average values (0-5 years) Median (IQR) Median (IQR) Median (IQR) p  value 
Number 9 25 7  
Mean Fasting Glucose (mmol/L) 8.4 (7.4 – 8.7) 9.5 (9.2 – 10.2) 13.2 (11.4 – 15.2) 0.010 
Mean Postprandial Glucose (mmol/L) (120 mins) 11.3 (10.7 – 12.3) 13.0  (11.3 – 14.2) 17.8 (15.6 -19.1 ) 0.024 
Mean M0 (*10
-9
 pmol/kg/min) 8.7 (5.9 - 10.3) 5.0 (4.1 – 6.7) 2.7 (2.5 – 2.9 ) 0.005 
Mean M1 (*10
-9
 pmol/kg/min) 29.3 (21.8 – 42.2) 19.4 (13.2 - 23.0) 8.0 (6.9 – 9.3) 0.015 
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5.5 Discussion 
This analysis shows a significant independent association between the progression of 
existent DR over a period of 5 years with the degree of hyperglycaemia and 
insulinopaenia observed in response to a MTT, conducted at the time of diagnosis. 
The fasting, postprandial and overall (HbA1c) glycaemic exposure at diagnosis all 
exhibits an independent association with DR progression. Furthermore, measures of 
fasting β-cell function, M0 and HOMA-B and postprandial β-cell
 
responsiveness
 
(M1), estimated at diagnosis, also showed an independent association with DR 
progression. This reflects that our T2DM subjects with poorer β-cell function and 
with a greater degree of hyperglycaemia and worsening insulin secretion on 
presentation were at a greater risk of their DR progressing during 5 years of follow-
up since diagnosis.  
 
In this study of newly-diagnosed, previously untreated T2DM subjects, who’s 
existent DR progressed by 5 years, had a higher baseline HbA1c (10.1%) compared 
to those remaining at the same stage of DR (8.6%) and especially those who 
regressed (6.7%). This association remained significant on univariate logistic 
regression. However, the HbA1c level at Years 1, 2, 5 post diagnosis and the mean 
value over the entire 5-year period did not show a significant association with 
progression of DR 
 
Baseline glycaemic control represented by the glycosylated haemoglobin level but 
not C-peptide secretion (random value) was highlighted to be important in the 
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Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), reported by 
Klein and colleagues (Klein R et al. 1995). They studied individuals with younger 
and older onset DM over 6 years. This was further examined by Looker et al. who 
studied 67 Pima Indian subjects with NPDR at baseline and similarly showed a 
significant association between baseline hyperglycaemia (HbA1c) and progression of 
DR (Looker HC et al. 2003). Kim et al. studied T2DM Korean subjects and showed 
a higher mean HbA1 during the follow-up period in progressors (to PDR) than the 
non-progressors (Kim HK et al. 1998). Thus, our finding relating HbA1c with 
progression of DR is in concordance with these studies. 
 
In addition our study clearly demonstrates that both fasting and postprandial 
hyperglycaemia coexistent with a deficient insulin response during a MTT conducted 
at diagnosis is associated with progression of DR by 5 years. In our study 
population, the FPG at diagnosis and at Year 2 was independently associated with 
progression of DR by 5 years. Although the FPG at Year 1 and 5 failed to reach 
significance, the mean FPG over the entire study period was significantly associated 
with progression of DR. FPI at diagnosis was higher in those subjects with DR 
progression, in comparison to those who remained at the same stage or regressed, but 
lost it significance after adjusting for the variables. FPI at year 1, 2, 5 and Mean FPI 
showed no association with DR progression.   
 
In a different population, the Verona Diabetes Study (Italy) in elderly T2DM 
subjects showed by the second eye examination after 4 to 5 years follow up, 45 
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patients had progressed to a more severe degree of DR (Zoppini G et al. 2009). 
Progression of DR was independently predicted by the average glycaemia (glycated 
haemoglobin or Mean-FPG) over the study period but not by glycaemic variability in 
the fasting state (CV-FPG). Similarly, the Blue Mountains Eye Study (Australia) 
determined the 5-year incidence and progression of DR in their population-based 
cohort (Mean age 66±8 years) during the period 1992–1994. The baseline risk 
factors associated with retinopathy progression, after adjusting for age and gender, 
were an increase in fasting blood glucose, and longer diabetes duration, (Cikamatana 
et al. 2007). 
 
Numerous other studies have also evaluated different glycaemic parameters that 
relate to progression of retinopathy. In 1986, Chen et al studied 471 T2DM subjects 
from primary health-care centres in northern Taiwan and over 4 years, the 
cumulative incidence of DR progression was 30% with the cumulative incidence of 
progression to PDR being 5.8%. Glycaemic control, as measured by the mean FPG 
and HbA1c, was significantly related to the progression of DR (Chen MS et al. 1995). 
In a more prolonged study involving Oklahoma Indians, after a mean follow-up time 
of 12.7 years, the overall incidence of PDR (354 participants) was 18.6%; 45% of 
those with BDR at baseline developed PDR. Significant independent predictors of 
PDR were FPG, duration of diabetes, plasma cholesterol, SBP and therapeutic 
regimen (Diet<OHA<Insulin) (Lee ET et al. 1992). FPG>11.1 mM (200 mg/dl) 
increased the risk of DR to 3.6 times that for a level <7.8 mM (140 mg/dl); 74% of 
those who had BDR and a baseline FPG>11.1 mM (200 mg/dl) developed PDR. 
(Lee ET et al. 1992). These four studies above corroborate our findings of an 
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association of baseline dysglycaemia facilitating the progression of DR. Our mean 
FPG over the 5 years was higher in progressors than those who remained at same 
stage or regressed, although it lost its significance after adjusting for the other 
putative risk factors. This is possible because the subjects were started on treatment 
post-diagnosis during the 5-year study period.  
 
Our study also reports that PPG at diagnosis and at Year 2 and the Mean PPG over 5 
years show an independent positive association with the progression of DR during 
the overall study period analysis, only baseline PPG shows an independent 
contribution. PPG at Ye. After regression ar 1 and 5 failed to reach statistical 
significance. This detailed postprandial glycaemic exposure has not been 
documented before. PPI at diagnosis showed a significant independent contribution 
to the progression of DR by 5 years, although the PPI at years 1, 2 and 5 and Mean 
FPI showed no association with the changes in DR. This can potentially be explained 
by the lower insulin secretion together with a more advanced stage of the disease 
process.   
 
In support of our findings, Shiraiwa et al. in the last decade have shown an 
independent correlation between postprandial plasma glucose and insulin with the 
progression of DR in T2DM Japanese subjects over a 5-year period. PPG was shown 
to be a stronger predictor than HBA1c in their cohort of patients with T2DM 
(Shiraiwa T et al. 2005b). A Finnish study also examined subjects with newly-
diagnosed T2DM in a 10-year prospective study (Voutilainen-Kaunisto RM et al. 
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2001). The frequency of retinopathy was determined by grading of 45° fundus 
photographs at baseline and after 5 and 10 years. The frequency of retinopathy in 
T2DM subjects increased sharply after 5 years and by 10 years, 55% of diabetic 
subjects showed signs of DR. The authors reported that FPG, 2 hour PPG and HbA1c 
at 5 years, but not at baseline, were predictors of DR at 10-year follow-up. However, 
fasting insulin and fasting C-peptide failed to show any association (Voutilainen-
Kaunisto RM et al. 2001). These findings are similar to ours in reporting an 
association of DR progression with FPG, 2 hour PPG and HbA1c, 5 years prior to its 
development. Further, Ohkubo et al. studied T2DM Japanese subjects over a 6-year 
period and concluded that intensive glycaemic control by multiple insulin injection 
therapy can delay both the onset and progression of DR. They proposed that a 
glycaemic threshold of HBA1c <6.5%, FPG <110 mg/dl and 2 hour PPG <180 mg/dl 
prevented the onset and progression of diabetic microangiopathy (Ohkubo Y et al. 
1995). 
 
A further observation in our study was that the overall glucose response to a test 
meal (AUC Glucose (0-240min) ) at diagnosis and at Year 1 and Year 2 post-diagnosis 
revealed an independent association in those who progressed, compared to those 
whose DR regressed over the 5-year study time period. However the AUC Glucose (0-
240min) at Year 5 and mean AUC Glucose (0-240min) over the 5-year observation period 
failed to reach statistical significance. The corresponding insulin response (AUC 
Insulin (0-240min)) at diagnosis showed a significant  independent contribution to the 
progression of DR by 5 years but AUC Insulin (0-240min) at year 1, 2, 5 and Mean AUC 
Insulin (0-240min) showed no association with progression of DR possibly as therapies 
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had been introduced. This reflects the finding of the overall glycaemic exposure to 
DR progression. 
 
In our analysis, the few newly diagnosed T2DM subjects who exhibited DR at 
diagnosis, followed by progression over 5 years had significantly lower fasting and 
postprandial β-cell responsiveness during a MTT at diagnosis and also over the 
entire 5-year study period. The mean values however, failed to retain their significant 
association post regression analysis. There was also a significant association between 
lower fasting and postprandial β-cell function at Year 1 and lower fasting β-cell 
responsiveness at Year 2, with progression of DR. These parameters however lost 
their significance during multivariate analysis. There was no noted association with 
any parameters of insulin resistance/sensitivity.  
 
This is an important parameter to consider here as there is limited mention of the 
influence of fasting and postprandial β-cell function with DR progression in the 
literature to date, except for the work of Suzuki and colleagues, who retrospectively 
studied the role of pancreatic -cell insulin secretory capacity (24-hour urinary C-
peptide) in the development of PDR in diabetic subjects with a duration of DM of 
greater than 10 years. The incidence of PDR during the 10-year follow-up period 
was highest in the group with the lowest 24-hour urinary C-peptide. These data are 
consistent with the view that low pancreatic -cell insulin secretory capacity may be 
a risk factor for the development of PDR (Suzuki K et al. 1989).  Whilst the WESDR 
showed that both younger and older-onset individuals with diabetes, treated with 
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insulin, with undetectable or low plasma c-peptide at baseline, had the highest rates 
of progression of DR, they found no relationship between DR progression and 
plasma c-peptide (Klein R et al. 1995).  
 
Our findings, utilising a more detailed assessment of β-cell function in both the 
fasting and postprandial states, have shown that the progression of existent DR by 5 
years in newly-diagnosed T2DM subjects was independently associated with a lower 
fasting and postprandial β-cell responsiveness at diagnosis. The fasting and 
postprandial insulinopaenia at diagnosis, in subjects who’s DR progressed, is a 
reflection of failing β-cell function at diagnosis resulting in fasting and postprandial 
hyperglycaemia. Of note is that the majority of parameters (FPG, PPG, AUC Glucose (0-
240min), PPI, AUC Insulin (0-240min), M0, M1 AND HOMA-B) at diagnosis contribute to the 
progression of DR, with no significant contribution from HbA1c and other glycaemic 
parameters at year 5. This is compatible with the early history of lesser glycaemic 
exposure leading to a delayed effect in progression of DR. In our study, we 
established an independent association of M0, HOMA-B and M1 with progression of 
DR by measuring β-cell function in response to a standardised meal challenge, 
employing both the CPR program (Hovorka R et al. 1998) and the HOMA 
methodologies  
 
Our analysis has demonstrated that in our subset of subjects with newly diagnosed 
T2DM, who present with DR at the time of diagnosis, both the fasting and 
postprandial glycaemic and β-cell responsiveness over a 5-year follow-up period 
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contribute significantly to the progression of DR. Fasting and postprandial 
glucotoxicity has an adverse effect on the retina seen at diagnosis and over the 5-year 
period which significantly increases the risk of progression of DR. Hence it becomes 
paramount that we aim to improve overall glycaemic control (HbA1c) at diagnosis 
but try to minimise both its component parts i.e. fasting and postprandial glycaemia. 
There are currently various antidiabetic agents which have varying effects on the 
fasting and postprandial glycaemic control. These should be chosen judiciously 
according to the existing pathophysiology (phenotype) and optimally used from the 
early years of a “diabetic subject’s journey”. This aim should minimise the risk of 
progression of DR, which could have a profound effect on a person’s quality of life 
due to the loss of vision and blindness.  
 
5.6 Summary 
 The factors that contribute significantly to the progression of DR include a 
lower fasting and postprandial β-cell responsiveness at diagnosis.  
 The postprandial and AUC Insulin (0-240min) insulinopaenia at diagnosis in 
subjects who go on to develop DR is a reflection of a failing β-cell function 
at diagnosis.  
 The early history of a significantly lower glycaemic exposure not leading to 
DR progression by 5 years in our study is indicative of better early glycaemic 
milieu at diagnosis leading to a long-term risk reduction for DR progression. 
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6.1 Discussion 
The aim of this thesis has been to assess the possible relationships between the 
glycaemic and β-cell secretory status and associated clinical risk factors with the 
presence and progression of DR over a 5-year period in individuals with T2DM. We 
recruited newly-diagnosed GAD antibody-negative and previously untreated T2DM 
subjects. The availability of data derived from a standard meal tolerance test and the 
insulin modified intravenous glucose tolerance test in a relatively large group of 
subjects with type 2 diabetes provided an unique insight into the dynamic glucose 
and insulin secretory responses to a nutrient and intravenous glucose challenge. This 
detailed information gave the opportunity to examine the real-world evolution of 
T2DM and its relationship with the presence, development and progression of DR. 
Type 2 DM subjects were studied near the time of diagnosis prior to any dietary or 
physical changes were made and after 1, 2 and 5 years of follow up. The analysis of 
the data has identified certain risk factors both at baseline and during the 5-year 
study period which contribute in a significant manner to the prevalence, incidence 
and progression of DR in subjects having presented with either no evidence of DR or 
with DR at diagnosis. 
 
Shortly after diagnosis in our subjects with type 2 diabetes we examined in detail the 
association between the state of dysglycaemia i.e. overall glycaemia (HbA1c) plus 
fasting and postprandial plasma glucose, β-cell function and insulin sensitivity with 
the presence of DR in our T2DM study population. Serial plasma glucose and insulin 
levels were measured during the standardized mixed meal challenge from which 
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indices of β-cell function i.e. HOMA-B, fasting (M0) and postprandial (M1) β-cell 
responsiveness and insulin sensitivity ie HOMA-S were derived. In addition, in a 
subgroup of subjects we also conducted the ‘Frequently Sampled Intravenous 
Glucose Tolerance test’ (FSIVGTT) employed to estimate the Acute Insulin 
Response to intravenous glucose (AIRG), Insulin Sensitivity (SI), and Glucose 
Effectiveness (SG).  
 
In the current literature as reviewed in detail earlier indicates that most studies have 
examined the contribution predominantly of overall glycaemic exposure (HbA1c) and 
to a lesser extent FPG to i) the prevalence of DR in newly-diagnosed T2DM 
subjects, ii) the incidence of DR in subjects with no DR at diagnosis and iii) 
progression of DR in subjects with DR at diagnosis over the 5-year study period 
(Appendix Table 1). However, reference to the association between other elements 
of glycaemia such as PPG, as well as β-cell function represented by fasting and 
postprandial insulin levels and fasting and postprandial β-cell responsiveness with 
the presence or progression of DR is very limited. Therefore in this thesis we have 
employed a much more detailed evaluation of glucose tolerance, β-cell function and 
insulin sensitivity using well accepted methodologies. 
 
In the initial analysis, the findings at diagnosis (Chapter 3) showed that the presence 
of DR is independently associated with a lower fasting β-cell responsiveness and 
consequent fasting and postprandial hyperglycaemia. In addition the insulin-
independent component of glucose tolerance was reduced and was also 
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independently associated with the presence of DR at diagnosis. Therefore, at the time 
of clinical diagnosis of type 2 diabetes we report an association between DR and 
fasting β-cell responsiveness and glucotoxicity both in fasting and postprandial state.  
 
In the second part of our analysis (Chapter 4) we followed up 233 subjects with no 
DR at diagnosis over a 5-year follow-up period. Our analysis established a strong 
and independent association between HbA1c fasting and postprandial 
hyperglycaemia (2 hour PPG and the overall 4 hour glucose (AUC (0-240min)) response 
to the test meal) at diagnosis and the incidence of DR. over this 5 year observation 
period. The derived measures of β-cell function HOMA-B and responsiveness when 
fasting (M0 and HOMA-B) and in response to the test meal (M1) along with SG 
(insulin-independent component of glucose tolerance) were all independently 
associated with the development of DR over the 5-year observation period. This 
suggests that by the time of diagnosis of T2DM, subjects who have a significantly 
reduced ß-cell
 
function are at risk of developing DR within a 5-year time period as a 
consequence of hyperglycaemia both fasting and postprandial (2-hour PPG and  
AUC Glucose (0-240min)) over a prolonged period of excess glycaemic exposure (HbA1c). 
Furthermore our data further emphasises the contribution of both fasting and 
postprandial components to the overall glycaemic exposure with all glycaemic 
parameters significantly and independently related to incident diabetic retinopathy 
over the 5 year observation period. However the long-term contribution of 
postprandial glycaemia was seen to be greater than the influence of FPG on the 
development of DR.  
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This analysis therefore suggests that impaired β-cell responsiveness, both in the 
fasting and postprandial state at or near the time of diagnosis resulting in increased 
postprandial and overall glycaemic exposure over the 5-year study period contribute 
significantly to the development of DR. The extent of insulinopaenia observed at 
diagnosis in those subjects who go on to develop DR already reflects a significant 
defect in β-cell function.  
 
Of note is that most parameters of glycaemic control and β-cell secretory status at 
diagnosis appear to be the main contributors to the development of DR as there was 
no difference in  HbA1c and other glycaemic parameters at year 5 between those who 
developed retinopathy and those who did not. The early history of a significantly 
lower glycaemic exposure not leading to incident DR by 5 years in our study is 
indicative of better early glycaemic milieu at diagnosis leading to a long-term risk 
reduction for DR incidence. 
 
In our study, we were also able to established an independent association between 
various measures of β-cell function in response to a standardised meal challenge, 
employing both the CPR program M0, and M1 (Hovorka R et al. 1998) and the 
HOMA methodology (HOMA-B) with incidence of DR. The incidence of DR was 
independently associated with a lower fasting and postprandial β-cell responsiveness 
at diagnosis. This resulted in hyperglycaemia both in the fasting and postprandial 
state, concurrent with fasting and postprandial insulinopaenia. In addition the 
insulin-independent component of glucose tolerance estimated at diagnosis was also 
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reduced and independently associated with the incidence of DR by 5 years in our 
newly diagnosed T2DM subjects.  
 
The final analysis (Chapter 5) in a small number of subjects with DR at presentation 
demonstrates an independent association between the progression of DR from 
baseline over a period of 5 years with the degree of hyperglycaemia and 
insulinopaenia revealed during the MTT when performed at or near the time of 
diagnosis. All measured glycaemic parameters including the fasting, postprandial 
and overall (HbA1c) glycaemic exposure at or near the time of diagnosis exhibited an 
independent association with DR progression. Indices of fasting β-cell function i.e. 
M0 and HOMA-B and the estimated postprandial β-cell
 
responsiveness
 
(M1) all 
showed an independent association with DR progression. This reflects that if on 
presentation of T2DM the poorer the ß-cell
 
function and greater degree of 
hyperglycaemia the greater the risk of their DR progressing by 5 years since 
diagnosis. 
 
We also demonstrated that when the fasting and postprandial glycaemic exposures 
from serial MTTs were averaged over the 5 year follow up period (Years 0, 1, 2 and 
5) these were associated with the progression of DR. The persistent state of 
hyperglycaemia despite the introduction of a small variety of oral hypoglycaemic 
agents such as metformin and a sulphonylurea to improve the glycaemic control 
reflected the continuing deficiency in fasting and postprandial β-cell responsiveness 
over the 5 years observation period.  
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The analysis conducted in our cohort of subjects with newly-diagnosed T2DM, who 
presented with DR, both the fasting and postprandial glycaemic β-cell 
responsiveness at both diagnosis and averaged over a 5-year follow up period 
contribute significantly to the progression of DR. Therefore, this provides additional 
evidence to support the relevance of postprandial hyperglycaemia and 
insulinopaenia, a consequence of deficient postprandial β-cell responsiveness, to the 
progression of existent DR. The importance of β-cell function in the fasting and 
postprandial state to overall dysglycaemia has not previously been well explored or 
documented. 
 
Hence it becomes paramount that we need to attempt to diagnose type 2 diabetes 
earlier and to target both fasting and postprandial hyperglycaemia to normalising 
overall glycaemic control to prevent the occurrence of diabetic retinopathy. This is 
based on our findings that there is clearly a long-term effect present which extends 
over a period of 5 years at least in support of early glycaemic control. For those with 
diabetic retinopathy at the time of diagnosis it is accepted that this may be indicative 
a prolonged pre-diagnostic period of glucose intolerance for up to 7 years. In 
addition, our study demonstrates to a greater extent than previous investigations, the 
already severely compromised state of β-cell function at the time of diagnosis, and 
its continuation despite the reduction in glycaemia and the introduction of 
sulphonylureas to facilitate insulin secretion. Normalising glycaemia is paramount 
and there are currently various antidiabetic agents (GLP 1 agonist or SGLT2 
inhibitors) who have varying effects on the fasting, postprandial glucose or both and 
therefore should be chosen according to the dysglycaemic profile. Appropriate 
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supplementation with insulin may also need to be considered in support of β-cell 
function and the opportunity to induce remission provided the risk of hypoglycaemia 
is minimised. The study also highlights the importance of obtaining relevant 
information to identify the phenotypic characteristics of the patient in an attempt to 
define the best treatment modality (Precision Medicine). The study also emphasises 
the importance of good control in patients with type 2 diabetes with or without 
evidence of diabetic retinopathy with the proviso that improvement in glycaemic 
control is introduced slowly in those previously under poor control and pre-existing 
diabetic retinopathy.  
 
Avoiding diabetic retinopathy and its progression to sight threatening diabetic 
retinopathy is a key priority of diabetes care today. Improved diabetes care as 
defined by improvement in glycaemic, BP control and fibrate therapy supported by 
the introduction of diabetic retinopathy screening services has relinquished diabetic 
retinopathy from the number one cause of blindness in the working age population. 
Maintaining eye health in persons with diabetes by preventing preventable causes of 
blindness such as diabetic retinopathy is currently a global priority in view of its 
devastating impact on the patient, the family and society in general. 
 
6.2 Limitations of Study 
Our study period extended from 1981 and 2007, which can be considered as a 
limitation as the population demographics may change over 3 decades. In addition, 
during this period, a greater awareness of T2DM came about and thus, this had the 
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potential to affect the length of preceding unknown duration of T2DM before 
diagnosis and therefore the effect on β-cell function. However, the longer duration of 
the study does reflect a detailed analysis of over almost three decades of prevalence, 
incidence and progression of existent DR in a Caucasian population with T2DM, 
resident in South East Wales from diagnosis over a five-year period.  
 
Another limitation of our study was that over its duration, because of serial 
developments in the measurement of HbA1c, we employed two different assays, 
although a validated conversion factor was employed. 
 
The subjects lost in follow up in our study would be considered as limitation for the 
longitudinal analysis. However when baseline characteristics of subjects who were 
not followed up over 5 years were compared to those who were followed up over 5 
years there was no significant difference noted (Appendix Table 3). However a 
greater number of subjects with long-term follow up data do give more robust data. 
 
The Diabetes Prevention Program reported more than 12% of subjects with T2DM 
had DR within approximately 3 years of diagnosis (Diabetes Prevention Program 
Research Group 2007 ). In comparison, in this study 16.5% of the subjects with 
newly-diagnosed T2DM, presenting with DR was investigated within 1-2 weeks of 
diagnosis, possibly indicating a slightly longer pre-clinical period in our cohort. This 
initial analysis was limited by its cross-sectional design thus making it difficult to 
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confirm a cause and effect relationship. However, the strength of our study lies in the 
recruitment of subjects within 1-2 weeks after diagnosis, the detailed assessment of 
dysglycaemia and β-cell function over an extended period of 5 years utilising the 
same methodology (a standardised meal tolerance test) complemented by an insulin 
modified intravenous glucose tolerance test at baseline, supported throughout the 
observation period by detailed analysis of the presence and severity of diabetic 
retinopathy.  
 
Early diagnosis and early good glycaemic control are both paramount in preventing 
or delaying the onset and progression of diabetic retinopathy. Protecting and/or 
enhancing β-cell function without inducing hypoglycaemia is an aim for the future.  
 
6.3 Future areas of research 
The literature to date complimented by the analysis of the data in this thesis 
demonstrates that the degree of fasting and postprandial hyperglycaemic exposure 
both contribute to i) the prevalence of DR in newly-diagnosed T2DM subjects, along 
with the ii) incidence of DR in subjects with no DR at diagnosis and iii) progression 
of DR in subjects with DR at diagnosis over a period of 5 years follow-up. However, 
the association of PPG is not extensively documented in the current literature, being 
limited to only 4 studies in non-Caucasian subjects. Therefore, treatment specifically 
targeting postprandial hyperglycaemic excursions is justified. As β-cell dysfunction, 
and insulin resistance are major contributors to dysglycaemia in type 2 diabetes the 
role of insulin supplementation and/or insulin sensitizers need to be considered and 
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their potential role elucidated in respect to the prevalence, incidence and progression 
of DR. This should ensure an appropriate and timely management of T2DM to 
prevent and limit DR and its effect on our day to day living. 
 
As stated our current study is limited by the numbers of subjects involved, the non-
random allocation of therapeutic modalities, the relatively poor glycaemic control 
achieved and the shortness of the observation period. Future studies should take 
these into consideration. A more extensive involvement of other putative risk factors 
such as blood pressure and fibrate therapy will need to be taken into consideration.  
 
In the current times, with a greater awareness of T2DM, it should be possible to 
investigate a study population at an even earlier stage in their T2DM, even to include 
persons with pre-diabetes, and follow them up over for a longer study period. Thus if 
the MTTs and FSIVGTTs were continued for an extended study period, it would 
demonstrate the prevalence, incidence and progression of DR in relation to the 
phenotypic characteristics of the patients including β-cell function, insulin sensitivity 
and other glycaemic indices in a more detailed fashion than at present. This would 
better delineate the natural history of DR in relation to the various above mentioned 
metabolic indices. Such future analysis would then have the potential to proceed 
from the more refined phenotypic characteristics of T2DM subjects to explore the 
genotypic makeup of these subjects and the risk of diabetic retinopathy.  
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A detailed analysis of the retinal vascular morphology of T2DM subjects may also 
reveal subtle changes, which have not been captured under the broad categories of 
grading of DR used in this study. These suggested future studies could accommodate 
the limitations of this study. 
 
6.4 Summary of key findings 
A cross-sectional analysis performed at the time of diagnosis of type 2 DM indicates 
that the prevalence of DR is associated with both the fasting and postprandial 
hyperglycaemia in the presence of impaired fasting β-cell function. The lower 
fasting and postprandial β-cell responsiveness at diagnosis in those with retinopathy 
was also evident over the 5 year study period despite the fact that glycaemic 
exposure at 5 years was similar between the groups with or without diabetic 
retinopathy. Elevated fasting, postprandial and overall glycaemic exposure at 
baseline were also independently associated with incident DR in those subjects with 
no evidence of DR at diagnosis.  
 
Finally, in the subjects with newly diagnosed T2DM, already with evidence of DR at 
the time of presentation, the fasting and postprandial hyperglycaemia and β-cell 
responsiveness at diagnosis and throughout the 5 years of follow-up period were 
significantly associated with the progression of existent DR. This reflects the highly 
probable aetiology and consequences of glucotoxicity both at diagnosis and over the 
5-year observation period.  
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The importance of the ‘long-term effect’ of dysglycaemia is strongly corroborated in 
this thesis with parameters at or early on in diagnosis having a significant 
contribution to the outcome after a period of 5 years. 
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Appendix Table 1: Summary of prospective studies on risk factors affecting the incidence and progression of diabetic retinopathy 
 
 
Population Numbers Study 
Duration 
(Years) 
Cumulative 
Prevalence 
Cumulative 
Incidence 
Retinopathy 
assessment 
methods 
Risk Factors 
WESDR  
(Klein R et al. 
1989a) 
Southern 
Wisconsin 
Age at DM 
diagnosis  
>30 years 
987 4 
(1980-
1984) 
- Insulin Users: 
NDR to DR  -  47%          
No PDR to PDR – 
7% 
DR progressed – 
34% 
Non - Insulin Users: 
NDR to DR  -  34%          
No PDR to PDR – 
2% 
DR progressed – 2% 
Fundus 
Photographs 
- 
Suzuki et al. 
(Suzuki K et al. 
1989) 
Japan 
DM 
duration  
>10 years 
160 10 - Incidence of PDR 
 
------------------------- 
Incidence of BDR 
 
Fundoscopic 
examination 
through dilated 
pupils using a direct 
ophthalmoscope by 
ophthalmologists 
24 hour urinary  
C-peptide 
concentration 
-------------------------
FPG 
Lee et al.  
(Lee ET et al. 
1992) 
Oklahoma 
Indians 
927 12.7 - Incidence of PDR – 
18.6 %: 
(45 % of those with 
BDR developed 
PDR) 
 
Fundus 
photographs 
through dilated 
pupils using a 
nonmydriatic 
camera (Canon 4 – 
45 NM) 
Duration of DM 
FPG 
Plasma Cholesterol 
SBP 
Treatment of DM 
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Population Numbers Study 
Duration 
(Years) 
Cumulative 
Prevalence 
Cumulative 
Incidence 
Retinopathy 
assessment 
methods 
Risk Factors 
Araki et al. 
(Araki et al. 
1993) 
Japan 
(> 60 
years) 
NDR at 1
st
 
visit 
110 5 - Incidence of DR 
 
Fundoscopic 
examination of the 
retina through 
dilated pupils using 
direct 
ophthalmoscope 
Duration of DM 
Baseline FPG 
Baseline HbA1 
Persistent proteinuria 
 
Chen et al. 
(Chen MS et al. 
1995) 
Taiwan 
T2DM 
471 4 - Incidence of DR: 
19.2 % 
Progression of DR: 
30 % 
Incidence of PDR: 
5.8 % 
Ocular fundoscopic 
examination by 
ophthalmoscope 
 
Mean FPG  
Mean HbA1c 
Henricsson et al. 
(Henricsson M 
et al. 1997) 
Sweden 
T2DM  
≥ 40 years  
 
1378 3.1 - - Fundus 
Photography 
HA1c 
Change of treatment 
Kim et al.  
(Kim HK et al. 
1998) 
Korea 
T2DM 
130 NDR 
at 
baseline 
 
56 NPDR 
at 
baseline 
5.3  - Incidence of  DR: 
44.4/1,000 person-
years 
 
Progression of DR 
to PDR: 37.5/1,000 
person-years 
 
Annual fundoscopic 
examination by 
ophthalmoscope 
Mean HbA1 
Gabir et al. 
(Gabir MM et 
al. 2000) 
Pima 
Indian 
adults 
5023 10 1999 WHO 
Criteria: 
IGT – 1.6 % 
DM –19.2 % 
Incidence of DR 
 
Direct 
ophthalmoscope 
through dilated 
pupils 
FPG 
2 hour PPG 
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Population Numbers Study 
Duration 
(Years) 
Cumulative 
Prevalence 
Cumulative 
Incidence 
Retinopathy 
assessment 
methods 
Risk Factors 
UKPDS 50 
(Stratton IM et 
al. 2001) 
United 
Kingdom 
T2DM 
Newly 
diagnosed 
 
 
 
 
1919 6  NDR (Year 0) – 
63% 
DR (Year 0) – 
37% 
NDR to DR  -  
23.2%  
DR progressed – 
29% 
         
 
 
 
 
Retinal photographs Development of DR: 
HbA1c  at diagnosis 
6 years glycaemic 
exposure 
SBP 
Not smoking 
Progression of DR: 
Age 
Male Sex 
HbA1c 
Not smoking 
WHO 
multinational 
study of 
vascular disease 
in diabetes 
(Keen H et al. 
2001) 
Type I and 
II DM 
2,877 8.4 - Any DR – 47.7% 
PDR – 9.7% 
Direct 
Ophthalmoscopy 
Any DR: 
Age 
Duration of DM 
FPG 
Serum TC 
SBP 
BMI 
Insulin treatment 
Proteinuria 
PDR: 
Age 
Duration of DM 
FPG 
Serum TC 
BMI 
Insulin treatment 
Proteinuria 
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Population Numbers Study 
Duration 
(Years) 
Cumulative 
Prevalence 
Cumulative 
Incidence 
Retinopathy 
assessment 
methods 
Risk Factors 
Voutilainen-
Kaunisto et al. 
(Voutilainen-
Kaunisto RM et 
al. 2001) 
Finland 
Newly 
diagnosed 
T2DM 
133 10 DR: 
8.9% - 
Diagnosis 
17.7% - Year 5 
55.7% - Year 10 
Severe  BDR: 
9.9% -Year 5 
34.1% -Year 10 
PPDR: 
4.8% - 
Diagnosis 
2.7% -Year 5 
15.3% -Year 10 
Frequency: 
0% - Diagnosis 
0.9% - Year 5 
7.3% - Year 10 
Incidence: 
8.8% - 5 years 
50% - 10 years 
45° Fundus 
Photographs 
Baseline: None 
5 year: 
FPG 
1 hour PPG 
2 hour PPG 
HbA1c 
Yoshida et 
al.(Yoshida Y et 
al. 2001) 
T2DM – 
No DR at 
1
st
 visit 
787 6.7 - 16.8% Direct and Indirect 
Ophthalmoscopy 
through dilated 
pupils 
Baseline: 
HbA1c 
Duration of DM 
Treatment of DM 
BMI 
5 year: 
HbA1c 
Duration of DM 
Janghorbani et 
al. (Janghorbani 
M et al. 2003) 
Iran 
Type I and 
II DM 
549 5.4  - 89.4/1000 person 
years (males) 
86.6/1000 person 
years (females) 
Indirect 
Ophthalmoscopy 
through dilated 
pupils and then 
Fundus 
Photography 
Age at 1
st
 review 
HbA1c 
FPG 
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Population Numbers Study 
Duration 
(Years) 
Cumulative 
Prevalence 
Cumulative 
Incidence 
Retinopathy 
assessment 
methods 
Risk Factors 
Looker et al. 
(Looker HC et 
al. 2003) 
Pima 
Indians –  
Arizona – 
USA 
Type I & II 
280 4 - 16.8% Retinal photographs 
(two standard fields 
for each eye) 
 
HbA1 (Overall 
glycaemia) 
OHG 
Shiraiwa et al. 
(Shiraiwa T et 
al. 2005b) 
Japan 
T2DM 
151 5 - Progression of DR 
 
Fundoscopic 
examination of the 
retina through 
dilated pupils by 
ophthalmologists 
 
PPG 
PPI 
 
Tapp et al. 
(Tapp RJ et al. 
2006) 
Mauritius 
Type I and 
II DM 
528 6 
(1992-98) 
- All: 
DR – 23.8% 
STDR – 0.4% 
Known DM and 
NDR at baseline: 
NPDR – 29.2% 
PDR – 1% 
Newly diagnosed 
DM 
NPDR – 19.1% 
Retinal photographs 
were taken using a 
TRC-50VT retinal 
camera in three 
fields of the right 
eye (centred on the 
optic disc; macula 
(temporal to the 
optic disc); and 
nasal to disc). 
Baseline: 
Duration of DM 
FPG 
 
ARIC (Wong 
TY et al. 2007) 
USA 
Type I and 
II DM 
(Age: 45 -
64) 
 
981 3 
(1993 – 
1996) 
 
27.2 % 10.1 % 45° Non-mydriatic 
retinal photograph 
of only one eye 
 
Mean arterial BP 
FPG 
Serum TC 
Fibrinogen 
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Population Numbers Study 
Duration 
(Years) 
Cumulative 
Prevalence 
Cumulative 
Incidence 
Retinopathy 
assessment 
methods 
Risk Factors 
Cikamatana et 
al. (Cikamatana 
et al. 2007) 
Australia 
(Older 
population) 
2334 5 
(1992-94) 
 
- Cumulative 
Incidence of DR: 
22.2 % 
 
Progression of DR 
to PDR: 4.1 % 
 
Retinal photographs 
(Modified ETDRS 
scale) 
 
Baseline FPG 
Duration of DM 
 
Manaviat et al. 
(Manaviat MR 
et al. 2008) 
Iran 
T2DM 
without DR 
120 4 - Cumulative 
Incidence of DR:  
5.8 % - 1
st
 year,  
20.3 % in 2
nd
 year 
24.4% in 3
rd
 year  
7.4 % in 4
th
 year 
 
Grades of DR: 
affected by: 
Ophthalmoscopic 
examination 
FPG 
Duration of DM 
SBP 
Zoppini et 
al.(Zoppini G et 
al. 2009) 
Italy – 
Verona 
Diabetes 
Study 
T2DM - 
Elderly 
746 4 -5 
 
- Incidence of DR 
Progression of DR 
 
Indirect 
Ophthalmoscopy 
after pupil dilation 
and then two field 
stereoscopic retinal 
photographs 
Average glycaemia 
over time – HA1c 
Mean FPG 
HDL 
Takao et al  
(Takao T et al. 
2010) 
Japan 
T2DM 
with NDR 
in 1
st
 visit  
(1966-79) 
170 33 (Mean) 
[27-40] 
- Incidence of NPDR Annual fundoscopic 
examination by 
ophthalmologists 
CV – FPG 
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Population Numbers Study 
Duration 
(Years) 
Cumulative 
Prevalence 
Cumulative 
Incidence 
Retinopathy 
assessment 
methods 
Risk Factors 
Takao et al. 
(Takao T et al. 
2011) 
Japan 
T2DM 
with NDR 
in 1
st
 visit  
(1966-79) 
170 33 (Mean) 
[27-40] 
- Incidence of PDR Annual fundoscopic 
examination by 
ophthalmologists 
CV – FPG 
FPG (5 years prior to 
event) 
HbA1c ( 10 years 
prior to event) 
Jones et al. 
(Jones CD et al. 
2012) 
Central 
Norfolk – 
UK 
Type I and 
II DM 
20,686 1990 - 2006 NDR – 79% 
NPDR – 18% 
PPDR – 2.9% 
5 Years: 
NDR to PPDR – 4% 
NDR to STMO – 
0.59% 
NDR to PDR – 
0.68% 
10 Years: 
NDR to PPDR – 
16.4% 
NDR to STMO – 
1.2% 
NDR to PDR– 1.5% 
5 Years: 
BDR to PPD – 23% 
BDR to STMO – 
5.2% 
BDR to PDR – 6.1% 
10 Years: 
NDR to PPDR – 
53% 
NDR to STMO -
9.6% 
NDR to PDR – 11% 
Two photographs of 
each eye were 
taken, one centered 
on the optic nerve 
and the other on the 
fovea, using Canon 
45NM or 46NM 
fundus cameras 
(Canon UK, 
Reigate, U.K.) with 
45° fields and 
Orion Eyecap and 
DRSS digital 
imaging software. 
 
Age 
Duration of DM 
Treatment of DM 
 Hypertension 
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Population Numbers Study 
Duration 
(Years) 
Cumulative 
Prevalence 
Cumulative 
Incidence 
Retinopathy 
assessment 
methods 
Risk Factors 
Perol et al. 
(Perol J et al. 
2012) 
French 
population 
Type I and 
II DM 
254 3 - 14% OPHIDAT 
telemedical network 
Duration of DM 
Microalbuminuria 
Macroalbuminuria 
Rudnisky et al. 
(Rudnisky CJ et 
al. 2012) 
Canada 980 All 
777 NDR 
7.6 - NDR to DR  - 
16.6% 
Stereoscopic  
mydriatic retinal  
photography 
 
HA1c 
SBP 
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Appendix Table 2 
 
Comparison of baseline characteristics of subjects who were not followed up over 5 years 
compared to those who were followed up over 5 years 
 
 All 
subjects 
Not followed up 
over 5 years 
Followed up 
over 5 years  
p value 
(between  
groups)  
Number 544 311 233  
Age at presentation (years) 54 (10) 55 (10) 54 (9) 0.52 
Male Sex (%) 393 (72) 238 (71) 155 (67) 0.28 
Weight (kg) 88 (17) 88 (17) 87 (16) 0.85 
BMI (kg.m
2
) 30.2 (5.0) 30.5 (5.5) 30.0 (5.2) 0.24 
Systolic blood pressure (mmHg) 137 (19) 139 (21) 134 (17) 0.02 
Diastolic blood pressure (mmHg) 83 (11) 83 (11) 83 (10) 0.78 
Total Cholesterol (mmol/L) 5.4 (1.2) 5.4 (1.1) 5.5 (1.2) 0.71 
HbA1c (%) 7.7 (2.0) 7.8 (2.0) 7.6 (2.1) 0.37 
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Appendix Table 3: Baseline characteristics of newly diagnosed type 2 diabetic subjects who developed DR at Years 1, 2 and 5 
 Develop DR at Year 1 Develop  DR at Year 2 Develop DR at Year 5  
Number 12 15 27 p value 
Fasting Glucose (mmol/L) 12.3  (9.0 - 14.6) 11.5 (9.6 - 14.1) 11.2 (9.6 – 13.4) 0.918 
Postprandial Glucose (mmol/L) (120 mins) 16.4 (13.9 - 19.5) 16.4  (13.0 – 18.1) 15.2 (12.8 - 18.2) 0.882 
HbA1c (%) 8.7 (8.0 - 10.1) 9.3 (8.5 – 10.1) 8.1 (7.0 – 9.6) 0.271 
AUC Glucose (0-240min) (mmol/L)                      13.8 (10.6 - 16.4) 13.9 (11.0 – 15.5) 12.8 (11.3 – 15.8) 0.984 
Fasting Insulin (pmol/L) 31.0 (13.5 - 53.0) 64.0 (34.8 - 116.5) 58.0 (28.0 – 101.0) 0.022 
Postprandial  Insulin (pmol/L) (120 mins) 108.5 (57.5 – 174.5) 240.0 (138.0 - 339.0) 246.0 (108.8 - 442.5) 0.097 
AUC Insulin (0-240min) (pmol/L) 74.2 (57.6 – 121.7) 156.2 (112.9 – 259.4) 180.4 (70.6 – 284.9) 0.064 
HOMA-B (%) 14.1 (5.9 – 31.6) 29.1 (19.3 – 42.3) 30.6 (12.3 – 61.4) 0.093 
HOMA-S (%) 116.1 (76.5 - 232.8) 54.9 (29.7- 86.7) 58.9 (35.5 - 102.9) 0.017 
HOMA-IR 0.9 (0.4 – 1.3) 1.9  (1.1 – 3.4) 1.7 (1.0 – 2.8) 0.017 
M0 (*10
-9
 pmol/kg/min) 2.4 (1.7 – 6.8) 4.1 (2.3 – 6.3) 4.3 (1.9 – 7.4) 0.057 
M1 (*10
-9
 pmol/kg/min) 7.7 (6.3 – 16.7) 9.9 (7.3 - 14.5) 11.5 (5.9 – 15.5) 0.086 
 
Data expressed as median (1
st
 – 3rd IQR), AUC = Area Under the Curve 
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Appendix Table 4 
Year 1 characteristics in subjects with No Diabetic Retinopathy (NDR) throughout 5 
years compared to those with Diabetic Retinopathy (DR) by 5 years of diagnosis of 
T2DM. Group A: Subjects who underwent MTT. 
 
 
 All subjects NDR 
 
DR 
 
p value 
 
Number 233 179 54  
Age at presentation (years) 55.0 (9.4) 55.0 (9.8) 56.0 (8.2) 0.661 
Male Sex (%) 175 (75) 139 (77.7) 36 (66.7) 0.075 
Weight (kg) 85.9 (16.2) 85.4 (16.4) 87.4 (15.3) 0.343 
BMI (kg.m
2
) 28.8 (6.5) 28.7 (6.0) 29.3 (8.1) 0.231 
Systolic blood pressure (mmHg) 131 (16) 130 (16) 133 (14) 0.238 
Diastolic blood pressure (mmHg) 80 (10) 79 (10) 81 (11) 0.224 
Total Cholesterol (mmol/L) 5.1 (1.1) 5.1 (1.1) 5.2 (1.0) 0.476 
HbA1c (%) 6.6  (1.2) 6.5 (1.1) 6.9 (1.4) 0.011 
 
Data expressed as Mean (± SD); Sex: Number (%); BMI = Body Mass Index 
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Appendix Table 5 
Year 2 characteristics in subjects with No Diabetic Retinopathy (NDR) throughout 5 
years compared to those with Diabetic Retinopathy (DR) by 5 years of diagnosis of 
T2DM.  Group A: Subjects who underwent MTT. 
 
 
 All subjects NDR 
 
DR 
 
p value 
 
Number 233 179 54  
Age at presentation (years) 56.0 (9.4) 56.0 (9.8) 57.0 (8.2) 0.661 
Male Sex (%) 175 (75) 139 (77.7) 36 (66.7) 0.075 
Weight (kg) 87.3 (16.6) 87.0 (16.6) 88.4 (16.6) 0.528 
BMI (kg.m
2
) 29.1 (6.9) 28.8 (6.8) 30.3 (7.3) 0.119 
Systolic blood pressure (mmHg) 129.3 (15.7) 128.6 (14.5) 131.7 (19.0) 0.461 
Diastolic blood pressure (mmHg) 78.3 (9.3) 78.0 (9.0) 79.3 (10.1) 0.386 
Total Cholesterol (mmol/L) 5.0 (1.1) 5.0 (1.1) 5.1 (1.0) 0.660 
HbA1c (%) 6.9 (1.5) 6.7 (1.4) 7.3 (1.5) 0.016 
 
Data expressed as Mean (± SD); Sex: Number (%); BMI = Body Mass Index 
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Appendix Table 6 
 
Year 5 characteristics in subjects with No Diabetic Retinopathy (NDR) throughout 
the 5 years compared to those with Diabetic Retinopathy (DR) by 5 years of 
diagnosis of T2DM. Group A: Subjects who underwent MTT. 
 
 
 All subjects NDR 
 
DR 
 
p value 
 
Number 233 179 54  
Age at presentation (years) 59.0 (9.4) 59.0 (9.8) 60.0 (8.2) 0.661 
Male Sex (%) 175 (75) 139 (77.7) 36 (66.7) 0.075 
Weight (kg) 85.1 (23.0) 85.0 (22.7) 85.4 (24.2) 0.528 
BMI (kg.m
2
) 29.1 (7.2) 29.0 (7.1) 30.0 (7.8) 0.163 
Systolic blood pressure (mmHg) 135.6 (17.3) 135.2 (16.8) 136.9 (18.8) 0.675 
Diastolic blood pressure (mmHg) 79.1 (10.1) 78.7 (10.5) 80.4 (8.8) 0.527 
Total Cholesterol (mmol/L) 5.2 (1.2) 5.2 (1.2) 5.1 (1.1) 0.604 
HbA1c (%) 7.5 (1.6) 7.4 (1.6) 8.0 (1.6) 0.009 
 
Data expressed as Mean (± SD); Sex: Number (%); BMI = Body Mass Index 
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